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We investigated the molecular role of the delta isoform of protein kinase C (PKCô) in 
toxicity induced by the Parkinsonian toxin MPP+. We also examined the role of PKCô in 
apoptotic death induced by the potential Parkinson's disease (PD) risk factor dieldrin in rat 
mesencephalic dopaminergic neuronal (N27) cells and in the primary mesencephalic 
neuronal model. Both the protein and mRNA levels of PKCô were selectively higher in the 
dopaminergic neurons in the substantia nigra (SN) region as compared to the cortex, 
brainstem, and striatum regions of rodent brains. PKCô protein co-localized with tyrosine 
hydroxylase (TH), the rate-limiting enzyme responsible for dopamine synthesis in 
dopaminergic neurons. siRNA designed against PCKô effectively silenced the expression of 
PKCô and reduced dieldrin or MPP+-induced apoptotic death of N27 cells and degeneration 
of primary dopaminergic neurons. Following dieldrin exposure in (N27) cells, we 
determined that the full-length PKCô is first cleaved in the cytoplasm, and the activated 
PKCô catalytic fragment subsequently translocates into the nucleus. The caspase-3 specific 
inhibitor (Z-DEVD-FMK), the cleavage resistant mutant of PKCô (PKCô-CRM), as well as 
the nuclear localization signal (NLS) deletion mutant of PKCô (PKCô-ANLS) all abolished 
the nuclear translocation of activated cleaved PKCô. The proteolytic activation of full-length 
PKCô and subsequent nuclear translocation of activated cleaved PKCô are integral events 
required for PKCô's pro-apoptotic function in apoptotic death of dopaminergic neuronal cells. 
Blockade of proteolytic activation of endogenous PKCô by PKCô-CRM also protected 
primary mesencephalic dopaminergic neurons from MPP+-induced degeneration. Moreover, 
we demonstrated that activated cleaved PKCô mediates Serl4 phosphorylation of histone 
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H2B followed by its nuclear translocation in apoptotic dopaminergic neuronal cells. Serl4 
phosphorylation of H2B and apoptosis can also be directly induced by the catalytic fragment 
of PKCô (PKCô-CF), but not by the regulatory fragment of PKCô (PKCô-RF), PKCô-CRM, 
PKCô-ÀNLS, or the dominant-negative mutant of PKCô (PKCô-DN). Transfection of PKCô-
CF also directly induced degeneration of primary mesencephalic dopaminergic neurons while 
PKCô-RF-transfected primary neurons remained intact. In addition, we also demonstrated 
that the N- and the C-terminals of PKCô are in close proximity in the tertiary structure, as 
demonstrated by fluorescence resonance energy transfer (FRET). By employing the CI or 
C2-like domain deletion mutant of PKCô (PKCô-AC 1 or PKCÔ-AC2), we showed that 
deletion of the C2-like domain, but not the CI domain, induces strong nuclear localization of 
PKCÔ. The exogenously expressed catalytic fragment of PKCô (PKCô-CF) also primarily 
localizes to the nucleus. Sequence analysis of the C2-like domain reveals a possible leucine-
rich nuclear export signal (NES); however, the C2-like domain is not sensitive to the nuclear 
export inhibitor leptomycin B (LMB), suggesting that this leucine-rich motif is not a 
functional NES. Moreover, the C2-like domain alone was fused to the N-terminal of a NES 
mutated form of Rev protein, the RNA binding protein of Equine Infectious Anemia Virus 
(EIAV), to generate the Rev chimera. Interestingly, the Rev chimera with the C2-like 
domain is still primarily localized in the nucleus. Thus, the N-terminal C2-like domain 
apparently regulates the subcellular localization of PKCô by masking the C-terminal NTS 
through the position obstacle in the tertiary structure, but not through NES or interaction with 
anchoring proteins. Taken together, our studies show that i) the novel PKC isoform family 
member PKCô is highly expressed in nigral dopaminergic neurons, ii) PKCô mainly 
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localizes in the cytoplasm by the position obstacle effect of the C2-like domain to the NLS, 
iii) neurotoxin exposure induces proteolytic activation of full-length PKCô and subsequent 
nuclear translocation of the PKCô cleaved fragment to cause histone H2B phosphorylation 
and apoptotic cell death, and iv) RNAi mediated suppression of PKCô protects dopaminergic 
neurons against neurotoxic insults. 
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CHAPTER I: GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation is written in an alternative dissertation format. It contains a general 
introduction, four research papers, a general conclusion, and an acknowledgement. The list of 
references cited is included at the end of each chapter. Chapter I, the general introduction, 
includes research objectives, background and literature review of my research subjects. 
Chapter II, "Suppression of caspase-3 dependent proteolytic activation of Protein Kinase C 8 
by small interfering RNA (siRNA) prevents MPP+-induced dopaminergic degeneration," has 
been published in Molecular and Cellular Neuroscience (25: 406-421, 2004). Chapter III, 
"Proteolyrically activated PKCÔ translocates to the nucleus and mediates Serl4 
phosphorylation of histone H2b in neurotoxin-induced apoptotic death of dopaminergic 
neuronal cells," Chapter IV, "Nuclear localization of PKCô is regulated by proximity of N-
terminal C2-like domain to the C-terminal nuclear localization signal (NLS)," and Chapter V, 
"Selectively high expression of oxidative-stress sensitive kinase Protein Kinase C delta 
(PKCô) contributes to the vulnerability of nigral dopaminergic neurons to the MPP+-induced 
degeneration," will be submitted for publication in Cell Death and Differentiation, the 
Proceedings of National Academy of Sciences, and the Journal of Neuroscience, respectively. 
Chapter VI contains the general conclusions. 
This dissertation contains the experimental results obtained by the author during his 
graduate study under the supervision of his major professor, Dr. Anumantha G. Kanthasamy. 
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Research Objectives 
Mechanisms of selective degeneration of nigral dopaminergic neurons in Parkinson's 
disease (PD) remain unsolved despite the many advances made during the past three decades. 
Environmental chemical exposure and genetic mutations have both been implicated in the 
pathogenesis of PD. Mutations in alpha-synuclein, Parkin and DJ genes are some key genetic 
defects associated with PD. Findings from in vitro and in vivo models of PD suggest that 
environmental neurotoxins-induced oxidative stress is one of the initial events that trigger the 
mitochondrial intrinsic apoptotic pathway in nigral dopaminergic neurons and apoptotic 
death (Beal, 2002; Dauer and Przedborski, 2003; Jenner, 2003; Olanow and Tatton, 1999). 
The deleterious nature of the metabolism of free cytosolic dopamine, the specific 
neurotransmitter employed by the dopaminergic neurons, potentially increases oxidative 
stress in dopaminergic neurons. The expression levels of several inherent factors involved in 
the regulation of free cytosolic dopamine levels have been implicated in the vulnerability of 
dopaminergic neurons (Hirsch et al., 1997; Uhl, 1998). Recent identification of genetic 
mutations of PTEN induced kinase 1 (PINK1) (Valente et al., 2004) and leucine-rich repeat 
kinase 2 (LRRK2) (Zimprich et al., 2004) in familial PD patients suggests that kinase might 
play an important role in the pathogenesis of PD. Our laboratory previously observed that 
neurotoxin exposure induces oxidative stress and activation of caspase-3 (Anantharam et al., 
2002; Kanthasamy et al., 2003; Kitazawa et al., 2003; Yang et al., 2004). The activated 
caspase-3 further mediates proteolytic activation of protein kinase C delta (PKCô) and 
promotes apoptotic death of rat pheochromocytoma (PC 12) (Anantharam et al., 2002) and rat 
mesencephalic dopaminergic neuronal (N27) cells (Kaul et al., 2003; Kitazawa et al., 2003; 
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Yang et al., 2004). However, the expression level of PKCô in nigral dopaminergic neurons 
and its detailed mechanisms in the apoptotic death of dopaminergic neuronal cells, including 
the localization change of activated PKCô, downstream events following the activation of 
PKCô, and the regulation of the nuclear localization of PCKô, have not been investigated. 
The major objectives of this dissertation are: 1) to determine the protein and RNA 
level of PKCô, as well as other PKC isoforms in nigral dopaminergic neurons of rodent 
brains; 2) to investigate the localization change of the activated cleaved fragments of PKCô 
and downstream events in the nucleus following the proteolytic activation of PKCô; 3) to 
investigate the regulatory role of the N-terminal regulatory fragment in the nuclear 
localization of full-length PKCô; and 4) to develop small interfering (siRNA) and small 
hairpin RNA (shRNA) against PKCô as a novel neuroprotective strategy to prevent 
dopaminergic neurons from neurotoxin-induced degeneration. Taken together, these studies 
will provide detailed mechanisms for PKCô's pro-apoptotic functions in the neurotoxin-
induced degeneration of dopaminergic neurons and may provide useful insights about the 
role of kinase in the pathogenesis of Parkinson's disease. 
Background and literature review 
This section provides background information related to the studies described in the 
dissertation: (I) Parkinson's disease and its pathogenesis; (II) Vulnerability of Substantia 
nigra pars compacta (SNc) dopaminergic neurons in Parkinson's disease; (III) Apoptosis in 
Parkinson's disease; (IV) Involvement of Serine/Threonine protein kinases in the apoptotic 
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signaling and neurodegenerative diseases; (V) Proteolytic activation and nuclear 
translocation of serine/threonine protein kinases in apoptosis; (VI) RNA interference (RNAi) 
and its neuroprotective application in neurodegenerative diseases. 
I. Parkinson's disease and its pathogenesis 
1-1: Parkinson's disease 
The clinical features of Parkinson's disease (PD) were first characterized by James 
Parkinson in his monograph, "An essay on the shaking palsy" in 1817 (Parkinson, 2002). 
Currently, Parkinson's disease is one of the most devastating neurodegenerative diseases 
among elders worldwide. In the U.S., about 2,000,000 individuals have been diagnosed with 
PD (Shastry, 2001). The incidence rate of PD is estimated at 0.3% among the general 
population and about 1-2% among the population over 65 in industrialized countries (de Rijk 
et al., 2000; Rajput, 1992). The prevalence of the disease increases up to 4-5% by the age of 
85 (Giasson and Lee, 2001). The higher incidence rate in the elder population implies that 
aging itself contributes to the pathogenesis of PD. On the other hand, Parkinson's disease 
also occurs in young people. Rare young-onset PD (YOPD), developing between 21 and 40 
years, or juvenile Parkinsonism (JP), with an onset age below 21 years, both have been 
reported (Paviour et al., 2004). 
The major clinical symptoms of PD are characterized as resting tremor, muscular 
rigidity, bradykinesia, and postural instability. Although dysfunction involved in movement 
mainly defines this disorder, various non-motor features are also found, including cognitive 
and psychiatric changes, sleep disturbances, and autonomic dysfunction (Samii et al., 2004). 
A resting tremor, uncontrollable involuntary shaking of the hand or foot (less common) with 
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frequency of 3-5 Hz (Samii et al., 2004), is usually considered the first symptom in most PD 
patients. Tremor is usually asymmetric at disease onset and worsens with anxiety, 
contralateral motor activity, and during ambulation. Rigidity is the raised resistance noted 
during passive joint movement that is uniform throughout the range of motion of that joint. 
Rigidity usually correlates positively with resting tremor, as more pronounced rigidity is 
found in the more tremulous limb (Samii et al., 2004). Bradykinesia, the most disabling 
symptom of early Parkinson's disease, results in difficulty with fine motor tasks, such as 
closing buttons or handwriting, as well as reduced arm swing during walking (Martinez-
Martin et al., 1994). Postural instability refers to the gradual development of poor balance, 
leading to an increased risk of falls. Postural instability is rarely seen in the early stage of PD. 
After decades of effort, the underlying pathological changes in Parkinson's disease 
have been well characterized. Anatomically, the most affected portion of the brain in PD 
patients is the basal ganglia (Albin et al., 1989). The basal ganglia is a group of functionally 
related subcortical nuclei that includes the neostriatum (comprised of the caudate nucleus 
and the putamen), the ventral striatum, the Globus pallidus (GPe and GPi), the subthalamic 
nuclei (STN), and the substantia nigra pars reticulata or pars compacta (SNr and SNc). The 
dopaminergic neurons in the SNc normally project to the GABAergic neurons at the striatum 
(mainly the caudate nucleus and putamen) to form the nigrostriatal circuit. The nigrostriatal 
circuit and subsequent neuronal circuit among the striatum, thalamus, brain stem, and cortex 
are further organized into the corticobasal gangliathalamocortical circuits, which critically 
control voluntary movement (Alexander, 1990). The basal ganglia-thalamocortical circuitry 
under normal and PD conditions is shown in Figure 1. One of the output pathways of the 
striatum is the projection of the striatal neurons to the GPi (referred to as the direct pathway) 
WVL 
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STRtAtUM 
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Br*«n Kl«m< 
Spinal con) 
to inhibit G ABA release from 
the GPi to the thalamus. On the 
other hand, striatial neurons also 
project to the GPe (referred to 
as the indirect pathway) to 
subsequently stimulate the 
Figure 1. The basal ganglia-thalamocortical circuitry under normal condition RPLPASP nf HARA frnm the GPP 
and Parkinson's disease (Modified from Wichmann, 2003) release 01 U 
to the subthalamic nucleus to inhibit glutamate release from the subthalamic nucleus to the 
SNr. The dopaminergic neurons projected from the SNc to the striatum normally release 
dopamine that is bound to the dopamine receptors in the postsynaptic GABAergic neurons. 
Because of the presence of two populations of striatal neurons that contain functionally 
distinct dopamine receptors, D1 or D2, dopamine apparently has dual roles in the modulation 
of the activity of basal ganglia output neurons. Dopamine released from SNc dopaminergic 
neurons excites GABAergic neurons in the striatum to either stimulate through the D1 
receptor (in the direct pathway) or inhibit through the D2 receptor (in the indirect pathway) 
the release of the inhibitory neurotransmitter, G ABA. The balance between direct and 
indirect pathways precisely controls the output of the basal ganglia and is critical to maintain 
normal motor function (Wichmann and DeLong, 2003). 
In the early 1960s, Parkinson's disease was shown to result largely from the 
degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) of basal 
ganglia (Albin et al., 1989). Later, many other studies consistently characterized the 
progressive and selective degeneration of dopaminergic neurons in the SNc and the resulting 
depletion of dopamine in the striatum in PD patients. The depletion of dopamine in the 
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striatum leads to increased activity in the indirect pathway and decreased activity in the direct 
pathway (Wichmann and DeLong, 2003). Both of these changes contribute to increased 
activity in the GPi, which results in the increased inhibition of subsequent thalamocortical 
and midbrain tegmental neurons and thus, the hypokinetic features of the disease (Kandel et 
al., 2000). The symptoms usually appear when the loss of dopaminergic neurons in the SNc 
reaches about 80% (Albin et al., 1989). In addition to the selective degeneration of the 
dopaminergic neurons in the SNc, formation of Lewy bodies, the intracellular inclusions of 
abnormal protein aggregation, is another pathological hallmark of Parkinson's disease 
(Hardy, 2003). Lewy bodies are widely found in many regions of the brain, particularly in the 
dopaminergic neurons of the SNc, the hypothalamus, the hippocampus, and the autonomic 
neurons of the esophagus and gastrointestinal tract and occasionally in the cortex (Dauer and 
Przedborski, 2003). Although the detailed mechanisms are still under intense investigation, 
the production of excessive misfolded proteins and the compromised ubiquitin-proteasome 
system are considered to play major roles in the formation of Lewy bodies (Dauer and 
Przedborski, 2003; Huang et al., 2004). Notably, the formation of the Lewy body is not 
unique in PD; in fact, Lewy bodies are also commonly found in the postmortem brains of 
Alzheimer's and several types of dementia patients (Dickson, 2002; Hardy, 2003; McKeith et 
al., 2003), suggesting that the abnormal protein aggregation in neurons is ubiquitously 
involved in the pathogenesis of various neurodegenerative diseases. 
1-2: Pathogenesis of Parkinson's disease 
Unlike the well-characterized pathological changes in PD, the pathogenesis of PD is 
still largely unclear, though great progress has been made in the past thirty years from studies 
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of MPTP-induced Parkinsonism and the genetic mutations identified in familial PD patients. 
Because the incidence rate of PD is higher in the elder population, aging itself has long been 
considered to play a role in the pathogenesis of PD. In the central nervous system, 
dopaminergic neurons are mainly distributed in the midbrain, particularly in the SNc region. 
At birth, the SNc contains approximately 400,000 dopaminergic neurons. As age increases, 
the number of dopaminergic neurons in the SNc declines, since dopaminergic neurons in the 
SNc normally degenerate at a rate of 2,400 neurons per year (Marsden, 1990). However, the 
number of remaining dopaminergic neurons in the SNc prevents the occurrence of PD 
symptoms when the degeneration process is not abnormally accelerated. Thus, normal aging 
is certainly associated with PD and is considered one of the risk factors for PD but does not 
cause this disorder alone (Samii et al., 2004). 
1-2-1 : Environmental factors in the pathogenesis of PD 
The pathogenesis of PD was not understood until the early 1980s. In 1983, Langston 
and colleagues reported a series of patients who developed acute Parkinsonism after 
accidental exposure to 1 -methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP), a toxic 
byproduct in the clandestine synthesis of a pethidine analogue (Langston et al., 1984). These 
patients also showed significant reduction in dopaminergic neuron activity in the basal 
ganglia, as normally seen in PD patients. Because MPTP-induced Parkinsonism in humans 
faithfully replicates the pathological features seen in PD patients, mechanisms of MPTP-
induced dopaminergic neuron degeneration are under intense investigation. Numerous in 
vitro cell and in vivo animal models (including primate) have been created to study the 
mechanisms of MPTP-induced Parkinsonism (Przedborski and Vila, 2003). All these models 
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show that dopaminergic neurons are severely degenerated following MPTP exposure and 
hypokinetic symptoms develop in animals (Speciale, 2002; Vila and Przedborski, 2003). 
MPTP itself is non-toxic but can cross the brain-blood barrier to enter the brain when 
administered to humans and mammals. In the brain, MPTP is converted into l-methyl-4-
phenyl-2,3-dihydropyridinium 
(MPDP+) by monoamine oxidase 
(MAO-B) in astrocytes (Markey et al., 
1984). The MPDP+ is unstable and 
spontaneously oxidized to l-methyl-4-
phenylpyridinium (MPP+) (Dauer and 
Przedborski, 2003). The MPP+ is 
released from astrocytes and 
Figure 2. The MPTP model of Parkinson's disease (Modified from Vila, 2003) 
selectively taken into dopaminergic neurons in the SNc through dopamine transporter (DAT) 
due to its similar structure to dopamine (Mayer et al., 1986; Uhl et al., 1985). 
Once inside the dopaminergic neuron, MPP+ is concentrated within the mitochondria 
by a mechanism that relies on the mitochondrial transmembrane potential, though it can also 
be sequestered into synaptosomal vesicles by vesicular monoamine transporter 2 (VMAT2) 
(Liu et al., 1992). MPP+ impairs oxidative phosphorylation by inhibiting the multi-enzyme 
complex I of the mitochondrial electron transport chain, which rapidly results in the low 
production of ATP in the neuron (Greenamyre et al., 2001; Ramsay et al., 1986; Vila and 
Przedborski, 2003). The decrease in ATP dramatically affects many processes in the neuron. 
Meanwhile, the MPP+-induced inhibition of the complex I also induces oxidative stress by 
hampering the flow of electrons through complex I, which further triggers the mitochondria-
c>" 
MPTP] .WPP-
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dependent apoptotic pathway (Cassarino et al., 1997; Kaul et al., 2003; Viswanath et al., 
2001). MPP+ can also directly interact with cytosolic enzymes (especially with those carrying 
negative charges) through its positive charges to interfere with their normal functions 
(Klaidman et al., 1993). Furthermore, perturbations in Ca2+ homeostasis are also observed 
within hours of MPTP administration in mice (Jackson-Lewis et al., 1995). After these initial 
events, multiple apoptotic responses are induced in the SNc dopaminergic neurons, including 
up-regulation of the Bcl-2 family protein Bax (Vila et al., 2001), activation of caspase-9 and -
3 (Hartmann et al., 2000; Viswanath et al., 2001), and DNA oxidation-induced activation of 
pro-apoptic c-Jun N-terminal kinase (JNK) (Saporito et al., 2000; Xia et al., 2001), which 
eventually promotes the apoptotic death of SNc dopaminergic neurons. 
Although studies of MPP+-induced SNc dopaminergic neuronal degeneration in 
animal models (including primate) have significantly contributed to our knowledge about the 
pathogenesis of PD, humans are rarely exposed to MPP+ (or MPTP), which are not found in 
the environment. In addition, the MPP+-induced dopaminergic neuronal degeneration in 
primates and humans has some features that differ from those observed in PD patients. The 
most significant pathological difference is that formation of the Lewy body, one of the 
hallmarks in PD pathology, was not found in MPTP-treated animals (Forno et al., 1993). 
Nevertheless, the discovery that MPTP causes acute Parkinsonism in humans brings attention 
to other environmental chemicals possibly involved in the pathogenesis of PD. Because of 
the observation that MPP+ strongly inhibits the complex I of mitochondria and induces the 
elevation of ROS, other complex I inhibitors become candidates of potential risk factors for 
PD. Interestingly, almost all these complex I inhibitors are also extensively used as 
herbicides or pesticides, like rotenone, paraquat, and diquat (Jenner, 2001). Animals exposed 
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to these chemicals all show SNc dopaminergic neuron degeneration and develop PD-like 
symptoms (Betarbet et al., 2000; Giasson and Lee, 2000; Jenner, 2001; McCormack et al., 
2002). In rotenone-exposed rats, formation of the Lewy body in the SNc is also induced 
(Betarbet et al., 2000). Various case-control studies (Tanner and Ben-Shlomo, 1999; Tanner 
et al., 1989) also strongly suggest an association between exposure to pesticides and the 
development of PD. Currently, several other pesticides are also under investigation for their 
potential role in the pathogenesis of PD. One, dieldrin, is classified as one of the most 
persistent bioaccumulative and toxic (PBT) chemicals by the US EPA. It is not clear as to 
whether dieldrin also inhibits mitochondria complex I; however, several studies have 
indicated that dieldrin exposure is positively associated with the increased incidence of PD. 
The most supportive piece of evidence is that a significant level of dieldrin was detected in 
the postmortem brains of PD patients, whereas dieldrin was not found in age-matched control 
brains (Corrigan et al., 1996; Fleming et al., 1994). In addition, dieldrin exposure depletes 
dopamine in brains of ducks, rats and ring doves (Heinz et al., 1980; Wagner and Greene, 
1978). Furthermore, previous studies from our laboratory and others also showed that 
dopaminergic cells are more sensitive to dieldrin-induced toxicity (Kitazawa et al., 2001; 
Sanchez-Ramos et al., 1998). The molecular/cellular mechanisms of dieldrin-induced 
dopaminergic neuronal degeneration are being investigated in our laboratory. 
Besides pesticides, other chemicals are also suggested to be risk factors for PD. 
Heavy metals, like manganese, copper, iron, lead, and aluminum, have been reported to have 
a positive association with PD incidence in various etiological studies (Gorell et al., 1997; 
Kuhn et al., 1998; Paik et al., 1999). Interestingly, smoking, caffeine, and alcohol (not 
including wine) seem to protect against development of PD, based on case-control studies 
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(Gorell et al., 1999; Hellenbrand et al., 1996a; Hellenbrand et al., 1996b; Morens et al., 1995). 
The wide distribution of chemicals, the extensive interaction between different chemicals in 
the environment, and the exposure of humans to various sources of chemicals make tracking 
human exposure to environmental chemicals difficult. Furthermore, recognizing the risk of 
environmental chemicals and their distinct contributions to the pathogenesis of PD remain a 
challenge. 
1-2-2: Genetic mutations in the pathogenesis of PD 
Initially, genetic predisposition in the pathogenesis of PD was not fully recognized 
because most cases of PD are sporadic. An epidemiology study of 20,000 monozygote (MZ) 
and dizygote (DZ) twins showed that the concordance of PD incidence is similar between 
MZ and DZ twins, suggesting 
that genetic predisposition does 
not play a major role in the 
pathogenesis of PD (Tanner et 
al., 1999). However, recent 
identification of a number of 
genetic mutations in various 
Gene Chromosome locus Gene product Mode of inheritance 
PARK1 4q21.3 a-synudein Dominant 
PARK2 6q25.2-<|27 Parkin Recessive 
PARK3 2q13 Unknown Dominant 
PARK4 4q15 Unknown Dominant 
PARKS 4q14 UCHL1* Dominant 
PARKS 1p35-p36 PINK1" Recessive 
PARK7 1p36 DJ-1 Recessive 
PARKS 12p11.2-q13.1 LRRKY Dominant 
PARK10 1p32 Unknown Dominant 
a. Ubiquitin C-terminal hydrolase L1 ; b. RTEN-induced kinase 1; c. Leucine-rich repeat Kinase 2 
Table 1. Genes associated with familial Parkinson's disease patients 
genes in familial PD patients implicates a direct pathogenic role of genetic predisposition in 
PD (Huang et al., 2004). The genes found mutated in familial PD patients (Table 1) include 
a-synuclein, parkin, ubiquitin carboxyl-terminal hydrolase 1 (UCHL1), DJ-1, PTEN-induced 
kinase 1 (PINK1), leucine-rich repeat kinase 2 (LRRK2), and several others that have been 
mapped but not yet cloned (Dawson and Dawson, 2003; Shen, 2004). Among these genes, a-
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synuclein, parkin, and ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) are mainly involved 
in protein aggregation and the ubiquitin-proteasome system. Other genes, hke DJ-1 and 
PTEN-induced kinase 1 (PINK1), appear to be related to the oxidative stress response. The 
discovery of genetic mutations in these genes indicates a strong connection between the 
protein degradation system and oxidative stress in the pathogenesis of PD. 
The first gene implicated in the pathogenesis of PD was a-synuclein. It was first 
identified in a large Italian-American family with autosomal dominant early-onset PD. The 
missense mutation A53T was found in exon 4 of the gene (Golbe et al., 1990). This mutation 
was also found in affected members of three Greek families with PD (Polymeropoulos et al., 
1997). Since then, different mutations in a-synuclein genes have been identified in different 
families with PD, including A3 OP and E46K mutations (Kruger et al., 1998; Zarranz et al., 
2004), and triplication of the a-synuclein gene (Singleton et al., 2003). Cellular studies 
reveal that a-synuclein is concentrated at pre-synaptic terminals, and is an important 
component of the Lewy body, the major PD pathological hallmark (Spillantini et al., 1997). 
Although tremendous efforts have been made to characterize a-synuclein's function, its 
exact physiological function remains unclear (Lotharius and Brundin, 2002). Recent studies 
with a-synuclein knock-out mice suggest that a-synuclein plays a role in synaptic vesicle 
cycling (Abeliovich et al., 2000). Cultured hippocampal neurons from these mice were found 
to have fewer synaptic vesicles than control mice, particularly in the reserve pool (Cabin et 
al., 2002). These mice also showed defects in synaptic transmission after prolonged, high-
frequency stimulation. Other studies suggest that a-synuclein may function like a chaperone-
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like protein (Recchia et al., 2004) or regulate gene expression (Baptista et al., 2003; 
Lindersson et al., 2004). 
Yet, the pathogenic function of a-synuclein in PD is much better established. Full-
length a-synuclein (140aa) normally is soluble in the cell, but at high concentrations, it can 
form protofibrils that are intermediate species in the fibrillization process from monomer to 
fibril (Lotharius and Brundin, 2002). The protofibrils further form the fibrils present in Lewy 
bodies in a nucleation-dependent manner. The A53T and A3 OP mutations identified in 
familial PD patients both increase the tendency for a-synucelin to form protofibrils (Conway 
et al., 2000a; Conway et al., 2000b); however, the A3 OP mutation inhibits the further 
formation of fibrils (Conway et al., 2000c). Along with evidence from other studies, the 
protofibrils are considered to be deleterious species and are highly toxic to the neurons 
(Bucciantini et al., 2002). Notably, various post-translational modifications, including 
phosphorylation (Fujiwara et al., 2002; Lee et al., 2004; Okochi et al., 2000), glycosylation 
(Munch et al., 2000), oxidation (Przedborski et al., 2001), nitration (Hodara et al., 2004; 
Souza et al., 2000), and ubiquitination (Shimura et al., 2001), have all been found in a-
synuclein. In particular, a-synuclein deposited in the Lewy body is found to be ubiquitinated 
(Tofaris et al., 2003), suggesting these post-translational modifications are involved in the a-
synuclein protofibril and fibril formation. Indeed, oxidative dimer formation has been 
demonstrated to be the critical rate-limiting step for a-synuclein fibrillogenesis in Parkinson's 
disease (Krishnan et al., 2003). Although the mechanisms by which a-synuclein-formed 
protofibrils lead to the degeneration of dopaminergic neurons are not clear, some evidence 
suggests that the desensitization of dopamine transporter (DAT) is inhibited when a-
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synuclein becomes aggregated, resulting in massive uptake of dopamine from the synaptic 
cleft into the dopaminergic neurons and high production of oxidative species (Sidhu et al., 
2004). The a-synuclein-formed protofibrils were also reported to permeabilize the synaptic 
vesicle, causing the increase in free dopamine in the cytosol and elevation of reactive oxygen 
species (Schulz et al., 2000). In contrast to the toxic effect of protofibrils, a-synuclein-
formed fibrils are considered to be neuroprotective and neutralize the toxic effect of 
protofibrils by forming inclusion bodies (Lotharius and Brundin, 2002). 
Besides a-synuclein, parkin and UCHL1 are two other genes mutated in familial PD 
patients. Genetic mutations of parkin are mainly identified in juvenile Parkinsonism and 
other early-onset PD patients (Lucking et al., 1998). Structurally, parkin is characterized as 
one of the members of ubiquitin E3 ligase, which attaches short ubiquitin peptide chains to 
proteins and tags them for degradation through the proteasome pathway. Although mutations 
in parkin are rarely found in sporadic PD patients, parkin is also found in Lewy bodies in 
sporadic PD patients, implicating its pathogenic role in both familial and sporadic PD (Vila 
and Przedborski, 2004). The direct link between loss of parkin function and dopaminergic 
neuron degeneration has not been established. Mutated parkin loses its E3 ligase activity, and 
thus is speculated to impair the neuron's ability to degrade the misfolded proteins, 
contributing to the abnormal protein aggregation. The E3 ligase activity of parkin was shown 
to modulate the sensitivity of cells to both proteasome inhibitor- and mutant a-synuclein-
dependent cell death (Vila and Przedborski, 2004). Several studies have shown the functional 
interaction between a-synuclein and parkin. One report even showed that a 22-KDa 
glycosylated form of a-synuclein is a substrate of parkin (Shimura et al., 2001). Other than 
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glycosylated a-synuclein, several other substrates of parkin have also been identified, 
including cyclin E, synphilin-1, and parkin-associated endothelin receptor-like receptor 
(Chung et al., 2001; Imai et al., 2001; Zhang et al., 2000); however, none of these substrates 
shows enriched expression in dopaminergic neurons or plays a particularly important role in 
dopaminergic neurons. It remains unknown how the loss of parkin function selectively leads 
to the degeneration of the SNc dopaminergic neurons. UCHL1 is another enzyme involved in 
the proteasome system. This enzyme catalyzes the hydrolysis of C-terminal ubiquityl ester to 
release ubiquitin from degraded protein and recycle it in the proteasome system. Current 
studies on UCHLl's pathogenic role in PD are inconclusive (Vila and Przedborski, 2004). 
The I93M mutation identified in PD patients decreases the activity of UCHL1; however, 
UCHL1 knock-out mice do not display dopaminergic neuronal degeneration, suggesting that 
the loss of UCHL1 function can be compensated for in vivo (Saigoh et al., 1999). Recently, 
UCHL1 was demonstrated to also have ubiquitin ligase activity upon dimerization, which 
might be related to its pathogenic role in PD (Liu et al., 2002). 
A number of other genes are being examined as genetic risk factors in PD, including 
genes involved in dopamine synthesis and metabolism, neurotrophic factors, genes involved 
in energy supply and oxidative stress response, genes involved in detoxification of 
metabolites, and genes involved in the maturation of dopaminergic neurons during 
development (Huang et al., 2004). It is highly likely that multiple mechanisms are present for 
the pathogenesis of PD as a result of the combinational effect of different genetic mutations 
and exposure to environmental chemicals. This complicates the development of a universal 
strategy to delay or cure PD, but could provide more targets for development of drugs which 
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specifically and effectively prevent degeneration of dopaminergic neurons involving 
different mechanisms and delay the further development of symptoms in PD patients. 
II. Vulnerability of substantia nigra pars compacta (SNc) dopaminergic neurons in 
Parkinson's disease 
In Parkinson's disease, dopaminergic neurons are most severely degenerated, though 
the degeneration of noradrenergic neurons (locus coeruleus), serotonergic neurons (raphe), 
and cholinergic neurons (nucleus basalis of meynert, dorsal motor nucleus of vagus, and 
cerebral cortex) is also observed (Dauer and Przedborski, 2003). In particular, the 
dopaminergic neurons in the SNc region are selectively degenerated, though dopaminergic 
neurons are predominantly localized not only in the SNc but also in the ventral tegmental 
area (VTA) and the retrorubral field of the midbrain (Korotkova et al., 2004; Riddle and 
Pollock, 2003). Within the SNc region, the degeneration of dopaminergic neurons is also not 
uniform. Dopaminergic neurons localized in the caudal, ventral, and lateral regions are more 
vulnerable than those in the rostral, dorsal, and medial regions (Gonzalez-Hernandez et al., 
2004; Hirsch et al., 1997). It is clear that some groups of the SNc dopaminergic neurons are 
more vulnerable to the same level of environmental insults or same degree of comprise from 
genetic mutations. Different inherent factors in dopaminergic neurons have been implicated 
in selective vulnerability. 
II-1 : Dopamine metabolism and vulnerability of dopaminergic neurons 
Dopamine, a catecholamine, is the specific neurotransmitter synthesized in and 
released from dopaminergic neurons. At the pre-synaptic terminal projected from 
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dopaminergic neurons, dopamine is synthesized from two steps of enzymatic reaction. 
Tyrosine is first converted to L-3,4-dihydroxyphenylalanine (L-dopa) by tyrosine 
hydroxylase (TH) and then to dopamine by aromatic amino acid decarboxylase (AADC) 
(Kandel et al., 2000). Synthesized dopamine is usually sequestered into vesicles for storage 
by vehicle membrane associated transporter 2 (VMAT2) and released to the synaptic cleft 
upon stimulation. The released dopamine is either bound by dopamine receptors residing on 
the membrane of post-synaptic neurons or reuptaken by dopamine transporter (DAT) on the 
pre-synaptic membrane. 
Dopamine (DA) itself has been shown to be one of the inherent factors that 
contributes to the susceptibility of dopaminergic neurons in PD (Carlsson and Fornstedt, 
MAO 1991; Hirsch et al., 1997). The metabolism 
DA + 02 + H,0 I DAPAC + NH, + H,0, 
DA+O, > SQ +02-+2W of dopamine and generation of reactive 
SOD 
DA + 02- + 2H* • SQ+HA . 
oxygen species is illustrated in Figure 3. 
HJOJ+FE2* » OH" + OH" + FE* 
H,o,*2GSH GPX , GSSG+2h2O Free cytosolic dopamine can auto-oxidize 
Figure 3. Dopamine metabolism and generation of reactive , - TT . , , , 
oxygen species (ROS) at normal pH into toxic dopamme-quinone 
species (SQ ), superoxide radicals (O2 "), and hydrogen peroxide (H2O2) (Graham, 1978; 
Lotharius and Brundin, 2002). Dopamine-quinone species can directly mediate modification 
of a-synuclein, which promotes its protofibril formation (Conway et al., 2001). Superoxide 
radicals are further converted into hydrogen peroxide by superoxide dismutase (SOD). 
Alternatively, dopamine is deaminated by monoamine oxidase (MAO) into 3, 4-
dihydroxyphenylacetic acid (DO?AC) and hydrogen peroxide (Maker et al., 1981). Although 
hydrogen peroxide itself is innocuous and is usually converted into water while glutathione 
(GSH) is oxidized to glutathione disulfide (GSSG) by glutathione peroxidase, it can also be 
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broken down into cytotoxic hydroxyl radicals in a reaction involving Fe2+ (Halliwell, 1992). 
More vulnerable dopaminergic neurons have lower expression of glutathione peroxidase than 
neurons preserved in PD (Damier et al., 1993), which suggests that more cytotoxic hydroxyl 
radicals are generated in those neurons. All these reactive oxygen species directly cause lipid 
peroxidation and protein or DNA oxidation, which in turn leads to the loss of normal enzyme 
function or membrane integrity. Because of the deleterious nature of the metabolism of 
dopamine, SNc dopaminergic neurons are more exposed to oxidative stress. Indeed, several 
studies have demonstrated that oxidative stress is more severe in the SNc region of PD brains, 
as indicated by lipid peroxidation and protein or DNA oxidation (Dexter et al., 1989; Floor 
and Wetzel, 1998; Jenner, 1998). 
The deleterious nature of the metabolism of dopamine necessitates tight control of the 
free dopamine level in the cytosol. The cytosolic level of dopamine depends on its synthesis 
and two transport processes mediated by DAT or VMAT2, respectively. Tyrosine 
hydroxylase (TH) is the key enzyme that catalyzes the rate-limiting reaction for 
catecholamine biosynthesis, including dopamine (Ramsey and Fitzpatrick, 2000). The 
activity of TH is regulated by its serine phosphorylation status and feedback inhibition of 
synthesized catecholamines in competition with tetrahydrobiopterin, the cofactor for TH 
(Nagatsu, 1995). The phosphorylation of different serine residues (Serl9, Ser31, and Ser40) 
on TH has been shown to increase its activity (Dunkley et al., 2004). Various 
Serine/Threonine kinases, including cAMP-dependent protein kinase A (PKA) (Lovenberg et 
al., 1975), cGMP-dependent protein kinase G (PKG) (Roskoski et al., 1987), protein kinase 
C (PKG) (Albert et al., 1984), Ca2+-calmodulin dependent protein kinase II (CaMKII) 
(Vulliet et al., 1984), extracellular signal-related kinase (ERKl/2) (Sutherland et al., 1993), 
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and the recently identified cyclin-dependent protein kinase 5 (Cdk5) (Moy and Tsai, 2004) 
are responsible for mediating the phosphorylation of different serine residues on TH. 
However, none of these kinases were shown to selectively phosphorylate TH to increase its 
activity and subsequent dopamine synthesis in different groups of dopaminergic neurons in 
the brain. It is also unknown whether TH activity is dramatically changed during the 
pathogenesis of PD. Moreover, previous studies have shown that no expression change in TH 
was found in postmortem brains of age-matched control subjects and PD patients. Studies on 
the differentiation of dopaminergic neurons in rodent brain development also show that TH 
expression is uniform in different groups of dopaminergic neurons and constant from the 
time TH expression is induced through adulthood (Simon et al., 2003). In contrast, DAT and 
VMAT2, two transporters involved in the uptake of dopamine from the synaptic cleft into the 
neuron and in sequestration of free dopamine from the cytosol into the vesicle, respectively, 
show significantly different expression patterns in different groups of dopaminergic neurons. 
DAT is only expressed in the dopaminergic neurons. It localizes on the plasma 
membrane to uptake released dopamine, thus regulating the intensity and duration of 
dopaminergic neurotransmission at the synapse. The expression pattern of DAT in different 
dopaminergic neurons is closely related to the neuronal vulnerability in PD. Immunostaining 
revealed that DAT has the highest expression in the caudal, ventral, and lateral regions of the 
SNc in monkey brains and postmortem brains of PD patients (Gonzalez-Hernandez et al., 
2004; Hitri et al., 1994). Likewise, dopaminergic neurons in these regions have the most 
severe loss in PD. The intensity of DAT staining decreases dramatically in the dorsal region 
of SNc and the VTA region. A similar pattern was also shown by in situ hybridization in rat 
(Sanghera et al., 1997; Uhl, 1998). More DAT in the plasma membrane could uptake more 
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dopamine and cause increased production of cytotoxic metabolites of dopamine. In addition 
to its uptake of dopamine into the dopaminergic neurons, DAT can also selectively uptake 
some toxic chemicals into dopaminergic neurons, like MPP+, 6-hydroxydopamine (6-OHDA), 
isoquinoline derivatives, and (3-carboline derivatives because of their structural similarity to 
dopamine (Storch et al., 2004). Since humans are widely exposed to environmental 
chemicals, more DAT on the plasma membrane of dopaminergic neurons facilitates certain 
neurotoxin entry into dopaminergic neurons, thus increasing their susceptibility to 
degeneration. The expression of DAT in neurons that lack DAT confers these neurons 
susceptibility to MPP+-induced toxicity (Gonzalez-Hernandez et al., 2004). The effect of 
DAT on the vulnerability of dopaminergic neurons has also been demonstrated in DAT 
knock-out or transgenic mice. In DAT heterozygous mice that express about one-half of the 
normal level of DAT, acute dopaminergic toxicity induced by MPTP is reduced to about one-
half of that found in wild-type mice (Gainetdinov et al., 1997). In the DAT overexpressed 
mice, DAT expression is increased over 130%; however, dopaminergic neurons become 
more vulnerable and 70% more dopaminergic neuronal loss is observed in comparison to that 
in wild-type control mice following MPTP treatment (Uhl, 1998). 
In contrast to the higher expression of DAT, vesicle membrane associated transporter 
2 (VMAT2) has a lower expression level in the more vulnerable dopaminergic neurons. 
VMAT2 is expressed in the monoaminergic neurons. Immunoelectron microscopy reveals 
that VMAT2 protein is more abundant in the processes of neurons of the VTA than in those 
of the SNc (Nirenberg et al., 1996). This was also observed by in situ hybridization of 
VMAT2 (Peter et al., 1995). Because VMAT2 can sequestrate dopamine into vesicles so that 
less cytotoxic metabolites of dopamine are produced, higher expression of VMAT2 is 
22 
considered to be protective and reduces the susceptibility of dopaminergic neurons to 
oxidative stress. Like DAT, VMAT2 can also sequestrate not only dopamine but also other 
toxic chemicals structurally similar High DAT expression Low VMAT2 expression 
More free cytosolic 
dopamine 
Auto-
oxidation or 
enzymatic 
reaction 
Elevated ROS generation 
More vulnerable DA neuron 
Low level of Glutathione 
peroxidase (Gpx) 
Figure 4. Regulation of free cytosolic dopamine level and the vulnerability 
of dopaminergic neurons 
to dopamine, like MPP+, into the 
vesicles. The neuroprotective 
effect of VMAT2 is supported by 
studies demonstrating that genetic 
or pharcological blockade of 
VMAT2 makes dopaminergic 
neurons more vulnerable to 
neurotoxins (Gainetdinov et al., 1998; Spéciale et al., 1998). The heterozygous mice that 
express one-half the normal levels of VMAT2 show more than twice as much MPTP-induced 
dopaminergic neuronal loss than that in wild-type mice (Takahashi et al., 1997). Based on 
the relationship between the vulnerability of dopaminergic neurons and the expression level 
of DAT and VMAT2, the ratio between DAT and VMAT2 expression levels may determine 
the susceptibility of dopaminergic neurons to degeneration (Edwards, 1993; Miller et al., 
1999; Uhl, 1998). 
II-2: Neuromelanin, iron and the vulnerability of dopaminergic neurons 
Dopaminergic neurons are the most highly pigmented cells in the human brain 
because of the preferential presence of neuromelanin (NM). Neuromelanin is an electron-
dense substance that locates in the NM granules characterized as organelles surrounded by a 
double membrane in the neuronal perikaryon (Zecca et al., 2001). NM is only present in 
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primates, like the chimpanzee, gibbon and human. The proposed connection between NM 
and the vulnerability of dopaminergic neurons is based on the observation that melanized 
dopaminergic neurons are the most severely degenerated, whereas non-melanized 
dopaminergic neurons are preserved in PD (Hirsch et al., 1997). 
Although it is not entirely clear, NM synthesis appears to be related to dopamine 
oxidation. Employing a chemical approach, a dopamine-NM compound was synthesized by 
the auto-oxidation of dopamine 
A (Double et al., 2002). Alternatively, 
—» ******** NM could be derived from quinones 
_ Cysteine 
- CyKt^ nyl-rJopamlne* 
or semiquinones, the oxidized 
Figure 5. Synthesis of Neuromelanin (NM) (Modified from Zecca, 2003) , . 
metabolite of dopamine with addition 
of a thiol group in mammalian brains (Fomstedt et al., 1986). NM synthesis was also 
experimentally induced in cultured rat substantial nigra neurons exposed to L-dopa (Sulzer et 
al., 2000). The experimental NM synthesis in rat neurons was blocked by overexpression of 
VMAT2, suggesting that an excess of cytosolic dopamine indeed contributes to the synthesis 
of NM (Liang et al., 2004). Although the pigmented dopaminergic neurons are consistently 
observed to be the most highly degenerated in PD, current knowledge about the effect of NM 
in the vulnerability of dopaminergic neurons is still contradictory. 
Because NM synthesis involves dopamine oxidation, more production of NM leads to 
the generation of a greater amount of free radicals during the oxidation of dopamine, which 
increases neuronal susceptibility (Double et al., 2002). Other evidence for its positive 
correlation with the vulnerability of dopaminergic neurons is that released NM from 
normally degenerated dopaminergic neurons during aging can stimulate release of the 
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neurotoxic mediators, including tumor-necrotic factor a (TNF-a), interleukin 6 (IL-6), and 
nitric oxide (NO) from microglia (Wilms et al., 2003). These factors potentially lead to a 
subsequent aggravation of neurodegeneration. Very recently, NM was shown to inhibit the 
enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells (Shamoto-
Nagai et al., 2004). Since abnormal proteasome activity has been strongly implicated in the 
pathogenesis of PD, preferential localization of NM in dopaminergic neurons and its 
inhibition of 26S proteasome activity could significantly contribute to the vulnerability of 
dopaminergic neurons in PD. 
On the other hand, the neuroprotective role of NM has also been suggested. The 
derivation of NM from quinones reduces the cytosolic level of quinones and prevents their 
potential damage to the neuron. In addition, NM can bind to toxins like MPP+ and a variety 
of metals, including Zn, Cu, Mn, Cr, Co, Hg, 
Pb, Cd, and in particular, Fe (Zecca et al., 
1994; Zecca et al., 1996). The accumulation of 
these metals and toxins in NM is considered to 
be protective, as the binding effectively 
inactivates their activity, thus significantly 
reducing their damage to the neuron. For example, the binding of NM to iron keeps it 
inactive and inhibits the production of hydroxyl radicals involving redox-active iron and 
hydrogen peroxide (Zareba et al., 1995). However, the protective NM can become cytotoxic 
depending on the cellular level of these metals and toxins, at least in the case of iron, as 
discussed below. With its binding ability to a variety of metals and toxic chemicals, NM is 
neuotoxic 
•NT» TNFt <v«j 
MvIiTôfabûn 
cfmKfcgka \ 
Figure 6. Possible role of NM in the pathogenesis of PD 
(Modified from Zecca, 2003) 
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speculated to act as a high capacity "waste handling center" to transport metals and toxins to 
lysosomes for their eventual degradation (Zecca et al., 2003). 
Iron is another factor relevant to the vulnerability of dopaminergic neurons. The 
increase in iron content (30-35%) only in the SNc has consistently been found in both 
postmortem Parkinsonian brains and in living patients by imaging techniques (Good et al., 
1992; Jellinger, 2000; Sofic et al., 1991). The regional increase in iron has also been reported 
in other neurodegenerative diseases, like Huntington's and Alzhemer's disease (Connor et al., 
1992; Smith et al., 1997). Very interestingly, the topographical distribution of the increased 
iron matches well with the degenerated regions in these disorders, suggesting a ubiquitous 
role of iron in the vulnerability of different neurons in different disorders (Double et al., 
2002). Although the mechanisms for the selective increase in iron in specific regions remain 
unclear, the increase in iron in the SNc is suggested to be partially due to the high amount of 
NM present in dopaminergic neurons, as iron accumulates in NM granules (Sofic et al., 
1991). 
Redox-active iron is potentially harmful to cells, as it is actively involved in the 
generation of hydroxyl radicals from superoxide or hydrogen peroxide. Thus, the selective 
elevation of iron in the SNc could promote the higher production of the hydroxyl radicals, 
making neurons more exposed to the oxidative stress. In addition, the effect of iron on the 
vulnerability of the SNc dopaminergic neurons is related to its cellular level and association 
with NM. When the cellular iron concentration is not high, NM can almost sequestrate all the 
iron into the granules, resulting in less free radical generation and an antioxidant effect; 
however, when the cellular iron concentration exceeds the threshold that NM can sequestrate, 
generation of free radicals is increased with increasing iron concentration (Zareba et al., 
1995). Interestingly, NM also appears to become a pro-oxidant in the presence of high iron 
concentrations, resulting in a measurably increased production of hydroxyl radicals measured 
with electron spin resonance (Pilas et al., 1988). Because of the dual effect of NM, when 
iron is selectively elevated in the SNc region due to unknown mechanisms, higher levels of 
cellular iron could be involved in the greater production of free radicals not only by itself but 
also by its modification of NM from neuroprotective to cytotoxic, resulting in the increased 
vulnerability of dopaminergic neurons. Still, many questions related to the effect of NM and 
iron on the vulnerability of SNc dopaminergic neurons remain unanswered. For example, are 
NM structure and properties modified in Parkinsonian brains (Lopiano et al., 2000)? How 
exactly does iron switch NM from anti-oxidant to pro-oxidant? What are the mechanisms 
responsible for the selective elevation of iron in the SNc? The development of new 
experimental tools and a model system are needed to answer these questions. 
II-3: Calbindin D28K and the vulnerability of dopaminergic neurons 
Calbindin-D28K (CB) is one of the Ca2+ binding proteins expressed in neurophils of 
the SNc and other regions of the brain (Andressen et al., 1993). The association between CB 
and the vulnerability of dopaminergic neurons is suggested from the observation that CB-rich 
dopaminergic neurons are much better preserved than CB-poor dopaminergic neurons in the 
SNc region in PD (Damier et al., 1999a, b). Based on the immunostaining pattern of CB, the 
SNc of the PD brain is subdivided into a CB-rich nigra matrix region and five CB-poor 
nigrosomes embedded in the matrix (Damier et al., 1999a). The examination of dopaminergic 
neuron loss by TH staining in these brains correspondingly reveals that the loss of 
dopaminergic neurons in the nigrosomes is significantly higher than the loss of dopaminergic 
neurons in the matrix. Even within the five nigrosomes, the degree of dopaminergic neuron 
loss is not uniform. The mechanisms of CB's selectively high expression in some groups of 
dopaminergic neurons are unknown; however, neurotrophic factors have been suggested to 
increase CB expression in neurons and further reduce the vulnerability of these neurons to 
degeneration induced by various insults (Alexi and Hefti, 1996; Cheng and Mattson, 1991; 
Prehn et al., 1994). The up-regulation of CB and its protective role is also shown in the 
cadmium-adapted U937 cells. Up-regulation of CB by cadmium was suggested to maintain 
intracellular Ca2+ homeostasis and confer resistance to Ca2+ rise-induced apoptosis in U937 
cells (Jeon et al., 2004). Although the protective role of CB has been characterized in vitro, 
the CB knock-out mice did not differ significantly in the MPTP-induced loss of 
dopaminergic neurons in comparison to the CB wild-type mice (Liang et al., 1996). It is still 
debatable as to whether the high expression of CB is directly related to the protective effect 
or is only a phenomenon observed simultaneously as other molecules are performing the real 
protective actions. 
These studies indicate that the expression levels of molecules involved in the 
regulation of free cytosolic dopamine and dopamine-induced oxidative stress are closely 
associated with the vulnerability of dopaminergic neurons in PD. It is very likely that 
expression levels of other molecules sensitive to oxidative stress also contribute to the 
vulnerability of dopaminergic neurons. In addition to the oxidative stress, proteasome 
dysfunction, activation of microglia and inflammation, and glutamate excitatory toxicity are 
also implicated in the pathogenesis of PD (Mattson, 2000; Vila and Przedborski, 2003). The 
expression levels of molecules involved in these systems, for example, selectively high 
expression of a cytotoxic substrate for proteasome, could potentially contribute to the 
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vulnerability of dopaminergic neurons. Studies investigating the vulnerability of 
dopaminergic neurons will provide important insights into the distinct pathogenic 
mechanisms of PD and help to identify selective targets for the development of 
neuroprotective drugs. 
III. Apoptosis in Parkinson's disease 
Apoptosis is a genetically regulated form of cell death that critically controls 
embryonic development and maintains tissue homeostasis in adults (Meier et al., 2000). The 
machinery regulating apoptosis is evolutionarily conserved from lower organisms, like C. 
elegans and Drosophila, to higher mammalians, like mice and humans (Aravind et al., 2001). 
Dysfunctional regulation of apoptosis in development and tissue homeostasis has been 
implicated in many human diseases, including cancer, neurodegenerative diseases, and 
autoimmune disease, etc. (Nijhawan et al., 2000; Yuan and Yankner, 2000). For the past 
twenty years, many genes involved in the regulation and execution of apoptosis have been 
identified, and the biochemical mechanisms of apoptosis have been well characterized. 
III-l : Signal transduction in apoptosis 
Apoptotic signaling was first identified in studies of programmed cell death in C. 
elegans. In the early 1990s, three apoptosis related genes, CED-3, CED-4, and CED-9, were 
first cloned by H.R. Horvitz and colleagues from C. elegans (Metzstein et al., 1998). Since 
then, major groups of regulators and executioners of apoptosis have been cloned across 
different species, including ligands and death receptors, adaptors, cysteinyl aspartate-specific 
proteases (caspases, including initiator caspases and effector caspases), B cell leukemia (Bel) 
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family proteins, non-caspase protease, etc. (Strasser et al., 2000). These regulators and 
executioners are coordinately involved in three major apoptotic signaling pathways: the 
extrinsic (receptor-mediated) or intrinsic (mitochondria-mediated) pathways and the caspase-
independent pathway (see Figure 7) (Orrenius et al., 2003). 
The extrinsic pathway mainly mediates apoptotic signals from the extracellular 
environment. The ligands, like Fas or TNF-related apoptosis-inducing ligand (TRAIL), bind 
to the death receptor and form the death-inducible signaling complex (DISC), resulting in the 
activation of pro-caspase-8, one of the initiator caspases (Chinnaiyan et al., 1995; Medema et 
al., 1997). The pro-caspase-8 directly activates pro-casapse-3 by cleavage, which 
subsequently cleaves target proteins in the cell, leading to cell death. The intrinsic apoptotic 
pathway is triggered by damage inside the cell and is mainly mitochondria centered (Wang, 
2001). Specific damage sensors located on different organelles detect the damage caused by 
either the external agents or internal dysfunction of physiological processes in the cells. Such 
damage includes toxins-induced loss of mitochondrial membrane integrity or elevation of 
reactive oxidative species, DNA-damaging agents or irradiation-induced DNA damage in the 
nucleus, abnormal protein folding or perturbations of calcium homeostasis in the 
endoplasmic reticulum (ER), etc. (Ferri and Kroemer, 2001). After the detection of damage 
by organelle-specific sensors, apoptotic signals are transmitted to the mitochondria and 
trigger the intrinsic pathway. The initial and most important steps in the intrinsic pathways 
are the release of cytochrome C. Cytochrome C normally resides in the inner membrane 
space of the mitochondria and is involved in oxidation phosphorylation, but becomes an 
apoptosome recruiting molecule in apoptosis (Li et al., 1997). Although not entirely clear, 
several models have been proposed to explain the release of cytochrome C from 
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mitochondria. Among these models, oligomerization of pro-apoptotic and anti-apoptotic 
members in the Bcl-2 family and their translocation to the outer membrane of mitochondria 
play critical regulatory roles (Vander Heiden and Thompson, 1999). The released 
cytochrome C recruits apoptosis protease activating factor 1 (Apaf-1) and pro-caspase-9 to 
form apoptosome, causing the activation of pro-caspase-9 and subsequent activation of pro-
caspase-3 by activated caspase-9 mediated cleavage (Li et al., 1997). 
Besides Bcl-2 family proteins, many other apoptosis regulators and regulatory roles in 
this pathway have also been characterized, including inhibitor of apoptosis proteins (IAP) as 
inhibitors of caspases (Srinivasula et al., 2001), and second mitochondrial activator of 
caspases (Smac) and Omi as negative regulators of IAPs (Du et al., 2000; Hegde et al., 2002), 
pro-thymosin-a (Pro-T) and the tumor suppressor putative HLA-DR-associated protein 
(PHAP) as regulators of apoptosome (Jiang et al., 2003). Moreover, caspase-independent 
mechanisms are also present in the intrinsic pathway. At least two proteins, apoptosis 
inducing factor (AIF) (Susin et al., 1996) and endonuclease G (EndoG) (Li et al., 2001) are 
released from mitochondria and translocate to the nucleus, inducing the appearance of 
chromatin condensation and DNA fragmentation, hallmarks of apoptosis. 
The extrinsic and intrinsic apoptotic pathways are connected. In the extrinsic 
pathway, as an alternative to caspase-8 mediated activation of caspase-3, caspase-8 can 
cleave Bid and induce its oligomerization with anti-apoptotic Bcl-2/xl followed by its 
translocation to the mitochondria, allowing oligomerization and insertion of pro-apoptotic 
Bax/Bak into the mitochondrial outer membrane to induce pore formation at the 
mitochondria and subsequent release of cytochrome C (Schmitz et al., 1999). Moreover, 
extensive cross-talks are present among different organelle-specific apoptotic pathways, 
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which allow different organelles to coordinately respond to apoptotic signals (Ferri and 
Kroemer, 2001). Caspase-3 activation is the central step in both the extrinsic and intrinsic 
apoptotic pathways. Activated caspase-3 cleaves various substrates that contain the DXXD 
tetrapeptide motif (Grutter, 2000; Nicholson and Thornberry, 1997). Cleavage of these 
substrates leads to the release of activated DNase (Enari et al., 1998), inactivation of 
enzymes for cell survival (Itoh and Horio, 2001), collapse of nuclear envelope structure 
(Buendia et al., 1999), and amplification of apoptotic signals (Leverrier et al., 2002), which 
globally accelerates the death process. 
In addition to the extrinsic and intrinsic pathways that exert caspase-3 as the major 
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Figure 7. Major signal transduction pathways in apoptosis (Modified from Orrenius, 2003) 
executioner, the noncaspase protease-mediated apoptotic pathway has also been described in 
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some cells. Noncaspase proteases characterized so far include cathepsins, calpains, and 
granzymes (Johnson, 2000). The Granzyme A (GrA)-mediated apoptotic pathway in the 
target cells, as employed by cytotoxic T lymphocytes (CTLs) and natural killer cells to 
defend against viruses and parasitic agents, has been well characterized (Beresford et al., 
2001; Fan et al., 2003). In this pathway, serine protease Granzyme A and the membrane pore 
formation protein perforin are secreted from CTLs or natural killer cells and enter into target 
cells through the perforin formed membrane pore (Liu et al., 1995). After entering the target 
cells, Granzyme A starts to cleave the inhibitor of GrA-activated DNase (IGAAD) protein 
complex that normally inhibits the endonuclease involved in the formation of single-stranded 
DNA nicks in the target cells. The GrA-mediated cleavage of the IGAAD complex releases 
GrA-activated DNase (GAAD), which further translocates to the nucleus and induces DNA 
strand break (Beresford et al., 2001; Fan et al., 2003). 
III-2: Apoptosis of nigral dopaminergic neurons in Parkinson's disease 
Apoptosis is not only a physiologically important process in neurogenesis; the 
aberrations in apoptosis control also contribute to the pathogenesis of a variety of 
neurological disorders, including Parkinson's disease (Mattson, 2000; Yuan and Yankner, 
2000). To demonstrate that dopaminergic neurons undergo apoptosis in PD, the apoptotic 
hallmarks were detected in postmortem brains of PD patients. By using the TdT-mediated 
dUTP digoxigenin nick end labeling (TUNEL) technique, apoptotic dopaminergic neurons 
were found in some Parkinsonian brains (Mochizuki et al., 1996). Subsequent studies, using 
other apoptotic characteristics, either succeeded or failed to detect apoptotic dopaminergic 
neurons in postmortem PD brain samples (Vila and Przedborski, 2003). In addition to the 
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apoptotic hallmarks, expression changes in key regulators or activation of key executioners 
in apoptotic pathways have also been observed. For example, a higher expression level of 
Bax, one of the pro-apoptotic Bcl-2 family proteins, was found in the SNc dopaminergic 
neurons of postmortem PD brains as compared to control brains (Hartmann et al., 2001a); 
increased activity of both initiator caspases, caspase-8, -9, and the effector caspase, caspase-3, 
have been observed in postmortem PD brains (Hartmann et al., 2000; Hartmann et al., 2001b). 
Because most SNc dopaminergic neurons in postmortem PD brains are usually degenerated 
at the time of pathological evaluation, the direct detection of apoptotic dopaminergic neurons 
in the postmortem PD brains is difficult and hard to reproduce. 
Numerous in vivo and in vitro models have been developed to investigate the 
mechanisms of MPP+-induced degeneration of dopaminergic neurons after MPP+ was found 
to cause degeneration of the SNc dopaminergic neurons and to induce acute Parkinsonism in 
humans. The establishment of these models also facilitates the investigation of the 
involvement of apoptosis in SNc dopaminergic neuron degeneration. In MPTP-administered 
mice, alteration of energy metabolism, generation of reactive oxygen species (Zarranz et al.), 
and perturbations in Ca2+ homeostasis were observed and suggested as upstream events to 
trigger various downstream apoptotic pathways (Vila and Przedborski, 2003). In this model, 
the pro-apoptotic Bax is strongly up-regulated (Vila et al., 2001), whereas anti-apoptotic Bcl-
2 is down-regulated (Sharma and Ebadi, 2003). The recruitment of the intrinsic apoptotic 
pathway and subsequent activation of caspase-9 and caspase-3 are also characterized 
(Viswanath et al., 2001). In addition to the intrinsic apoptotic pathway, the extrinsic 
apoptotic pathway is also recruited in the degeneration of SNc dopaminergic neurons, as 
caspase-8 is activated in MPTP-administered mice (Hartmann et al., 2001b; Viswanath et al., 
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2001). The activation of both intrinsic and extrinsic apoptotic pathways is also observed in 
PD models developed using other neurotoxins or genes involved in familial PD, suggesting 
apoptosis is a fundamental mode of cell death in the degeneration of SNc dopaminergic 
neurons in PD (Lev et al., 2003; Tatton et al., 2003). 
IV. Involvement of serine/threonine protein kinases in apoptotic signaling and 
neurodegenerative diseases 
Serine/threonine phosphorylation of a wide range of apoptotic components, including 
major apoptotic regulators (Bcl-2 family proteins), executioners (caspases), organelle-
specific stress sensors, various effectors downstream of caspase activation, and apoptosis-
involved transcriptional factors, have been found in different systems. The serine/threonine 
phosphorylation of apoptotic components dramatically modulates their pro- or anti-apoptotic 
property to either promote or inhibit the apoptotic process (Cross et al., 2000b). 
IV-1: Survival and apoptotic serine/threonine kinases in the apoptotic signaling 
Many upstream serine/threoine protein kinases responsible for phosphorylation have 
been identified and categorized as either survival or apoptotic kinases based upon the effect 
of phosphorylation on these apoptotic components. Survival kinases mainly include protein 
kinase B (PKB, also known as Akt), full-length P21-activated protein kinase 2 (PAK-2), 
extracellular signal-related kinase (ERK), pp90 ribosome S6 kinase (Rsk), and a, (31, s 
isoforms of protein kinase C (PKCa, PKCJ3I, PKCs). PKB, PAK-2, ERK, and Rsk all can 
phosphorylate Bad, one of the pro-apoptotic members in the Bcl-2 family, causing its binding 
to chaperone protein 14-3-3 and blocking its translocation to mitochondria and induction of 
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cytochrome C release (Bonni et al., 1999; Scheid and Duronio, 1998; Yuan and Yankner, 
2000). ERK and Rsk also phosphorylate transcription factor cAMP response element binding 
protein (CREB) to further induce expression of survival genes (Bonni et al., 1999; Yuan and 
Yankner, 2000). In addition, PKB can phosphorylate caspase-9 to reduce its activity 
(Cardone et al., 1998). It also can phosphorylate Forklhead transcription factor (FKHRL) to 
inhibit transcription of death-inducing genes like Fas ligand (Brunet et al., 1999). Besides the 
mitochondrial apoptotic pathway, phosphorylation of the elongation factor 2a (eIF2a) by 
ER-resident type I transmembrane protein kinase (PERK) in the ER, in response to the 
accumulation of unfolded proteins in the ER, shuts down the translation before the 
degradation of all unfolded proteins and protects cells against unfolded proteins-induced 
apoptosis (Ferri and Kroemer, 2001; Kadowaki et al., 2004). 
Apoptotic kinases promoting apoptosis mainly include C-Jun N-terminal kinases 
(JNKs), p38 mitogen-activated protein (MAP) kinase, apoptosis signal-regulating kinase 1 
(ASK1), mammalian sterile 20-like kinase (Mst), and 8, 9 isoforms of protein kinase C 
(PKC5, PKC0). In particular, JNK/p38 MAP kinase and ASK1 all belong to the MAP kinase 
family and are major kinases involved in the stress-induced apoptotic signaling (Davis, 2000; 
Matsuzawa and Ichijo, 2005). ASK1 is one of the very upstream kinases in the MAP kinase 
family that mediates activation of INK and p38 after its activation by oxidative stress, the 
extracellular death signal TNF or Fas ligand, or ER stress (Matsukawa et al., 2004; Takeda et 
al., 2003). INK is involved in both the mitochondrial-mediated intrinsic and death-receptor-
mediated extrinsic apoptotic pathways. In the intrinsic pathway, activation of INK is required 
for stress-induced release of cytochrome C, but the exact mechanism is not yet clear 
(Toumier et al., 2000). However, both Bcl-2 and Bcl-xl, two anti-apoptotic members in the 
Bcl-2 family, have been found to be phosphorylated by JNK in vitro, and the phosphorylation 
inhibits their anti-apoptotic property (Maundrell et al., 1997; Yamamoto et al., 1999), which 
might be one of the mechanisms for JNK's function in the induction of stress-induced release 
of cytochrome C. JNK's involvement in the extrinsic pathway is linked to the ER unfolded 
protein-induced apoptotic signaling. Unfolded proteins in the ER bind to the ER chaperone 
Bip/Grp78, resulting in the dissociation of Bip to the Irel-a, a transmembrane ER 
serine/threonine kinase, and its auto-activation (Katayama et al., 1999). The activation of 
Irel-a recruits the cytosolic adapter protein TRAF2, leading to activation of the upstream 
kinase ASK1 and subsequent activation of JNK (Urano et al., 2000). MAP kinase p38 is 
usually activated along with JNK and also mediates stress-induced apoptotic signaling 
(Takeda et al., 2003). 
Mst kinase is in another apoptotic kinase family. The pro-apoptotic function of Mst is 
related to the JNK/p38 MAP pathway, as different genetic analyses have suggested that Mst 
acts upstream of JNK/p38 MAP kinase to directly activate JNK/p38 MAP kinase (de Souza 
and Lindsay, 2004). In addition, Mst can also be proteolytically activated by activated 
caspase-3 and translocate to the nucleus, mediating phosphorylation of histone H2B and 
facilitating chromatin condensation (Cheung et al., 2003; Lee et al., 2001; Lee and Yonehara, 
2002). The pro-apoptotic function of apoptotic kinases has been extensively demonstrated by 
genetic analysis in cells or knock-out mice; however, biochemical mechanisms of these 
apoptotic kinases in apoptotic signaling have not been well characterized, largely due to the 
failure to identify their specific substrates in the apoptotic signaling pathways. So far, only 
several transcription factors, AP I, p53, and NF-KB and possibly members of the Bcl-2 
family, have been suggested to be the substrates for these apoptotic kinases (Cross et al., 
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2000b; Ferri and Kroemer, 2001). More efforts are needed to identify substrates and to better 
elucidate the regulation of apoptotic kinases in the signal transduction of apoptosis. 
IV-2: Activation of protein kinase C delta (PKC8) and its function in apoptosis 
Protein kinase C delta (PKC8) is one of the novel PKC members. So far, more than 
11 isoforms have been categorized in the PKC family and subdivided into three major 
subfamilies, i.e., conventional PKC (a, (31, (3II, y), novel PKC (8, £, Tj, 0), and atypical PKC 
(T/X, 0 (Newton, 2003; Spitaler and Cantrell, 2004). A conserved structural property of the 
PKC family, PKC8 contains N-terminal regulatory and C-terminal catalytic fragments that 
are connected by a hinge region harboring the caspase-3 recognition and cleavage motif 
catalytic fragment (Kikkawa et al., 2002). The 
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molecules (diacylglycerol, 
DAG or phorbol 12-
myristate 13-acetate, PMA) and a C2-like domain that lacks the Ca2+ binding capacity. The 
regulatory fragment also contains a pseudosubstrate that binds to the catalytic site in the 
tertiary structure and keeps the kinase inactivated. PKCS is ubiquitously expressed in most 
tissues and cell types (Leibersperger et al., 1991; Wetsel et al., 1992). In murine tissue, a high 
expression level of PKC8 was found in the epidermis, placenta, uterus, brain, lung, and 
Figure 8. Classification and primary structure of PKC isoforms 
kidney (Leibersperger et al., 1991). In the central nervous system, PKC8 is highly expressed 
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in the thalamus, septal nuclei, and purkinje cells in the posterior cerebellum (Barmack et al., 
2000; Naik et al., 2000); however, the expression of PKCÔ in the SNc dopaminergic neurons 
has not been investigated. 
Diverse functions of PKC8 have been described in different cells. The function of 
PKCô appears to be closely related to its activation mechanism (Gschwendt, 1999; Kikkawa 
et al., 2002). Three mechanisms for the activation of PKCô have been suggested: the first is 
membrane translocation. The translocated PKC S either binds to the phosphatidylserine (PS) 
on the plasma membrane or diacylglycerol (DAG) generated from phosphatidylinositol 4,5 -
bisphosphate (PIP2) by phospholipase C (PLC) or the exogenously added lipid molecule 
PMA. The binding of lipid molecules changes the conformation of PKCô, releasing the 
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Figure9. Functional domains of PKC5 (Nishizuka, 1992; 
Toker, 1998). The lipid-mediated activation of PKCô is mostly involved in its normal 
physiological function as downstream effector of the G-protein coupled receptor (GPCR) or 
other receptors (Nishizuka, 1992). The second mechanism of activation of PKCô is 
proteolytic cleavage. Caspase-3-mediated proteolytic cleavage of PKCô removes the 
pseudosubstrate along with the whole regulatory domain to persistently activate the kinase 
(Emoto et al., 1996; Emoto et al., 1995). The proteolytic activation of PKCô mainly responds 
to apoptotic stimuli and promotes the cell death process (Brodie and Blumberg, 2003). The 
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third mechanism of activation of PKCô is phosphorylation. Both serine/threonine and 
tyrosine phosphorylation activate PKCô (Blass et al., 2002; Konishi et al., 2001; Toker, 
1998). The activation loop at the terminal of the catalytic domain contains threonine 505 and 
serine 643 and 662 (Newton, 2003). The phosphorylation of these serine/threonines possibly 
by 3 -phosphoinositide-dependent kinase 1 (PDK-1) facilitates the conformational change for 
the removal of pseudosubstrate from the catalytic site and is sufficient for activation of the 
kinase (Hodgkinson and Sale, 2002; Le Good et al., 1998). Extensive tyrosine 
phoshphorylation has been found at various tyrosine sites (Blass et al., 2002; Konishi et al., 
2001). The effect of tyrosine phosphorylation on the activity of PKCô depends on the 
individual tyrosine sites; in particular, Y311 and Y332 phosphorylated PKCô recovered from 
HaOa-treated cells has been found to be constitutively active and independent of DAG 
(Konishi et al., 1997; Konishi et al., 2001). 
The involvement of PKCô in apoptosis has been well demonstrated in different cells 
(Brodie and Blumberg, 2003). In most of cases, PKCô is pro-apoptotic, though some studies 
suggest that it is anti-apoptotic. Depending on the apoptotic stimuli and cell types, PKCô can 
translocate to the mitochondria, nucleus, endoplasmic reticulum (ER), golgi, as well as the 
plasma membrane in apoptotic cells (Brodie and Blumberg, 2003). Translocation of PKCô to 
the mitochondria was shown to facilitate the mitochondrial pore formation, promote 
cytochrome C release, and induce the redistribution of Bcl-2 family proteins (Majumder et al., 
2000; Murriel et al., 2004; Sitailo et al., 2004). The translocation of PKCô to the nucleus was 
linked to nuclear events that either regulate the mitochondrial apoptotic pathway or facilitate 
the collapse of nuclear structure in apoptotic cells (Cross et al., 2000a; DeVries et al., 2002). 
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A potential feedback mechanism between PKCô and caspase-3 at either the nucleic or 
mitochondrial level has been suggested to amplify apoptotic signals by increasing caspase-3 
activity (DeVries et al., 2002; Leitges et al., 2001; Leverrier et al., 2002). Although PKCô 
has been found to undergo caspase-3-dependent proteolytic activation and promote 
neurotoxin-induced apoptotic death of dopaminergic neuronal cells (Kaul et al., 2003; 
Kitazawa et al., 2003), the detailed mechanisms, including the localization change of 
activated PKCô and downstream events following the activation of PKCô, have not been 
investigated in dopaminergic neuronal cells. 
IV-3: Involvement of serine/threonine kinases in neurodegenerative diseases 
Abnormality of serine/theroine protein kinases is also implicated in the 
neurodegenerative diseases (Wagey and Krieger, 1998). In Parkinson's disease, recent 
studies have identified mutations in the PTEN-induced kinase 1 (PINK1) or leucine-rich 
repeat kinase 2 (LRRK2) from familial PD patients. Both PINK1 and LRRK2 appear to be 
involved in Ras/MAP kinase signaling, as suggested by preliminary studies (Shen, 2004). A 
mutation in PKCy was also shown to cause Parkinsonian syndrome in the rat (Craig et al., 
2001). In MPTP-administered mice, JNK was activated and promoted the apoptotic death of 
dopaminergic neurons (Saporito et al., 2000; Xia et al., 2001). Moreover, casein kinase-1 and 
-2 (CK-1 and -2) were found to phosphorylate a-synuclein which was mutated in familial PD 
patients (Lee et al., 2004; Okochi et al., 2000). The phosphorylation regulates a-synuclein 
and synphilin-1 interaction and inclusion body formation (Lee et al., 2004). In Alzheimer's 
disease, several kinases, like glycogen synthase kinase-3 (GSK3) and cyclin-dependent 
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kinase 5 (Cdk5), cause hyperphosphorylation of the microtubule associated protein Tau (Jope 
and Johnson, 2004; Stoothoff and Johnson, 2005). Hyperphosphorylation of Tau prevents the 
normal assembly of Tau with microtubules and the orderly polymerization of microtubules, 
to promote the formation of intracellular neurofibrillary tangle (NFT) (Stoothoff and Johnson, 
2005). GSK3 also facilitates the production of (3-amyloid (A|3) peptide (Phiel et al., 2003). 
Activation of GSK3 was also observed in the neurons exposed to A|3, and inhibition of GSK3 
activity protects neurons from A|3-induced neurotoxicity (Jope and Johnson, 2004). In 
Huntington's disease, PKCô associates with intranuclear inclusions in a transgenic model of 
Huntington's disease (Zemskov et al., 2003). The extensive involvement of serine/threonine 
protein kinases in various neurological disorders demonstrates the importance of fully 
understanding their exact roles, especially their regulation or mediation roles in the 
pathogenesis of these neurological disorders. 
V. Proteolytic activation and nuclear translocation of serine/threonine protein kinases 
in apoptosis 
V-l : Proteolytic activation of serine/threonine kinases and their function in apoptosis 
Serine/threonine protein kinases have emerged as one main category of substrates of 
activated caspase-3. Serine/threonine protein kinases identified as substrates of caspase-3 
include focal adhesion kinase (FAK) (Wen et al., 1997), mutated in ataxia telangiectasia 
kinase (ATM) (Tong et al., 2000), DNA dependent protein kinase catalytic subunit (DNA-
PKcs) (Itoh and Horio, 2001), p21-activated protein kinase 2 (PAR2) (Jakobi et al., 2003), 
LIM-kinase 1 (LIMK1) (Tomiyoshi et al., 2004), first level mitogen-activated kinase 1 
(MEKK1) (Cardone et al., 1997), mammalian sterile 20-like (Mst) kinase family (de Souza 
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and Lindsay, 2004; Lee et al., 2001), Rho associated kinases IROCKI (Coleman et al., 2001), 
protein kinase N (PKN) (Takahashi et al., 1998), sterile 20-related kinase (SLK) (Sabourin et 
al., 2000), hematopoietic progenitor kinase 1 (HPK1) (Chen et al., 1999), and two isoforms 
of protein kinase C (PKCô and PKCÔ) (Datta et al., 1997; Emoto et al., 1995). Most of these 
kinases, except for FAK, ATM, and DNA-PKcs, are normally inactivated due to the binding 
of the auto-inhibitory motif located on the regulatory domain of the catalytic site in their 
tertiary structure. Therefore, caspase-3-mediated proteolytic cleavage removes the auto-
inhibitory domain and leads to the constitutive activation of kinases. However, caspase-3-
mediated cleavage inactivates ATM, DNA-PKcs, and FAK activity. Inactivation of ATM and 
DNA-PKcs abolishes their phosphorylation to the downstream kinase DNA-damage-induced 
kinases (Chk) and inhibits the phosphorylation of transcriptional factor p53 and its 
degradation, resulting in down-regulation of anti-apoptotic Bcl-2 and up-regulation of pro-
apoptotic proteins, Bax, Noxa, and PUMA (Ferri and Kroemer, 2001). The inactivation of 
FAK disrupts the intergin-mediated cell attachment to the extracellular matrix or other cells 
and promotes cell death (Wen et al., 1997). 
The proteolytically activated kinases all promote apoptosis as the overexpression of 
the catalytic domain is sufficient to induce apoptosis, and the dominant-negative form of 
kinases inhibits their pro-apoptotic function. Some of them, MEKK1, HPK1, Mst, and SLK, 
are suggested to amplify apoptotic signals by forming nuclear or mitochondrial feedback 
loops as caspase activity increased along with the proteolytic activation of these kinases (de 
Souza and Lindsay, 2004; Widmann et al., 1998). Indeed, the JNK pathway has been 
ubiquitously found to be activated by these kinases after their proteolytic activation in 
different cell lines (Chen et al., 1999). In addition, proteolytically activated kinases more 
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often serve as effectors to directly mediate the morphological and biochemical changes in 
apoptotic cells, which eventually accelerate the apoptotic process. Proteolytic activation of 
ROCK1, LIMK 1, PAK2, PKN, SLK, MST, HPAK65 is involved in the appearance of 
different apoptotic morphology and biochemical changes, including formation of membrane 
blebbing and the apoptotic body, cell and nucleus shrinkage, collapse of the nuclear envelope, 
chromatin condensation, etc. (Chen et al., 1999; Coleman et al., 2001; Cross et al., 2000a; 
Rudel and Bokoch, 1997; Sabourin et al., 2000; Tomiyoshi et al., 2004). 
The ectopic expression of cleaved active hPAK65 was found to associate with 
cellular and nuclear shrinkage in apoptosis (Lee et al., 1997). The proteolytic cleavage of 
SLK releases not only an activated kinase domain, but also an actin-dissembling domain, 
which efficiently promotes the cytoskeleton fiber disassembly in apoptosis (Sabourin et al., 
2000). ROCKI, the Rho-associated kinase, after its proteolytic activation, plays an essential 
role in membrane blebbing in the apoptotic cells by phosphorylating myosin light chain to 
induce actomyosin contractility (Coleman et al., 2001; Sebbagh et al., 2001). Proteolytically 
activated LIMK1 is another kinase involved in the membrane blebbing of apoptotic cells 
(Tomiyoshi et al., 2004). Activated LIMK1 can stabilize ROCK-induced actomyosin 
contractile structures and phosphorylate cofmlin to inactivate it. As cofmlin is an actin-
binding protein that stimulates depolymerization of actin filament, its inactivation thus 
promotes actin filament assembly in the blebbing process of apoptotic cells (Tomiyoshi et al., 
2004). PAR2 is another kinase that can be proteolytically activated and contributes to the 
morphological and cytoskeletal changes in apoptosis (Rudel and Bokoch, 1997), though the 
exact mechanism is not yet clear. PKC5, one of the novel PKC isoforms, can also be 
proteolytically activated by caspase-3. Activated PKC8 mediates phosphorylation of lamin B 
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and increases its susceptibility to caspase-3-mediated cleavage, thus facilitating the collapse 
of the nuclear envelope in apoptotic cells (Cross et al., 2000a). Major biochemical changes in 
the apoptotic cells include DNA fragmentation and chromatin condensation. The 
fragmentation of chromatin is due to the action of caspase-activated DNase (CAD) or several 
other DNases, like endonuclease G (Endo G) and Granzyme A-activated DNase (GAAD) 
(Orrenius et al., 2003). However, the mechanisms of chromatin condensation are still unclear. 
It has been suggested that post-translational modification of histones may play an essential 
role in the condensation of chromatin in apoptosis, as histone phosphorylation has been 
associated with chromatin condensation in mitosis (Ajiro, 2000; Cheung et al., 2000; Nowak 
and Corces, 2004). Recently, proteolytically activated Mstl was shown to translocate to the 
nucleus and mediate phosphorylation of histone H2B which is associated with chromatin 
condensation in apoptotic cells (Cheung et al., 2003). 
Protein kinases that can be proteolytically activated are normally regulated by other 
signaling molecules and are involved in other cellular processes. For example, full-length 
MEKK1 and PAK2 are normally activated by p21 GTP-binding protein Ras or Cdc42/Rac 
(Knaus and Bokoch, 1998). The activated full-length MEKK1 and PAK2 promote cell 
survival (Jakobi, 2004). ROCK1 is normally regulated by Rho GTPase and LIMK is 
activated by Rho-ROCK and Rac/Cdc42-PAK, regulating actin cytoskeleton reorganization 
(Coleman et al., 2001; Tomiyoshi et al., 2004). However, proteolytic activation of protein 
kinases in apoptosis and their extensive mediation roles in the apoptotic morphological and 
biochemical changes suggest that proteolytic cleavage serves as an important switch that 
converts these kinases from their normal function to pro-apoptotic function. Knowledge of 
the proteolytic activation of these serine/threonine kinases provides a target for drug 
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development to specifically inhibit the proteolytic cleavage instead of inhibiting the normal 
kinase activity, which could block the apoptotic morphological and biochemical changes and 
rescue the cells from death or delay the death process. 
V-2: Mechanisms of nuclear/cytoplasmic transport 
Subcellular localization and trafficking of protein kinases are important, as kinases 
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Figure 10. NLS/NES mediated Nuclear import/export 
(Modified from Kaffman, 1999) 
their activators or substrates for 
rapid transmission of signals 
and fulfillment of their effector 
function (Teruel and Meyer, 
2000). The nucleocytoplasmic 
transport of kinases is 
particularly important because 
the cytoplasm and nucleus are 
two major compartments for all 
activities in the cell. Although 
molecules smaller than 40KDa 
can passively diffuse into the 
nucleus, nucleocytoplasmic transport is mainly regulated by the nuclear import and export 
machinery that includes nuclear localization signal (NLS)Znuclear export signal (NES), 
importin/exportin, and Ran GTPase (Moroianu, 1999). For nuclear import, proteins bearing 
the nuclear localization signal (NTS) are bound to the import receptor, importin. The protein-
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importin complex is then targeted to the nuclear pore complex (NPC) and translocates into 
the nucleus. In the nucleus, proteins are dissociated from importin as importin binds to the 
Ran-GTP. For nuclear export, the export receptor exportin only binds to NES containing 
proteins in the presence of Ran-GTP. The protein-exportin-Ran-GTP complex is transported 
out of the nucleus and proteins are disassociated when Ran-GTP undergoes hydrolysis 
induced by Ran-GTPase activating protein (Ran-GAP) and Ran-binding protein 1 (Kaffman 
and O'Shea, 1999). 
V-3: Regulation of nuclear localization of serine/threonine kinases by proteolytic 
cleavage in apoptosis 
In apoptosis, many kinases undergo NLS or NES dependent transport between the 
nucleus and the cytoplasm. For example, ERK translocates to the nucleus and phosphorylates 
transcriptional factor CREB in response to neurotrophic factors induced cell survival (Ajenjo 
et al., 2004; Yuan and Yankner, 2000). Interestingly, proteolytic cleavage of kinases by 
caspase-3 closely regulates their nucleocytoplasmic localization, which further regulates their 
distinct function in apoptosis (Jakobi, 2004). The regulatory role of proteolytic cleavage in 
kinase subcellular localization and function is based on the observation that full-length PAR2 
is predominantly localized in the cytoplasm and is involved in cell survival, whereas the 
cleaved PAR2p34 translocates to the nucleus and promotes apoptosis (Jakobi et al., 2003; 
Knaus and Bokoch, 1998). Full-length PAR2 contains an N-terminal regulatory and a dé­
terminai catalytic domain. Although the regulatory domain contains a functional NES motif 
and the hinge region contains a functional NLS motif, the nuclear export seems dominant 
over the nuclear import, and thus full-length PAR2 predominantly localizes in the cytoplasm. 
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After the cleavage, however, the NES is removed along with the regulatory domain; the 
nuclear import mediated by the NLS in the hinge region becomes dominant and leads to the 
nuclear localization of cleaved PAR2p34 (Jakobi et al., 2003). Similar to the PAR2, two 
functional NES are found in the C-terminal regulatory domain of Mstl to keep full-length 
MStl in the cytoplasm (Lee and Yonehara, 2002; Ura et al., 2001). The proteolytic cleavage 
removes both NES along with C-terminal regulatory domain and induces nuclear 
translocation of cleaved Mstlp36 (Ura et al., 2001). PKCô is another kinase that the cleaved 
catalytic domain tmaslocates to the nucleus (Brodie and Blumberg, 2003). Functional NLS 
has been found in the C-terminal catalytic domain and no functional NES has been found yet 
(DeVries et al., 2002). Intriguingly, although it contains only functional NLS, but not 
functional NES, PKCô is primarily localized in the cytoplasm, though a small fraction is 
localized in the nucleus. It is likely that the NLS in PKCô is normally kept, possibly by the 
N-terminal regulatory domain, in the incompetent status, and the proteolytic cleavage could 
convert the NLS from incompetent status into competent status by removing the regulatory 
domain, thus promoting its nuclear translocation. 
VI. RNA interference (RNAi) and its neuroprotective application in neurodegenerative 
diseases 
RNA interference (RNAi) is a new form of post-transcriptional gene silencing (PTGS) 
discovered within the past 10 years. The endogenous process down-regulates gene expression 
by either inducing the sequence-specific degradation of complementary mRNA or by 
inhibiting translation, or possibly by promoting DNA methylation or formation of 
heterochromatin (Harmon, 2002). After its initial discovery in C. elegans, the RNAi 
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phenomenon has been observed in many other systems, including Arabidopsis (also called 
co-suppression or virus induced gene silencing, VIGS), fungi, Drosophila, various 
mammalian cells and animals (Fire et al., 1998; Flammond et al., 2001; Schwarz et al., 2002). 
Meanwhile, endogenous micro RNA (miRNA) encoding genes are being rapidly and widely 
identified in different species, including humans, and are implicated in regulation of various 
physiological processes (Bartel, 2004). 
VI-1: Mechanisms of RNA interference 
The machinery and mechanisms of RNAi are being rapidly revealed after the intense 
studies conducted during the past several years. The mechanisms of RNAi have been 
conserved across different species, though specific adjustments are present in different 
species. For example, in C. elegans and plants, RNAi is heritable and shows a systematic 
(spreading throughout the whole organism) nature of silencing; in Drosophila and mammals, 
it shows cell-
autonomous, non-
\ heritable silencing 
f X W \ \ \ (Harmon, 2002). All 
^ ' ' 4. I I 
- _ -, x "— , t? / species have a Dicer 
^ ^ " y/ enzyme that belongs 
to the RNase IE 
Figure 11. General mechanisms of RNAi (Modified from Han non, 2002) ribonudcasc family 
and catalyzes the conversion of exogenous long (300-500bp) double-strand RNA (dsRNA) to 
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21-23bp small interfering RNA (siRNA) (Bernstein et al., 2001). The generated siRNA 
usually contains 5' phosphates and 2 nt 3' overhangs, as characteristic of RNase III cleavage 
products (Elbashir et al., 2001b). The double-strand siRNA is then separated by helicase so 
that only one strand is incorporated into a nuclease complex, RNA induced silencing 
complex (RISC) (Nykanen et al., 2001; Zamore et al., 2000). This complex, after binding to 
siRNA, is activated in an ATP dependent manner and leads to the degradation of target 
mRNA that is complementary to the siRNA (Nykanen et al., 2001; Zamore et al., 2000). In 
addition to the degradation of target mRNA, the RISC-siRNA complex can also down-
regulate gene expression by translational inhibition or by promoting chromatin remodeling, 
including DNA methylation, heterochromatin formation, and DNA rearrangements (Bartel, 
2004; Schramke and Allshire, 2004). In mammals, however, exogenously introduced long 
dsRNA is recognized as viral RNA by mammalian cellular defense systems, which activates 
RNA-dependent protein kinase (PKR). Activated PKR subsequently phosphorylates protein 
synthesis initiation factor EIF-2a and leads to the inhibition of all protein synthesis in the 
cells (Gil and Esteban, 2000). Therefore, in mammals, siRNA, instead of dsRNA, is directly 
used for induction of specific silencing effects (Elbashir et al., 2001a). 
The observation that very small amounts of dsRNA can induce strong RNAi effects 
which spread throughout the organism in plants and C. elegans suggests that RNAi in these 
organisms may have specific mechanisms to amplify and spread RNAi signals (Harmon, 
2002). The dsRNA-induced silencing effect in these organisms requires proteins similar in 
sequence to a tomato RNA-directed RNA polymerase (RdRP) (Schiebel et al., 1998). 
Genetic studies in Arabidopsis and C. elegans have identified several mutants that might act 
as RdRP to produce extra dsRNA using initially generated siRNA as the primer (Dalmay et 
al., 2000; Mourrain et al., 2000). The additionally produced dsRNA can be further cleaved by 
Dicer enzyme to produce more siRNA, thus increasing the silencing effect. It has also been 
speculated that the RISC-siRNA complex may induce chromatin structure alteration and 
produce aberrant mRNA, which can also be employed by RdRP to produce extra dsRNA 
(Harmon, 2002). For systemic RNAi effects, a transitive RNAi phenomenon has been 
observed in which the silencing signal moved along a particular gene from 3'-5' (in C. 
elegans) or in both directions (in plants) (Baulcombe, 2002a, b). In addition, it has also been 
speculated in plants that silencing signals could be passed to adjacent cells through cell-cell 
junctions (movement of RNA and proteins via cell-cell junctions is well characterized), or 
even further through the vasculature (Harmon, 2002; Voinnet et al., 1998). Indeed, the sid-1 
gene is required for a systemic silencing effect in C. elegans. This gene encodes a 
transmembrane protein that may act as a channel for import of the silencing signal in C. 
elegans (Winston et al., 2002). Interestingly, SID-1 homologues are absent in Drosophila, 
consistent with the lack of systemic spreading of the silencing effect in flies (Hannon, 2002). 
VI-2: Design of siRNA for mammalian systems 
RNAi provides a powerful tool for characterization of gene function as the loss-of-
function phenotype can be quickly linked to a specific gene. Indeed, genome-wide RNAi 
screening has been carried out in several plants and invertebrates (Dykxhoom et al., 2003; 
Hammond et al., 2001). In mammals, though long dsRNA fails to induce specific silencing 
effects because it triggers cellular defense systems, specific silencing effects have been 
successfully achieved by an alternative short siRNA strategy (Elbashir et al., 2001a; Mittal, 
2004). Although the short siRNA sequence is mainly based on the target mRNA sequence, 
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the selection of exact target sites on the target mRNA is still difficult and thus not every 
designed siRNA is effective. Basically, short siRNA (21 bp) needs to have a phosphorylation 
group at the 5' end and 2nt UU overhang at the 3' end, so a typical siRNA would be 5'P-
(N19)UU-3\ where N is any of four nucleotides (Mittal, 2004). 
In addition, several empirical criteria based on the biochemical mechanisms of RNAi 
have been suggested in the selection of target sites and structural requirements of siRNA 
sequences (Mittal, 2004; Reynolds et al., 2004). These criteria include: 1) the target sequence 
has overall low to medium GC content (30-50%) that facilitates its interaction with RISC 
complex and its unwinding; 2) the internal stability should be lower in the 5' antisense strand 
but higher in the 5' sense strand to promote the incorporation of antisense but not the sense 
strand into the RISC complex, i.e., choose A or U instead of G or C at the 3' end of the sense 
strand that forms weaker hydrogen bonds (Schwarz et al., 2003); 3) no internal repeats or 
palindromes are present in the siRNA that reduce liklihood of formation of an siRNA dimer; 
4) the presence of a U at position 10 of the sense strand that promotes RISC mediated 
cleavage of mRNA and dissociation of the RISC-siRNA complex. These criteria significantly 
improve the efficiency of designed siRNA, though all designed siRNAs still need to be tested. 
Designed siRNA can be either chemically synthesized or generated via in vitro transcription 
(Holle et al., 2004; Yu et al., 2002). For in vitro transcription, the DNA template for siRNA 
is usually linked to a T7 promoter so that both sense and antisense strands can be transcribed 
in vitro by T7 RNA polymerase and annealed to generate the functional double strand siRNA. 
Recently, expression of vector-based small hairpin RNA (shRNA) has become 
preferred, as it can consistently induce a silencing effect for the observation of some late 
phenotypes and allows establishment of a stable cell line. The design of shRNA is based on 
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the recent progress made in the natural production and maturation of micro RNA (miRNA) in 
cells (Bartel, 2004). The miRNA is maturated from pri-miRNA transcribed from miRNA 
genes. The cleavage of U6 Sense 
promoter strand 
Antisense 
strand Terminator 
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| transcription 
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Figure 12. Schematic diagram of shRNA expression cassette and the generation 
of siRNA from expressed shRNA 
pri-miRNA by Drosha 
RNase III endonuclease 
in the nucleus releases a 
60-70nt stem loop 
intermediate, known as 
the miRNA precursor 
(pre-miRNA) (Lee et al., 
2002; Zeng and Cullen, 2003; Zeng et al., 2003). The stem loop shaped pre-miRNA is then 
exported out of the nucleus and cleaved by Dicer endonuclease to generate the mature double 
strand miRNA (Lee et al., 2003). Based on this model, small DNA oligonucleotide that 
contains sense and antisense strands complementary to the target mRNA and interspaced by 
loop nucleotides is cloned into an expression vector driven by RNA polymerase III promoter, 
like small nuclear RNA (snRNA) U6 or HI RNA (Paddison et al., 2002; Paul et al., 2002; 
Sui et al., 2002). Similar stem loop structure, like pre-miRNA, would be formed after the 
DNA oligonucleotide is transcribed in the cell. This expressed stem loop "pre-siRNA" can 
then be cleaved by Dicer to generate functional siRNA in the cells. This strategy of 
producing siRNA and induction of a silencing effect has become a choice method, especially 
for in vivo experiments in which delivery of siRNA is usually very inefficient. 
VI-3: Application of RNAi-mediated neuroprotective strategy in neurodegenerative 
diseases 
The high efficiency of siRNA in mammalian cells, along with its target specificity 
and easy handling, has provided a new neuroprotective strategy for neurodegenerative 
diseases. Because RNAi can specifically down-regulate specific genes, dominant mutated 
alleles implicated in the pathogenesis of different neurodegenerative diseases are potentially 
good targets for therapeutic gene silencing (Mittal, 2004). The selective RNAi targeting of 
only the dominant mutated allele is critical, as the normal allele can still produce proteins for 
its normal function in the cells. This approach has been recently demonstrated in the selective 
silencing of mutated ataxia-3, contributing to the polyglutamine (polyQ) toxicity in 
spinocerebellar ataxia type 3 (SCA3) (Xia et al., 2004). In the polyglutamine disorders, the 
expansion of the CAG repeat in the genes causes the additional incorporation of glutamine 
that changes the protein's conformation and promotes the abnormal aggregation. In this study, 
effective siRNA targeting the CAG repeat was first designed, but down-regulated both the 
mutant and wild-type genes. Instead, other siRNAs targeting a single nucleotide 
polymorphism (SNP) located immediately 3' to the CAG repeat, which is in linkage 
disequilibrium with the disease-causing CAG expansion and segregates with the disease 
allele in most families, were designed and effectively silenced only the expression of the 
mutated allele and not the wild type allele (Xia et al., 2004). Similar strategies have also been 
successfully applied to other dominant disease-causing alleles, including the missense 
mutation Tau V337M underlying the disorder frontotemporal dementia with Parkinsonism 
(Miller et al., 2003), the TorsinA gene underlying a form of dystonia, a missense mutation of 
muscle acetylcholine receptor (AchR) a subunit S226F that causes the slow channel 
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congenital myasthenic syndrome (SCCMS) (Gonzalez-Alegre et al., 2003), and a tandem 
missense mutation of the amyloid precursor protein APPsw underlying Alzheimer's disease 
(Miller et al., 2004). Such technologies show promise for application in other 
neurodegenerative diseases in which mutated disease-causing dominant alleles are implicated. 
For the more common sporadic form of neurodegenerative diseases, progress in the 
investigation of apoptotic death of neurons will likely lead to identification of cytotoxic 
proteins that underlie the pathogenesis of diseases as potential targets for RNAi. In our 
laboratory, we have demonstrated that down-regulation of the oxidative stress sensitive 
kinase PKCô by siRNA effectively protects dopaminergic neurons from MPP+-induced 
toxicity (Yang et al., 2004). The down-regulation of prostate apoptosis response-4 (Par-4) by 
siRNA protects against cell death in a Cu/Zn superoxide dismutase (Cu/Zn-SOD) transgenic 
mouse model of Amyotrophic lateral sclerosis (ALS) (Xie et al., 2005). The many enzymes 
and kinases shown to facilitate the production of free radicals or cell death may be good 
targets for RNAi. However, because many of these molecules are involved in both 
physiological and pathological processes, the effect of the down-regulation of these targets 
on normal physiological process must be considered and be autonomously or artificially 
compensated for in the cells. 
Most of the successful siRNA-mediated neurprotective strategies have been 
demonstrated in cells by direct transfection of siRNA or introduction of vector expressing 
shRNA. In some cell lines, chemically synthesized or in vitro transcribed siRNA can be 
easily introduced into the cells by electroporation or lipophilic reagents (Mittal, 2004). 
However, these approaches are limited by their transient nature, as introduced siRNAs are 
usually degraded in several days (Dykxhoorn and Lieberman, 2005). Although the 
expression of shRNA partially solves this problem by facilitating the establishment of a 
stable cell line, both the synthetic siRNA and vector-based shRNA often fail to efficiently 
deliver siRNA into neuronal cells or non-dividing primary neurons due to the very low 
transfection efficiency in these cells (Mittal, 2004). In addition, an in vivo mammalian animal 
model demonstrating the neuroprotective effect of siRNA is required to really demonstrate 
that siRNA could be a good therapeutic reagent. Also, new tools for the efficient introduction 
and long term expression of siRNA in neurons in vivo are required. 
Numerous viral vectors have been developed from adenovirus, recombinant adeno-
associated virus (AAV), retrovirus, and lentivirus to solve the siRNA delivery problem in 
vivo (Brenner and Malech, 2003; Kirik and Bjorklund, 2003; Rubinson et al., 2003). Among 
these viral vectors, the replication-deficient lentiviral vector is most desirable because 
lenti virus can infect not only the dividing cells but also the non-dividing cells, and can 
integrate its genome efficiently into the genome of host cells (Blomer et al., 1997; Kafri et al., 
1997; Mittal, 2004; Miyoshi et al., 1997). To deliver the siRNA into the neuron, a shRNA 
cassette that contains the RNA polymerase III promoter, shRNA template, and RNA 
polymerase III terminator is first cloned into the replication-deficient lentiviral vector, and 
then lentivirus is produced by infection of the 293FT cells. The produced lentivirus, after 
concentration, can be directly injected into the brain to infect certain groups of neurons. 
Lentiviral vector mediated delivery of shRNA has been successful in mice and inhibits the 
expression of co-transfected reported plasmids (Lewis et al., 2002; McCaffrey et al., 2002), 
of the endogenous pro-apoptotic Fas receptor (Song et al., 2003), and of the tyrosine 
hydroxylase (TH) gene in the brain (Hommel et al., 2003). Recently, inducible lentiviral 
vectors have also been developed, which provide more flexibility to create animal disease 
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models and to test the neuroprotective effect of specific siRNA (Wiznerowicz and Trono, 
2003). By using the inducible lentiviral vector, in principle, shRNA targeting any genes can 
be transduced into the mice and inducibly expressed to allow the observation of some late 
phenotypes (Mittal, 2004). This approach, compared to the large scale ethylnitrosurea (ENU) 
mutagenesis, is much less laborious and more effective. 
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CHAPTER II: SUPPRESSION OF CASPASE-3 DEPENDENT PROTEOLYTIC 
ACTIVATION OF PROTEIN KINASE C8 BY SMALL INTERFERING RNA (SiRNA) 
PREVENTS MPP-INDUCED DOPAMINERGIC DEGENERATION 
A paper published in Molecular and Cellular Neuroscience 
Yongjie Yang, Siddharth Kaul, Danhui Zhang, Vellareddy Anantharam, 
Anumantha G. Kanthasamy 
ABSTRACT 
The cellular mechanisms underlying the neurodegenerative process in Parkinson's 
disease are not well understood. Using RNA interference (RNAi), we demonstrate that 
caspase-3 dependent proteolytic activation of protein kinase C ô (PKCô) contributes to the 
degenerative process in dopaminergic neurons. The Parkinsonian toxin MPP+ activated 
caspase-3 and proteolytically cleaved PKCô into catalytic and regulatory subunits, resulting 
in persistent kinase activation in mesencephalic dopaminergic neuronal cells. The caspase-3 
inhibitor Z-DEVD-FMK and the caspase-9 inhibitor Z-LEHD-FMK effectively blocked 
MPP+-induced PKCô proteolytic activation. To characterize the functional role of PKCô 
activation in MPP+-induced dopaminergic cell death, RNAi mediated gene knock-down was 
performed. Among four siRNAs designed against PKCô, two specifically suppressed PKCô 
expression. The application of siRNA abolished the MPP+-induced PKCô activation, DNA 
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fragmentation, and TH positive neuronal loss. Together, these results suggest that proteolytic 
activation of PKCô may be a critical downstream event in the degenerative process of 
Parkinson's disease. 
INTRODUCTION 
Understanding the cellular mechanisms involved in the selective loss of nigral 
dopaminergic neurons in Parkinson's disease (PD) remains a formidable challenge. 
Apoptosis has recently been recognized as an important mode of cell death in PD, mainly by 
the identification of key markers of apoptotic cell death including mitochondrial cytochrome 
c release, caspases activation and DNA fragmentation in PD pathology (Dodel et al., 1998; 
Hartmann et al., 2000; Mizuno et al., 1998; Viswanath et al., 2001). Major insights into the 
neurodegenerative process in PD have been gained from the use of the mitochondrial toxin 
MPTP (l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine), which faithfully replicates the salient 
Parkinsonian symptoms and pathology (Albanese et al., 1993; Betarbet et al., 2002; Langston 
et al., 1984). MPTP is converted to its ionic metabolite MPP+ ( 1 -methyl-4-phenylpyridinium) 
in the brain, which induces a series of apoptotic signaling events including reactive oxygen 
species (ROS) generation, mitochondrial dysfunction, cytochrome c release, caspases 
activation, and DNA fragmentation in cell culture and animal PD models (Cassarino et al., 
1997; Cassarino et al., 1999; Hartmann et al., 2000; Lee et al., 2000; Lotharius and O'Malley, 
2000; Viswanath et al., 2001; Wu et al., 2003). Furthermore, ROS is one of the major 
contributors to apoptotic cell death in dopaminergic neurons (Seal, 2002; Ischiropoulos and 
Beckman, 2003; Lotharius and Brundin, 2002; Olanow and Tatton, 1999). However, little is 
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known about the molecules and mechanisms that act downstream of caspases during MPP+-
induced apoptotic cell death in dopaminergic neurons. 
Phosphorylation is a major cellular signaling mechanism by which many critical 
neuronal functions including cell survival, differentiation, and death are regulated. One of the 
key members of phosphorylation signaling is protein kinase C (PKC) family. It includes 13 
isoforms, which are classified mainly into three subgroups based on their dependence upon 
diacylglycerol (DAG) and Ca2+ for activation (Dempsey et al., 2000; Gschwendt, 1999; 
Maher, 2001). The conventional PKC isoforms (PKC a, pi, (311, and y) require DAG and 
Ca2+ for activation, the novel PKC isoforms (PKC ô, s, r|, 0, and (i) require only DAG but 
not Ca2+ for activation and the atypical PKCs (PKC Ç, X and i) require neither Ca2+ nor DAG 
for activation. Kinase activation involves autophosphorylation followed by translocation to 
the cell membrane and other organelles (Brodie and Blumberg, 2003; Gschwendt, 1999; 
Kikkawa et al., 2002). Recent studies have shown that PKCô can be proteolytically activated 
by caspase-3 during apoptotic cell death in non-neuronal cells (Emoto et al., 1996; Mandil et 
al., 2001; Meinhardt et al., 1999; Pongracz et al., 1999; Reyland et al., 1999). These studies 
characterized the function of PKCô activation in apoptotic cell death mainly by utilizing the 
pharmacological inhibitor rottlerin or dominant-negative mutants. The non-specific nature of 
this pharmacological inhibitor (Davies et al., 2000) and the inherent problems with 
overexpression (Buchner, 2000; Gschwendt, 1999) warrant use of a more powerful tool to 
investigate the function of PKCô in dopaminergic cell death. 
Double-strand RNA (dsRNA)-mediated RNA interference (RNAi) is emerging as a 
powerful tool to characterize gene function by genetic loss-of-function analysis. This novel 
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post-transcriptional gene silencing mechanism was first demonstrated with great success in 
plants, C. elegans, Drosophila (Barstead, 2001; Carmell et al., 2002; Elbashir et al., 2001a; 
Hammond et al., 2001; Hasuwa et al., 2002; Morel and Vaucheret, 2000; Shi, 2003; Sorensen 
et al., 2003; Vaucheret et al., 2001; Vaucheret and Fagard, 2001; Xia et al., 2002) and more 
recently in cultured mammalian cells as well as in animal models (Carmell et al., 2002; 
Elbashir et al., 2001a; Hasuwa et al., 2002; Shi, 2003; Sorensen et al., 2003; Xia et al., 2002). 
Small interfering RNA (siRNA), usually 21 bp, is widely applied in mammalian cell cultures 
as compared to 300-500 bp dsRNA in non-mammalian systems (Donze and Picard, 2002; 
Krichevsky and Kosik, 2002; Paddison et al., 2002). Because of its high efficacy, selectivity 
and ease of application, RNAi is now a preferred method over pharmacological inhibitor 
studies, the antisense technique, and overexpression analysis (Jen and Gewirtz, 2000; 
Opalinska and Gewirtz, 2002). In the present study, we demonstrate that proteolytic 
activation of PKC5 by caspase-3 facilitates apoptotic cell death in an in vitro model of 
Parkinson's disease and suppression of PKCô expression using siRNA rescues dopaminergic 
neuronal cells from MPP+-induced cell death. 
RESULTS 
MPP+ exposure induces caspase-3 mediated proteolytic activation of PKCô 
Activity of the key effector cysteine protease caspase-3 was measured in rat 
mesencephalic clonal dopaminergic neuronal (N27) cells treated with the Parkinsonian toxin 
MPP+ (300 jxM). Maximal caspase-3 activation of 228% over untreated control cells was 
observed 36 hr following MPP+ treatment (Fig 1 A). Activation of caspases by MPP+ was also 
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confirmed by in situ caspase staining (Fig IB). All the MPP+-treated cells showed intense 
green florescence indicative of caspase activation, while untreated cells showed very low 
levels of caspase activation. 
Interestingly, MPP+ exposure for 36 hr also induced the proteolytic cleavage of native 
PKCô (72-74 kDa) to yield catalytically active (41/38 kDa) fragments (Fig 2A). Co-
treatment with the caspase-3-specific inhibitor Z-DEVD-FMK almost significantly reduced 
MPP+-induced proteolytic cleavage of PKCô, indicating that caspase-3 mediated the cleavage 
of PKCô (Fig 2A). Densitometric analysis revealed an 81% inhibition of PKCô cleavage by 
Z-DEVD-FMK. Moreover, we sought to determine whether caspase-9, the upstream initiator 
of the mitochondrial-mediated caspase cascade, contributes to the caspase-3-dependent 
proteolytic cleavage of PKCô. The caspase-9-specifïc inhibitor Z-LEHD-FMK significantly 
blocked MPP+-induced PKCô cleavage (Fig 2B). Thus, caspase-9 might be the upstream 
initiator caspase that proteolytically activates caspase-3, which subsequently cleaves PKCô. 
Caspase-3-mediated proteolytic cleavage of PKCô results in the permanent 
dissociation of the regulatory subunit from the catalytic subunit, resulting in the persistently 
active catalytic fragment. Therefore, we performed immunoprecipitation kinase assays to 
determine if caspase-3-dependent proteolytic cleavage of PKCô increased its kinase activity 
during MPP+ treatment. A 36hr exposure to 300 (J.M MPP+ increased PKCô enzymatic 
activity 239% in comparison to untreated control cells (Fig 2C). Co-treatment with the 
caspase-3 specific inhibitor Z-DEVD-FMK completely blocked MPP+-induced increases in 
PKCô enzyme activity, suggesting that caspase-3 mediated proteolytic activation of PKCô 
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contributed to the increases in kinase activity. To further determine whether MPP+ treatment 
alters PKCô gene expression in dopaminergic neuronal cells, we conducted RT-PCR 
analysis. As shown Figure 2D, the PKCô mRNA level remained unchanged after MPP+ 
treatment. PKCô translocation was also examined by extraction of membrane and cytosolic 
fractions and by Western blot analysis. PKCô did not translocate to the membrane during 
MPP+ treatment (Fig 3A). Cleavage of the other major PKC isoform, PKCa (Fig 3B), was 
not detected either, suggesting that the PKCô isoform is mainly activated by proteolytic 
cleavage during MPP+ treatment. 
Design and generation of siRNAs 
To determine the functional role of proteolytic activation of PKCô in apoptotic cell 
death, genetic loss-of-function analysis was performed using siRNA. Four siRNAs were 
designed: three targeted different positions within the coding region (siRNA-ô-1, 2 and 4) 
and one (siRNA-Ô-3) targeted the 3'UTR of PKCô mRNA (Fig 4A). Choice of target sites 
was based on previous empirical criteria (Elbashir et al., 2001b). A non-specific siRNA 
(siRNA-NS) was also designed to serve as a negative control. For each siRNA, sense and 
antisense templates were designed based on each target sequence and partial T7 promoter 
sequence (Fig 4B). siRNAs were prepared using an in vitro transcription method employing 
Ambion's silencer siRNA construction kit (Ambion,Austin, TX). Synthesized double 
stranded siRNAs were examined for transcriptional efficacy and purity in the native PAGE 
gel as shown in Fig 4C. All the siRNAs except siRNA-ô-3 were transcribed efficiently, as 
depicted by the single band of expected size. siRNAs were also labeled with Cy3-fluorescent 
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dye using the Ambion's silencer siRNA labeling kit (Ambion,Austin, TX) to determine the 
transaction efficiency as well as to identify the siRNA-transfected cells. The transfection 
efficiency determined by counting the number of Cy3 positive cells at 24 hr post-transfection 
was about 80%. 
Selective suppression of PKCÔ expression by siRNA 
We next examined the ability of siRNAs to suppress endogenous PKCô expression. 
N27 cells were transfected with 5-25 nM of siRNA-ô-1, 2, 3, 4 and siRNA-NS using the 
TranslT-TKO transfection reagent (Mirus, Madison, WI). Cell lysates were extracted at 24 
and 48 hrs post transfection and the levels of PKCô protein expression were determined by 
Western blotting. siRNA-ô-1 and siRNA-8-4 significantly suppressed PKCô expression in a 
time- and dose-dependent manner (Fig 5 A&B). Densitometric analysis revealed 12%, 26%, 
and 66% reduction in endogenous PKCô protein expression following transfection with 5 nM, 
10 nM, and 25 nM siRNA-ô-4 for 24 hr, respectively. Unlike siRNA-ô-4, PKCô expression 
was significantly reduced in siRNA-ô-1-transfected cells only at 48 hr post-transfection and 
densitometric analysis revealed 69% reduction following transfection with 25 nM siRNA-ô-1. 
On the other hand, PKCô expression was not significantly suppressed in siRNA-ô-2- and 
siRNA-ô-3-transfected N27 cells at either 24 hr or 48 hr (data not shown). siRNA-NS had no 
silencing effect on PKCô expression at either 24 hr or 48 hr post-transfection (Fig 5 A&B). 
Notably, siRNA-ô-4 and siRNA-ô-1 did not alter the expression level of the closely related 
novel PKC isoform PKCs, indicating their high selectivity for PKCô (Fig 5 A&B). Moreover, 
temporal analysis of PKCô expression in cells transfected with siRNA-ô-4 revealed that the 
64 
suppression of PKCS expression by siRNA-ô-4 was maximal at 24 hr post-transfection (Fig 
5C). RT-PCR analysis of PKCô mRNA also revealed a 50% reduction in PKCS mRNA level 
with siRNA-5-4 treatment as compared to siRNA-NS treatment (Fig 5D), indicating that 
siRNA-ô-4 effectively degrades PKCô transcripts, which subsequently reduces PKCô protein 
expression. 
In situ localization of siRNA and PKCô immunohistochemistry 
We next performed siRNA labeling and immunostaining studies to determine if 
PKCô expression was specifically suppressed in siRNA-ô-4-transfected cells. After 
transfecting N27 cells with Cy3-labeled siRNA-ô-4, PKCô immunostaining and Hoechst 
33342 counterstaining were used to identify PKCô protein and nucleus, respectively. PKCô 
immunofluorescence revealed a strong and equal distribution of the kinase in the cytoplasm 
of normal N27 cells (Fig 6C). In siRNA-ô-4-transfected cells, Cy3-labeled siRNA 
accumulated largely in the cytoplasm at the same time PKCô protein expression was 
significantly reduced, indicating that siRNA-ô-4 transfection indeed suppressed the 
expression of PKCô (Fig 6A). In siRNA-NS transfected cells, merged yellow fluorescence 
was clearly observed, suggesting that Cy3-labeled siRNA-NS still accumulated but PKCô 
protein expression was not altered at all (Fig 6B). The fluorescence intensity of PKCô 
immunoreactivity was also quantified using Metamorph image analysis software. As shown 
in Figure 6D, siRNA-ô-4-transfected cells showed an approximate 71% reduction in PKCô 
expression as compared to control cells, whereas PKCô expression was not significantly 
changed in siRNA-NS-transfected cells compared to controls cells. Furthermore, cellular 
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morphology and integrity were not changed in siRNA-transfected N27 cells as compared to 
normal N27 cells, indicating that the cells tolerate siRNA treatment. 
Suppression of MPP-induced PKCô kinase activity and DNA fragmentation by siRNA-
Ô-4 
To determine if siRNA-ô-4 blocks MPP+-induced PKCô activity, we performed an in 
vitro kinase assay following immunoprecipitation of PKCô in control and siRNA-ô-4-
transfected cells after MPP+ exposure. PKCô kinase activity was significantly increased by 
215% in cells exposed to MPP+ (300 pM) for 36 hr as compared to untreated control cells 
(Fig 7A). MPP+ did not induce PKCô activity in siRNA-ô-4-transfected cells, demonstrating 
that siRNA-ô-4 effectively suppressed PKCô expression and thereby attenuated MPP+-
induced proteolytic activation of PKCô. To further characterize the functional role of PKCô 
activation in apoptotic cell death, we examined the effect of siRNA-ô-4 on MPP+-induced 
DNA fragmentation. DNA fragmentation was increased 2-fold in N27 cells following MPP+ 
treatment and was almost completely blocked in siRNA-ô-4 transfected cells (Fig 7B), 
demonstrating the key proapoptotic function of PKCô in MPP+-induced dopaminergic cell 
death. 
Suppression of PKCô expression by siRNA-ô-4 in primary mesencephalic neuronal 
cultures 
The efficiency of siRNA-ô-4 at suppressing PCKô expression was further examined 
in primary dopaminergic neurons. Cy3-labeled siRNAs were transfected into primary 
66 
mesencephalic cultures isolated from rat El7 embryos. Tyrosine hydroxylase (TH) and 
PKCô immunostaining were performed 24 hr post-transfection to determine the efficiency of 
siRNA incorporation in dopaminergic neurons and to measure PKCô expression, respectively. 
As depicted in Figure 8A, Cy3-labeled siRNA-ô-4 effectively incorporated in TH positive 
neurons and the siRNAs localized mainly in the cytoplasm. Quantitative analysis of PKCô 
expression, as measured by the fluorescence intensity of PKCô immunoreactivity, in siRNA-
Ô-4- or siRNA-NS-transfected TH positive neurons revealed a 42% reduction in PKCô 
expression (Fig 8B). Collectively, these results demonstrate that siRNA-ô-4 efficiently 
incorporates in primary dopaminergic neurons and suppresses PKCô expression. 
Neuroprotective effect of siRNA-ô-4 against MPP-induced dopaminergic toxicity in 
primary mesencephalic neurons 
We further examined whether or not siRNA-ô-4 protects against MPP+-induced 
neurotoxicity in nigral dopaminergic neurons. TUNEL staining and nuclei counterstaining 
with Hoechst 33342 were employed to detect in situ DNA fragmentation induced by MPP+ 
treatment. TUNEL and TH dual staining is complicated by MPP+ treatment, which results in 
significant loss of TH positive cells. However, dopaminergic neurons in primary 
mesencephalic cultures can be readily identified by their large cell bodies and extensive 
neuronal processes as compared to other cell types. After selecting a field that contains these 
neurons, we performed TUNEL imaging. As shown in Figure 9A, Cy3-labeled si-RNA-ô-4 
and siRNA-NS were found in the cytoplasm and around nuclei. TUNEL staining showed that 
MPP+ treatment induces apoptosis in siRNA-NS treated cells. The TUNEL positive cells also 
67 
showed chromatin condensation, as observed by Hoechst 33342 staining. However, siRNA-
ô-4-transfected neurons showed no TUNEL staining and the nuclei remained intact during 
MPP+ treatment. These results indicate that siRNA-8-4 prevents MPP+-induced DNA 
fragmentation in primary mesencephalic neurons. To further demonstrate siRNA's protective 
effect in dopaminergic neurons, the number of TH positive neurons was counted; 
quantification of TH positive neurons is considered to be a reliable method of determining 
MPP+-induced dopaminergic toxicity in primary mesencephalic cultures (Callier et al., 2002; 
Choi et al., 1999). Treatment with 10 pM MPP+ for 48 hr substantially decreased the number 
of dopaminergic neurons by over 87% as compared to untreated control cells (Fig 9B). 
However, MPP+-induced TH+neuronal loss was dramatically reduced to 33% in the siRNA-
ô-4-transfected primary neurons, demonstrating a significant neuroprotective effect of 
siRNA-ô-4. siRN A-N S -transfected primary neurons were not significantly protected 
following MPP+ exposure (Fig 9B). Figure 9C summarizes the actual number of TH positive 
neurons in each treatment group. Together, these results demonstrate that suppression of 
PKCô expression by siRNA protects against dopaminergic degeneration induced by MPP+. 
Cytotoxicity testing following siRNA-ô-4 treatment 
In conventional gene silencing methods such as antisense mediated knock-down, 
cytotoxicity is always a major concern because of the high concentration of antisense 
oligonucleotides introduced into cells and/or the nucleotide modifications made to the 
antisense probes. To investigate whether siRNA suppresses gene expression without causing 
significant toxicity to cells, we monitored lactate dehydrogenase (LDH) release in the 
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extracellular media as a marker of cytotoxicity (Kanthasamy et al., 1995). As shown in 
Figure 10, LDH levels in the extracellular medium of either siRNA-8-4- or siRNA-NS-
transfected cells were not significantly different from untreated control cells, indicating that 
siRNA treatment is not significantly toxic to mesencephalic neuronal cells. 
DISCUSSION 
The present study demonstrates that MPP+ induces proteolytic activation of PKCô in 
a caspase-3 dependent manner, which subsequently contributes to apoptotic cell death in 
mesencephalic dopaminergic cells. Notably, siRNA against rat PKCô mRNA effectively 
blocked MPP+-induced PKCô activation and DNA fragmentation in dopaminergic neuronal 
cells, suggesting that PKCô is an important proapoptotic molecule in dopaminergic 
degeneration. To our knowledge, this is the first report demonstrating a siRNA based 
neuroprotective strategy in a cell culture model of Parkinson's disease. 
Oxidative stress is considered a key mediator of neurodegenerative processes in 
Parkinson's disease because of the extreme sensitivity of nigral dopaminergic neurons to 
oxidative insults (Ischiropoulos and Beckman, 2003; Jenner, 2003; Lotharius and Brundin, 
2002). The Parkinsonian neurotoxin MPP+ induced cell death model serves as an useful 
model to delineate the cellular mechanisms underlying degenerative process in Parkinson's 
disease (Kaul et al., 2003; Kaur et al., 2003; Lotharius et al., 1999). Recent studies have 
demonstrated that reactive oxygen species (ROS) generated from mitochondrial and/or non-
mitochondrial sources (Lotharius and O'Malley, 2000) appear to contribute to MPP+-induced 
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neurodegeneration (Kaur et al., 2003; Lee et al., 2000; Lotharius et al., 1999; Wu et al., 2003). 
MPP+-induced ROS generation has been previously shown to promote mitochondrial 
cytochrome c release, caspase-9 activation and subsequently caspase-3 dependent apoptotic 
cell death (Jackson-Lewis et al., 1995; Viswanath et al., 2001). However, caspase-8 mediated 
apoptotic cascade does not seem to be critical to MPP+-induced apoptotic cell death (Kaul et 
al., 2003; Vila and Przedborski, 2003). In this study, we showed that MPP+ induces 
activation of caspase-3 within 36 hr of MPP+ treatment. Our result is in agreement with 
recent reports which identified caspase-3 as a critical factor in the selective apoptotic cell 
death of dopaminergic neurons in the MPTP mouse model and in post mortem brains of 
patients with PD (Dodel et al., 1998; Hartmann et al., 2000). Recently, we showed that ROS 
scavengers and a caspase-9 inhibitor block MPP+ induced capase-3 activation (Kaul et al., 
2003). In the present study, we further demonstrate that caspase-9 inhibitor Z-LEHD-FMK 
significantly inhibit MPP+ -induced PKCô proteolytic cleavage. Taken together, these results 
suggest that mitochondrial mediated caspase cascade involving cytochrome c release and 
activation of caspase-9 and caspase-3 may be important upstream events in the proteolytic 
activation of PKCô. 
The downstream cellular events initiated by caspase-3 have not been clearly defined 
in dopaminergic cell death following exposure to MPP+. Although the DNA repair enzymes 
Poly (ADP-ribose) polymerase (PARP) (Eamshaw et al., 1999; Tewari et al., 1995), DNA-
PK (Itoh and Horio, 2001), and several nuclear envelope proteins (Martelli et al., 2001) are 
characterized as substrates of caspase-3 in non-neuronal cells, their contribution to 
dopaminergic neuronal cell death is unclear. Since phosphorylation is a key regulatory 
mechanism in apoptotic signaling, we focused our attention on the PKC isoforms in the 
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present study. The majority of studies have shown that activation of PKC isoforms mainly 
suppresses apoptosis in a variety of non-neuronal cell types (Brodie and Blumberg, 2003; 
Dempsey et al., 2000; Gschwendt, 1999; Kikkawa et al., 2002; Maher, 2001). However, 
accumulating evidence indicates that apoptotic stimuli and oxidative insults induce activation 
of the novel PKC isoform PKCô (Ha et al., 2001; Kikkawa et al., 2002; Majumder et al., 
2001; Otieno and Kensler, 2000; Sun et al., 2000) PKCô can be activated through at least 
three different mechanisms: (i) translocation to the plasma membrane, (ii) phosphorylation at 
tyrosine, serine or threonine, and (iii) caspase-3-mediated proteolytic cleavage (Kikkawa et 
al., 2002). Our data demonstrate a persistent activation of PKCô during MPP+ treatment 
resulting from proteolytic cleavage mediated by caspase-3 that leads to permanent 
dissociation of the catalytic subunit of PKCô from the regulatory subunits. The caspase-3 
inhibitor Z-DEVD-FMK blocked 81% of PKCô cleavage as determined by the densitometric 
analysis of Western blot data whereas a complete inhibition was observed with Z-DEVD-
FMK on PKCô activity (Fig 2C). This difference may be due to the residual effect of the 
cleaved fragments detected in the Western blot or may due to effectiveness of a newly 
prepared caspase-3 inhibitor used in the kinase assay. Furthermore, PKCô did not translocate 
to the membrane, indicating that proteolytic activation is the major form of activation of 
PKCô during MPP+ treatment. 
Our findings clearly demonstrate that siRNA inhibits PKCô in an isoform specific 
manner, which has never been possible with the use of pharmacological inhibitors. For 
example, rottlerin has been widely used as an inhibitor of PKCô (Basu et al., 2001; Reyland 
et al., 1999), but recent reports indicate that rottlerin can inhibit other kinases including MAP 
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kinases (Davies et al., 2000). The mechanisms of action of siRNA in the present study may 
be due to translational suppression of PKCô because siRNA-ô-4 effectively inhibited both 
PKCÔ mRNA (Fig. 5D) and the protein expression (Fig. 5A). Previous studies have shown 
the suppression of mRNA and protein levels following siRNA treatments (Hannon, 2002; 
Irie et al., 2002; Nagy et al., 2003). Recently, Kaasinen et al reported that PKCô expression 
was induced following a kainate lesion or in ischemic brain damage (Kaasinen et al., 2002). 
However, we did not find any significant induction of PKCô mRNA expression up to 36 hr 
of MPP+ treatment. The induction of PKCô expression in kainate and ischemic cell death 
may be related to the neuronal excitation associated with excitotoxicity. In this regard, 
neuronal excitation due to glutamate treatment found to increase PKCô activation which is 
independent of cleavage (Ahlemeyer et al., 2002). Blockade of MPP+-induced proteolytic 
activation PKCô and DNA fragmentation by siRNA-ô-4 in N27 cells clearly establishes 
proapoptotic function for PKCô in neuronal apoptosis. Tunnel staining in MPP+-treated 
primary mesencephalic dopaminergic neurons further extends the apoptotic function of 
PKCô in dopaminergic neuronal degeneration. In primary mesencephalic cultures, the effect 
of siRNA on PKCô protein suppression (42%) and dopaminergic neuronal survival (54%) 
showed a reasonable correlation, further supporting the proapoptotic role of PKCô in 
dopaminergic neuronal cell death. 
We also found that siRNA transfected cells were phenotypically similar to control 
cells, suggesting that siRNA treatments are well tolerated by neuronal cells. Thus, siRNA-
mediated knock-down of PKCô appears to be an extremely effective method of gene 
inactivation that does not induce significant toxicity. Because of the high specificity and low 
toxicity of siRNAs, the therapeutic application of this technique has recently been explored 
(Caplen, 2003; O'Neil et al., 2001). Xia et al., 2002 demonstrated as proof of principle that 
siRNA technology could attenuate neurodegeneration in an animal model of Huntington's 
disease. 
Although the cellular events downstream of PKCô responsible for cell death are not 
well understood, PKCô has been shown to regulate a number of molecules that are associated 
with the cell death process including scrambalase (Frasch et al., 2000), DNA protein kinase 
(DNA-PK) (Bharti et al., 1998), heat-shock proteins-25/27 (Maizels et al., 1998), lamin B 
(Cross, 2000 #14), human RAD9 (Yoshida et al., 2003) and the redox sensitive transcription 
factor NF-KB (Page et al., 2003). Recently, PKCô was also shown to translocate to the 
nucleus upon activation (DeVries et al., 2002). Thus, PKCô may exert its proapoptotic 
function by interacting with the one or more of the downstream effectors. Studies are 
underway to identify key PKCô interacting proteins that might contribute to apoptotic cell 
death in dopaminergic neurons. 
In conclusion, we demonstrated that proteolytic activation of PKCô facilitates 
dopaminergic cell death in cell culture models of PD and selective targeting of the 
proapoptotic kinase PKCô by siRNA could rescue dopaminergic neurons. The proapoptotic 
function PKCô in dopaminergic degeneration may have therapeutic implications in 
Parkinson's disease. 
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MATERIALS AND METHODS 
Reagents 
MPP+ ( 1 -Methyl-4-phenylpyridinium), protease cocktail, ATP, protein-A-sepharose, 
and anti-P-actin antibody were obtained from Sigma-Aldrich (St. Louis, MO); CaspACE® kit 
was purchased from Promega; Z-DEVD-FMK was obtained from Alexis Biochemicals (San 
Diego, CA); Z-LEHD-FMK was purchased from BD Biosciences (San Diego, CA). Ac-
DEVD-AMC (Acetyl-Asp-Glu-Val-Asp-7-Amino-4-Methyl-Coumarin) and the rabbit 
polyclonal antibody for tyrosine hydroxylase were obtained from Calbiochem Bioscience, 
Inc. (King of Prussia, PA); antibodies to PKCô, PKCa, and PKCs were purchased from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-rabbit and anti-mouse secondary 
antibodies and the ECL chemiluminescence kit were purchased from Amersham Pharmacia 
Biotech. (Piscataway, NJ). Alexa 488 conjugated anti-rabbit antibody and Hoechst 33342 
were purchased from Molecular Probes, Inc. (Eugene, OR). The Cell Death Detection ELISA 
plus Assay Kit was purchased from Roche Molecular Biochemicals (Indianapolis, IN), [y-
32P] ATP was purchased from Perkin Elmer Life Science Products (Boston, MA). The 
Bradford protein assay kit was purchased from Bio-Rad Laboratories (Hercules, CA). RPMI, 
fetal bovine serum, L-glutamine, penicillin, and streptomycin were purchased from 
Invitrogen (Gaithesburg, MD). The siRNA silencer construction kit and labeling kit were 
purchased from Ambion, Inc (Austin, TX). TranslT-TKO Reagent was purchased from 
Miras (Madison, WI). Oligonucleotides were synthesized and PAGE purified with Integrated 
DNA Technology (Iowa City, IA). Quantity One 4.2.0 software was purchased from Bio-Rad 
(Hercules, CA) and Vector NTI software was purchased from InforMax Inc., (Frederick, 
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MD). TUNEL kit was purchased from Upstate Biotechnology (Lake Placid, NY). cDNA 
synthesis kit and Taq enzyme were purchased from Invitrogen, Inc., (Carlsbad, CA). 
Cell culture 
The immortalized rat mesencephalic dopaminergic neuronal cell line (N27) was a 
kind gift from Dr. Kedar N. Prasad, University of Colorado Health Sciences Center (Denver, 
CO). N27 cells were grown in RPMI 1640 medium containing 10% fetal bovine serum, 2 
mM L-glutamine, 50 units penicillin, and 50 j-tg/ml streptomycin. Cells were grown in a 
humidified atmosphere of 5% CO2 at 37°C as previously described (Anantharam et al., 2002; 
Kitazawa et al., 2003), and 4-5 days old cells were used for the experiments. 
Primary mesencephalic neuronal culture 
Primary mesencephalic neuronal cultures were prepared from the ventral 
mesencephalon of gestational 16-17 day old rat embryos as described in detail elsewhere 
(Madhavan et al., 2003; Wang et al., 1995). Briefly, dissected tissues were maintained on ice 
cold calcium free BBSS supplemented with gentomycin (50 mg/ml) and 
penicillin/streptomycin (200units/ml) and then dissociated in BBSS solution containing 
trypsin (0.25%) for 15 min. The dissociated cells were plated at equal density (0.5 x 106 
cells) in 30 mm diameter tissue culture wells pre-coated with poly-L-lysine (1 mg/ml). 
Cultures were maintained in a chemically defined, serum-free medium consisting of 
neurobasal medium fortified with B-27 supplements, L-Glutamine (500 pM), penicillin (100 
IU/ml) and streptomycin (100 pig/ml) (Life Technologies). The cells were maintained in a 
humidified CO2 incubator (5% CO2, 37°C) for 24 hr and then treated with cytosine 
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arabinoside (10 jjM) for 24 hr to inhibit glial cell proliferation. Half of the culture medium 
was replaced every 2 days. Approximately 6-7 day old cultures were used for experiments. 
Treatment paradigm 
Transacted and untransfected N27 cells were treated with 300 pM MPP+ for 36 to 42 
hr at 37°C. Primary neuron was exposed to lOfjM MPP+ for 48hr. MPP+ was added to siRNA 
transacted cells 24 hr post-transfection. In caspase-3 and caspase-9 inhibitor studies, cells 
were co-treated with Z-DEVD-FMK or Z-LEHD-FMK and MPP+. Untreated cells were used 
as a negative control. 
Design and preparation of siRNAs 
siRNAs were prepared by an in vitro transcription method. Target sites were selected 
based on previously established empirical criteria (Elbashir et al., 2001b) Initially, four 
siRNA (siRNA-8-1, 5-2, 6-3, and 5-4) target sites specific to rat PKCô mRNA (gi: 
18959249), as determined by blast analysis, were chosen. One non-specific siRNA (siRNA-
NS) was also chosen based on random sequence. For each siRNA, sense and antisense 
templates were designed based on each target sequence and partial T7 promoter sequence 
(Donze and Picard, 2002). All template oligonucleotides were chemically synthesized and 
PAGE purified. In vitro transcription, annealing, and purification of siRNA duplexes were 
performed using the protocol supplied with the silencer siRNA construction kit (Ambion, Inc. 
Austin, TX). Briefly, ~ 2 jj.g of each single-strand (ss) transcription template was first 
annealed with the T7 promoter and filled in by Klenow DNA polymerase to form double-
strand transcription templates. For preparation of each siRNA duplex, transcription reactions 
were first performed with separated antisense and sense templates using the T7 RNA 
polymerase provided with the kit and then annealed to form siRNA duplexes. Then the 
siRNA duplex was treated with DNase and RNase to remove the extra nucleotides of 
transcribed siRNA to meet the structural 3'UU overhang and 5'phosphate requirement 
(Elbashir et al., 2001b). 
siRNA transfection 
N27 Cells (50-70% confluency) and primary mesencephalic neurons were transfected 
with siRNA duplexes using the protocol supplied with the TransïT-TKO Reagent (Miras 
Corp, Madison, WI). Briefly, the TKO reagent was first diluted (1:100) into RPMI 1640 
medium for about 15 min, and then the siRNA duplex was added to the medium to form a 
lipid-siRNA complex. Following additional 15 min incubation, transfection was initiated by 
adding the lipid-siRNA complex to 24-well or 6-well plates. The final concentration of 
siRNA varied from 5 to 25 nM. 
Cy3 labeling of siRNAs 
Purified siRNA duplexes were labeled using the silencer siRNA labeling kit (Ambion, 
Austin, TX). Briefly, ~5 |ig siRNA duplex was added to the Cy3 labeling reagent and the 
reaction mixture was then incubated at 37°C in the dark for 1 hr. The unlabeled Cy3 was 
removed by ethanol precipitation. The labeled siRNAs were then delivered to cells by 
transfection. Cy3 labeled siRNAs in transfected cells were visualized using a Nikon inverted 
fluorescence microscope (Model TE-2000U) and pictures were captured with a SPOT digital 
camera (Diagnostic Instruments, Sterling Heights, MI). 
Isolation of cytoplasmic fractions 
Cytoplasmic fractions were isolated as described previously (Anantharam et al., 
2002). Briefly, after treatment, the N27 cells were harvested with trypsin/EDTA solution and 
spun at 200 x g for 5 min. Cell pellets were then washed twice with ice-cold PBS (1 mM 
sodium phosphate, 15 mM NaCl, and pH 7.4) and resuspended in 200 fj.1 of hypotonic buffer 
(10 mM HEPES, pH 7.9, 1.5 mM MgClz, 10 mM KC1, 1 mM DTT, and protease inhibitor 
cocktail diluted 1:100). Triton-X 100 (final concentration 0.5%) was then added to the 
homogenization and vortexed vigorously for 15 sec. Cell lysates were centrifuged for 30 min 
at 14,000 rpm and supematants were collected. Protein concentrations were determined using 
a Bradford protein assay kit. 
Western blotting 
Equal amounts of cytoplasmic protein (10-20|ag) were loaded in each lane and 
separated on a 10% SDS-polyacrylamide gel as described previously (Anantharam et al., 
2002). Proteins were then transferred to nitrocellulose membrane by electro-blotting 
overnight (4°C, 25 V). Non-specific binding sites were blocked by treating the nitrocellulose 
membranes with 5% non-fat dry milk TBST solution (10 mM Tris, 150 mM NaCl, and 0.1% 
Tween 20) for 1 hr. The nitrocellulose membranes were then incubated with primary 
antibodies for 1 hr at RT (anti-PKCa, 5 or s antibodies, 1:2000). The primary antibody 
treatment was followed by treatment with secondary HRP-conjugated anti-rabbit or anti-
mouse IgG (1:2000) for 1 hr at RT. Secondary antibody-bound proteins were detected using 
an ECL chemiluminescence kit (Amersham). To confirm equal protein loading, blots were 
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reprobed with P-actin antibody (1:5000). Gel photographs and densitometric analysis were 
performed with a Kodak image station (Model 1000R, Rochester, New York). 
RT-PCR 
After treatment, cells were lysed in 1 ml TRIZOL reagent and total RNA was isolated 
by chloroform extraction and precipitated by ethanol. First, total RNA was treated with 
DNase I to remove DNA contamination and then reversely transcribed into first strand cDNA 
using the SuperScript III first-strand synthesis system (Invitrogen, Inc, Carlsbad, CA) as 
described in the kit instructions. Quantitative PCR was performed with PKCô primers and 
control GAPDH primers as previously described (Suzuki et al., 2000). The primer sequences 
used were as follows: rat PKCô - forward: 5' gggctacgttttatgcagct 3'; reverse: 5' 
agcaggtctgggagctcact 3'; rat GAPDH - forward: 5' atgggaagctggtcatcaac 3'; reverse: 5' 
tgtagcccaggatgccctt 3'. The PCR reaction was performed in DNA thermal cycler. The 
amplified products were visualized on agarose gel impregnated with ethidium bromide and 
the intensity of amplified products was measured with a Kodak image station. 
Immunocytochemistry 
Immunostaining of PKCô was performed 24 hr post-transfection in untransfected, 
Cy3-siRNA-ô-4, and Cy3-siRNA-NS transfected N27 cells. Cells grown on poly L-lysine 
coated glass cover slips were gently washed with PBS twice, fixed in 4% paraformaldehyde, 
washed 3X7 min with PBS, permeabilized, and blocked with blocking reagent (0.4% BSA, 
5% goat serum, and 0.2% Triton-X 100 in PBS) for 20 min. Cells were then incubated with 
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anti-PKCô rabbit polyclonal antibody (1:200 in blocking reagent) overnight at 4°C and then 
washed 4X8 min with PBS. PKCô was visualized by incubation with Alexa 488-conjugated 
g o a t  a n t i - r a b b i t  s e c o n d a r y  a n t i b o d y  ( 1 : 2 0 0  i n  P B S )  a t  R T  f o r  9 0  m i n .  A f t e r  a n o t h e r  4 X 8  
min PBS wash, Hoechst 33342 (final concentration of 10 (ig/ml in PBS) was added to stain 
the cell nuclei at RT for 3 min. Finally, cells were washed once in PBS and mounted on a 
slide with Antifade mounting medium. The cells were observed under a Nikon inverted 
fluorescence microscope (Model TE-2000U) and pictures were captured with a SPOT digital 
camera (Diagnostic Instruments, Sterling Heights, MI). For primary neurons, 
immunostaining of TH was performed using rabbit polyclonal TH antibody (1:200). 
Quantitative analysis of immuno fluorescence was measured by defining the region of 
interest (ROl) in Metamorph image analysis software and plotted in Prism software. 
Immunoprecipitation kinase assay 
PKCô enzymatic activity was assayed using an immunoprecipitation kinase assay as 
previously described (Anantharam et al., 2002). After treatment with MPP+, N27 cells were 
washed twice with PBS and resuspended in 200 jj.1 of PKC lysis buffer (25 mM HEPES, pH 
7.5, 20 mM ^-glycerophosphate, 0.1 mM sodium orthovanadate, 0.1% Triton X 100, 0.3 M 
NaCl, 1.5 mM MgCl], 0.2 mM EDTA, 0.5 mM DTT, 10 mM NaF, and 4 fj.g/ml each of 
aprotonin and leupeptin). The cells were homogenized by sonication for 15 sec under ice-
cold conditions. The cytoplasmic factions were collected by centrifuging the cell lysates at 
14,000 x g for 30 min. Protein concentrations were determined by Bradford protein assay. 
Cytoplasmic protein (0.2-0.4 mg) was immunoprecipitated overnight at 4°C using 4 jj,g of 
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anti-PKCô antibody. The immunoprecipitates were then incubated with protein-A-sepharose 
for 1 hr at 4°C. The protein-A bound antigen-antibody complexes were then washed 3 times 
with PKC lysis buffer, 3 times with kinase buffer (40 mM Tris, pH 7.4, 20 mM MgCb, 20 
(j,M ATP, and 2.5 mM CaCl2), and resuspended in 20 jul of kinase buffer. Reactions were 
started by adding 20 jal of reaction buffer containing 0.4 mg Histone HI and 5 (J,Ci of [y-32P] 
ATP (3,000 Ci/mM) to the immunoprecipitated samples and incubated for 10 min at 30°C. 
SDS gel loading buffer (2X) was then added to terminate the reaction, the samples were 
boiled for 5 min, and the products were separated on a 12% SDS-PAGE gel. The 
phosphorylated HI histone bands were detected using a Personal Molecular Imager (FX 
model, Bio-Rad) and quantified using Quantity One 4.2.0 software (Bio-Rad, Hercules, CA). 
Enzymatic assay for caspase-3 
Caspase-3 activity was measured as previously described (Yoshimura et al., 1998). 
Briefly, cells were spun down after treatment and the pellets were lysed with Tris buffer (pH 
7.4, 50 mM Tris HC1, 1 mM EDTA, and 10 mM EGTA) containing 10 fj,M digitonin for 15 
min at 37°C. Lysates were centrifuged at 900 x g for 3 min and the resulting supematants 
were incubated with a specific fluorogenic caspase-3 substrate (Ac-DEVD-AMC, 10 JJM) at 
37°C for 1 hr. Cleaved substrate was monitored at excitation X 380 nm and emission X 460 
nm using a multiwell fluorescence plate reader (Model: Gemini XS, Molecular Devices, 
Sunnyvale, CA). Caspase-3 activity was calculated as fluorescence units per mg protein per 
hour and expressed as percentage of control. 
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In situ analysis of caspase activity 
A cell-permeable fluorescent probe FITC-VAD-FMK was used in this assay. The 
experimental procedure was performed according to Promega's CaspACE® kit, with some 
minor modifications. N27 cells were grown on poly-L lysine (0.1 mg/ml) coated cover slips 
for 24 hrs. After exposure to MPP+, the cells were treated with 10 JIM FITC-VAD-FMK for 
20 min at 37°C in the dark. Cells were then rinsed once with PBS and fixed with 10% 
buffered formalin for 30 min at room temperature in the dark. After fixation, the cells were 
washed twice and observed under a Nikon Diaphot microscope. Pictures were captured with 
a SPOT digital camera (Diagnostic Instruments, Sterling Heights, MI). 
Quantification assay for DNA fragmentation 
DNA fragmentation was measured using a recently developed Cell Death Detection 
ELIS A plus Assay Kit (Molecular Biochemicals, Indianapolis, IN) (Anantharam et al., 2002; 
Reyland et al., 1999). Briefly, cells were spun down at 200 x g for 5 min and washed twice 
with IX PBS. Cells were then incubated with a lysis buffer (supplied with the kit) at RT. 
After 30 min, samples were centrifuged and 20 pi aliquots of the supernatant were then 
dispensed into streptavidin-coated 96 well microtiter plates followed by addition of 80 pi of 
HRP-conjugated antibody cocktail, and incubated for 2 hr at RT with mild shaking. After 
incubation, unbound components were removed by washing with the incubation buffer 
supplied with the kit. The nucleosomes retained by the antibody cocktail in the 
immunocomplex were quantified spectrophotometrically with ABTS as an HRP substrate. 
Measurements were made at 405 nm and 490 nm using a SpectroMax 190 spectrophotometer 
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(Molecular Devices, Sunnyvale, CA). The difference of absorbance between OD 405 and OD 
490 nm was used to measure the actual DNA fragmentation level. 
TUNEL staining 
Primary neurons were cultured on coverslip in 6-well plates. After siRNA 
transfection and MPP+ treatment, cells were washed by IX PBS and fixed with 4% 
paraformaldehyde for 15min and permeabolized with 0.2% Triton-X containing 0.2% BSA 
in PBS for another 15 min. Cells were then incubated in TdT end-labeling cocktail 
(50fj,l/coverslip) containing Biotin-dUTP, TdT buffer and TdT for 60 min at RT and reaction 
was stopped by immersing cells in IX TB buffer. After the wash, the neurons were incubated 
in blocking reagent containing avidin-FITC for 30 min at RT and then washed with IX PBS. 
Nucleus counterstaining was then performed by incubating cells with Hoechst 33342 for 3 
min. Cells were washed with IX PBS and mounted on slides. The cells were observed and 
pictures captured as described in the immunocytochemistry section. Quantitative analysis of 
fluorescence immunoreactivity was measured by defining the region of interests (ROI) in 
Metamorph software and plotted in Prism software. 
Lactate Dehydrogenase (LDH) Assay 
LDH activity in the cell-free extracellular supernatant was quantified as an index of 
cell death (Kanthasamy et al., 1995). We modified the original method to a 96-well format 
(Kitazawa et al., 2001). Briefly, both untransfected and siRNA transfected N27 cells were 
plated in 96-well plate and 24 hr after transfection 10 jal of the extracellular supernatant was 
added to 200 pi of 0.08 M Tris buffer (pH 7.2) containing 0.2 M NaCl, 0.2 mM NADU, and 
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1.6 mM sodium pyruvate. LDH activity was measured continuously by monitoring the 
decrease in the rate of absorbance at 339 nm using a microplate reader (Molecular Devices, 
Sunnyvale, CA) and the temperature was maintained at 37°C during reading. Changes in 
absorbance per minute (ôA/ôT) were used to calculate LDH activity (U/I), using the 
following equation: U/I = (ôA/ôT) x 9682 x 0.66, where 9682 was a coefficient factor, and 
0.66 was a correction factor at 37°C. 
Data analysis 
Data analysis was performed using Prism 3.0 software (GraphPad Software, San 
Diego, CA). Data from PKCô kinase, DNA fragmentation and LDH assays were first 
analyzed using one-way ANOVA. Bonferroni's post-test was then performed to compare all 
groups and differences with p<0.05 were considered significant. To analyze the caspase-3 
enzymatic activity results, the paired t-test was used. 
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Control 
Control MPP* 
Figurel: MPP+ treatment activates caspase-3 in rat mesencephalic dopaminergic 
neuronal (N27) cells. 
(A) Caspase-3 enzyme activity increases significantly after MPP+ (300 JIM) exposure for 36 
hr. Caspase-3 activity was assayed using a specific fluorogenic substrate, Ac-DEVD-AMC 
(10 (iM), as described in the Methods. The data represent the mean + S EM from two separate 
experiments in triplicate (**, p<0.01; N=6). (B) MPP+ (300 |iM) treatment for 36 hr also 
induces caspase activation as observed by in situ staining using FITC-VAD-FMK as a 
substrate. 
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Figure 2: Caspase-3 and Caspase-9 cascade mediate MPP-induced proteolytic 
activation of PKCô in N27 cells. 
A) Co-treatment with Z-DEVD-FMK (50 p,M) blocks the MPP+ (300 pM) induced 
proteolytic cleavage of PKCô cleavage (38-41 kDa), (B) Caspase-9 inhibitor Z-LEHD-FMK 
(50pM) also blocks proteolytic cleavage of PKCô, (C) MPP+ induced PKCô kinase activity is 
suppressed by caspase-3 inhibitor with Z-DEVD-FMK (50 pM), and (D) No change in PKCô 
mRNA level during MPP+ treatment as measured by RT-PCR. Cells were treated with 300 
pM MPP+ for 36 hr in the presence or absence of caspase inhibitors. Cells were then lysed 
and the lysate was used for Western blot analysis and kinase assay. To confirm equal protein 
loading in Western blot, the membranes were reprobed with (3-actin antibody. For RT-PCR 
analysis, total mRNA was isolated from MPP+ (300 pM for 36 hr) treated cells and then 
reverse transcription was performed with the use of Superscript III first-strand synthesis 
system (Invitrogen, Carlsbad, CA). GAPDH was used as internal control. Images are 
representative from three separate experiments. The kinase assay data represent the mean + 
SEM from two separate experiments in triplicate (***, pO.OOl; N=6). 
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Control Z-DEVD-FMK (50fxM) 
Native PKCÔ (72/74 KDa) 
Cleaved PKCô (41/38 KDa) 
P-actin (43 KDa) 
B. Control Z-LEHD-FMK (50fiM) 
Native PKCô (72/74 KDa) 
Cleaved PKCô (41/38 KDa) 
P-actin (43 KDa) 
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Figure 3: Specificity of proteolytic activation of PKCô during MPP+ treatment 
(A) No membrane translocation of PKCô following MPP+ treatment. After treatment with 
300 pM MPP+ for 36 hr, cytosol and membrane fractions were separated and used for 
determining PKCô translocation. (B) No proteolytic activation of PKCa during MPP+ 
treatment. Whole cell lysates were prepared after MPP+ (300 pM) treatment for determining 
PKCa cleavage. All experiments were repeated three times and representative images are 
presented. 
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Figure 4: Design and Synthesis of siRNAs against PKCô. 
(A) Schematic representation of the primary structure of rat PKCô mRNA (gi: 18959249) 
and four target sites of siRNA. The exact position of each target site was shown in the 
diagram and GC% was calculated with Vector NTI software (InforMax Inc., Frederick, MD). 
(B) Template sequences of siRNA duplexes. A pair of sense and antisense templates was 
designed to generate siRNA duplexes. The partial T7 promoter sequence (underlined) was 
also included in each template. All oligonucleotides were synthesized and PAGE purified by 
Integrated DNA Technology (Iowa City, IA). (C) In vitro transcription of siRNA. In vitro 
transcription, annealing, and purification of siRNA duplexes were performed using the 
protocol supplied with the silencer siRNA kit (Ambion Inc, Austin, TX). The siRNAs were 
separated on 12% PAGE and visualized by ethidium bromide staining. All siRNAs except 
siRNA-ô-3 showed the specific transcription products of expected size. 
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siRNA-5-3: 
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siRNA-5-4 
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siRNA 5-1 5-2 5-3 5-4 NS 
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Figure 5: Suppression of PKCô expression in N27 cells transfected with siRNA-ô-1 and 
siRNA-ô-4. 
(A) Isoform specific suppression of PKCô expression at 24hr post-transfection with siRNA-
ô-4, (B) Isoform specific suppression of PKCô expression at 48hr post-transfection with 
siRNA-ô-1, (C) Time course analysis of PKCÔ expression in cells transfected with siRNA-ô-
4. (D) RT-PCR analysis of PKCô mRNA expression in siRNA-ô-4 and siRNA-NS 
transfected N27 cells. PKCô expression in N27 cells transfected with different siRNAs was 
determined by immunoblotting at 24 hr and 48hr post transfection. Final concentrations of 
siRNAs varied from 5 nM to 25 nM. To examine the specificity of siRNAs and verify equal 
protein loading, the membranes were reprobed with PKCs (90 kDa), one of the closest 
isoforms of PKCô, and P-actin (43 kDa) antibodies, respectively. For RT-PCR analysis, total 
mRNA was extracted 24 hr after siRNA transfection. All experiments were repeated three 
times and representative images are presented. 
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Figure 6: In situ localization of siRNA and immunochemistry of PKC8 in siRNA 
transfected N27 cells. 
(A) Cells transfected with Cy3-labeled siRNA-5-4 (25 nM) showing greatly reduced PKC6 
expression. (B) Cells transfected with Cy3-labeled siRNA-NS (25 nM) showing no change in 
PKCô expression. (C) Untransfected N27 cells showing normal PKC8 expression. (D) 
Quantitative analysis of in situ suppression of PKCô expression by siRNA-8-4 in N27 cells. 
For PKCô immunostaining, cells were permeablized and incubated with PKC8 antibody 24 
hr post-transfection and then visualized with Alexa 488 (green) conjugated anti-rabbit 
antibody. siRNA was visualized by labeled Cy3 (red) fluorescence. The nuclei were 
visualized by Hoechst 33342 counterstaining (blue). Cy3-labeled siRNAs were prepared 
prior to transaction according to the silencer siRNA labeling kit (Ambion Inc, Austin, TX). 
Cells were observed under a Nikon inverted fluorescence microscope and pictures were 
captured with a SPOT digital camera (Diagnostic Instruments, Sterling Heights, MI). For in 
situ quantitative analysis of PKCô expression, fluorescence immunoreactivity of PKC5 was 
measured in each group using Metamorph image software and data plotted in Prism software. 
Experiments were repeated three times and representative images are presented. 
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Figure 7: Ablation of MPP-induced PKCô kinase activity and DNA fragmentation by 
siRNA-ô-4 in mesencephalic dopaminergic neuronal cells. 
(A) Transfection of siRNA-ô-4 prior to MPP+ exposure (300 p,M for 36 hr) reduces PKCô 
kinase activity to the control level. (B) Transfection of siRNA-ô-4 almost completely 
protects cells against MPP+-induced DNA fragmentation. Sub-confluent cultures of N27 cells 
were transfected with siRNA-ô-4 (25 nM) for 24 hr and the cells were treated with MPP+ for 
42 hr. After exposure to MPP+, the N27 cells were harvested, lysed, and analyzed. 
Untransfected N27 cells not exposed to MPP+ were used as controls. The data represent the 
mean + SEM from two separate experiments in triplicate (*, p<0.05; **, p<0.01 and ***, 
pO.OOl; N=6). 
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Figure 8: In situ suppression of PKCô expression by siRNA-ô-4 in primary 
mesencephalic cultures. 
(A) Localization of siRNA-ô-4 in TH positive neuron. (B) Quantitative analysis of in situ 
suppression of PKCô by siRNA-Ô-4 in primary mesencephalic cells. Primary mesencephalic 
neurons were cultured from El5 rat embryo midbrain and then transfected with Cy3-labelled 
siRNA (red). PKCô or TH immunostaining was performed 24hr post-transfection of siRNA, 
by using PKCô or TH antibodies and then visualized separately with Alexa 488 (green) 
conjugated anti-rabbit antibody. The nuclei were counterstained by Hoechst 33342 (blue). 
Stained primary neurons were observed under a Nikon inverted fluorescence microscope and 
pictures were captured with a SPOT digital camera (Diagnostic Instruments, Sterling Heights, 
MI). For in situ quantitative analysis of PKCô expression, fluorescence immunoreactivity of 
PKCô was measured from neurons in each group using Metamorph software and the data 
plotted in Prism software. The data represent the mean ± SEM from two separate 
experiments in triplicate (*, p<0.05; N=6). 
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Figure 9: siRNA-ô-4 prevents MPP-induced apoptotic death in primary 
mesencephalic TH positive neurons. 
(A) TUNEL staining in MPP+ treated rat primary mesencephalic neurons. Primary 
mesencephalic cultures were transfected with Cy3 labeled siRNAs and then exposed to 10 
|jM MPP+ for an additional 48 hr. FITC-TUNEL staining and Hoechst 33342 nuclear staining 
were performed. (B) Quantitative analysis of TH positive neurons following siRNA-5-4 
transfection and MPP+ treatment. After siRNAs transfection, cells were exposed to 10 pM 
MPP+ for 48 hr and then TH positive neurons were identified using anti-TH antibody 
exposure. Data represent the mean + SEM from two separate experiments in triplicates (*, 
p<0.05; N=6). (C) Total number of TH+ neurons per 5000 mesencephalic primary cells 
counted in each group. 
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Figure 10: siRNAs are non-toxic to mesencephalic dopaminergic neuronal cells. 
siRNA-ô-4 and siRNA-NS (25 nM) were transfected into N27 cells. Following the 24 hr 
transfection, cell free culture medium was collected, and LDH activity was measured 
spectrophotometrically. Values represent mean ± SEM for two separate experiments in 
triplicate (*, p<0.05; N=6). 
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CHAPTER III: PROTEOLYTICALLY ACTIVATED PKCÔ TRANSLOCATES TO 
THE NUCLEUS AND MEDIATES SER14 PHOSPHORYLATION OF HISTONE 
H2B IN APOPTOTIC DEATH OF DOPAMINERGIC NEURONAL CELLS 
A paper submitted to Cell Death and Differentiation 
Yongjie Yang, Vellareddy Anantharam, Anumantha Kanthasamy 
ABSTRACT 
We previously showed that oxidative stress sensitive kinase PKCô promotes 
apoptotic death in dopaminergic neurons following neurotoxin exposures (Kitazawa et al., 
2003; Yang et al., 2004). However, its mechanism has not been well understood. In the 
present study, we determined that the full-length PKCô is first cleaved in the cytoplasm and 
the activated cleaved PKCô subsequently translocates into the nucleus. The caspase-3 
specific inhibitor Z-DEVD-FMK, the cleavage resistant mutant of PKCô (PKCô-CRM), as 
well as the nuclear localization signal (NLS) deletion mutant of PKCÔ (PKCô-ANLS) 
abolishes the nuclear translocation of activated cleaved PKCô. Our study showed that 
proteolytic activation of full-length PKCô and subsequent nuclear translocation of activated 
cleaved PKCô are integral events required for PKCô's pro-apoptotic function in apoptosis of 
dopaminergic neuronal cells. Moreover, we demonstrated that activated cleaved PKCô, after 
its nuclear translocation, mediates Serl4 phosphorylation of histone H2B in apoptotic 
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dopaminergic neuronal cells. Serl4 phosphorylation of H2B and apoptosis can also be 
directly induced by the catalytic fragment of PKCô (PKCô-CF), but not by the regulatory 
fragment of PKCô (PKCô-RF), dominant-negative mutant of PKCô (PKCô-DN), PKCô-
CRM, or PKCô-ANLS. Taken together, our study suggests that proteolytically activated 
PKCô translocates into the nucleus and mediates Serl4 phosphorylation of H2B to promote 
neurotoxin-induced apoptosis of dopaminergic neuronal cells. 
INTRODUCTION 
Mechanisms of selective degeneration of midbrain dopaminergic neurons in 
Parkinson's disease (PD) remain elusive despite intensive studies into the pathogenesis of PD. 
Although the recent identification of a number of genetic mutations that cause several groups 
of familial PD shed light on the understanding of the mechanisms of dopaminergic neuron 
degeneration (Dawson and Dawson, 2003; Greenamyre and Hastings, 2004; Shen, 2004), 
exact causes of sporadic PD cases, which account for over 90% of total PD patients, are still 
not clear. On the other hand, the discovery that mitochondria complex I inhibitor l-methyl-4-
phenyl-1,2,3,6,-tetrahydropyridine (MPTP) induces Parkinsonism in humans (Langston et al., 
1984) suggests that exposure to environmental neurotoxins can contribute to dopaminergic 
neuron degeneration in sporadic PD patients (Dauer and Przedborski, 2003; Langston et al., 
1984; Vila and Przedborski, 2003; Wichmann and DeLong, 2003). Mouse and primate 
models exposed to MPTP or other mitochondria complex I inhibitors have been developed 
and exhibit degeneration of midbrain dopaminergic neurons and PD-like symptoms (Betarbet 
et al., 2002; Betarbet et al., 2000; Dauer and Przedborski, 2003; McCormack et al., 2002). 
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Interestingly, most of these mitochondria complex I inhibitors (paraquat, rotenone) are also 
commonly used pesticides, which implicates the potential pathogenic role of pesticides in PD 
(Betarbet et al., 2002; Giasson and Lee, 2000; Greenamyre et al., 2001; Jenner, 2001). As 
supportive evidence, epidemiological studies have also found that incidence rate of sporadic 
PD is higher among farming communities (Jenner, 1998; Seidler et al., 1996; Tanner and 
Langston, 1990). 
Dieldrin is an organochlorine pesticide that was widely used decades ago for the 
control of soil pests. Although it has been banned for about thirty years, the wide exposure of 
humans to dieldrin still exists through its persistent accumulation in the environment 
(Kitazawa et al., 2001, 2003). It is not clear as to whether dieldrin also inhibits mitochondria 
complex I; however, several studies have indicated that dieldrin exposure is positively 
associated with the increased incidence of PD. In fact, significant levels of dieldrin were 
detected in postmortem brains of PD patients, whereas no dieldrin was found in age-matched 
control brains (Corrigan et al., 1998; Fleming et al., 1994). Also, dieldrin exposure depletes 
dopamine in brains of ducks, ring doves and rats (Heinz et al., 1980; Sharma et al., 1976; 
Wagner and Greene, 1978). Furthermore, our previous studies also show that dopaminergic 
cells are highly sensitive to dieldrin induced toxicity (Kitazawa et al., 2001; Kitazawa et al., 
2002). 
By employing the well-developed MPTP (as well as other neurotoxin) cell and animal 
models of PD, it has been demonstrated that neurotoxin induced oxidative stress is one of the 
earliest events that triggers diverse downstream apoptotic pathways and induces the 
activation of executioner caspases in dopaminergic neurons (Beal, 2002; Greenamyre et al., 
2001; Hartmann et al., 2000; Hartmann et al., 2001; Jenner, 2003). Activated executioner 
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caspases directly mediate cleavage of a wide range of downstream substrates and lead to cell 
death. Protein kinases, one of the major signal transducers in the cell, have emerged as one 
major category of substrates for activated caspases. Kinases in different families, including 
Raf-1 and AKT (Widmann et al., 1998b), ATM, MEKK-1 (Widmann et al., 1998a), 
hPAK2/hPAK65 (Jakobi et al., 2003; Lee et al., 1997), PKC isoform ô and 9 (Datta et al., 
1997; Emoto et al., 1995), PKN (Takahashi et al., 1998), ROCK1 (Coleman et al., 2001), 
SLK (Sabourin et al., 2000), HPK1 (Chen et al., 1999), LIMK1 (Tomiyoshi et al., 2004), and 
Mst (de Souza and Lindsay, 2004; Huang et al., 2002), have been identified as substrates of 
activated caspases. Cleavage of these kinases not only regulates their activity (activation or 
inactivation), but also induces their relocation inside the cell, which moves kinases proximal 
to their specific substrates and transduces specific apoptotic signals (Jakobi, 2004; Teruel and 
Meyer, 2000). The proteolytic cleavage of ATM, for example, inactivates the protein, further 
impairing the DNA repair mechanism of cells in response to DNA damage (Smith et al., 
1999). In other cases, caspases mediated cleavage activates certain kinases, like Mst, and 
induces its nuclear translocation to facilitate apoptosis (Cheung et al., 2003; Huang et al., 
2002). 
Protein kinase C delta (PKCô), a member of the novel PKC family, is one of the 
kinases identified as a downstream target of caspase-3 in many different cell types, including 
dopaminergic neuronal cells, in response to apoptotic stimuli (Anantharam et al., 2002; 
Brodie and Blumberg, 2003; Kitazawa et al., 2003; Reyland et al., 1999). As a member of the 
novel PKC family, PKCô contains a lipid-sensitive C1 domain and a Ca2+ binding deficient 
C2 domain. The binding of lipid molecules (diacylglycerol or 4-phorbol 12-myristate 13-
acetate) induces rapid translocation of PKCô to the plasma membrane and activates the 
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kinase through conformational change that removes the pseudosubstrate from the catalytic 
site (Newton, 2003). The lipid-mediated activation allows PKCô to send normal transducing 
signals from receptors (Nishizuka, 1992). Moreover, the serine/threonine phosphorylation of 
its activation loop at its C-terminal by PDK-1 also contributes to PKCô's activation (Newton, 
2003; Toker, 1998). In apoptotic cells, caspase-3 mediated proteolytic cleavage of PKCô 
removes its regulatory fragment containing the pseudosubstrate and leads to persistent 
activation of the kinase (Kanthasamy et al., 2003; Kikkawa et al., 2002). The diverse 
mechanisms for the activation of PKCô raise an interesting question as to whether the 
proteolytic activation of full-length PKCô is necessary and specific for its function in 
apoptosis. Simultaneous with the activation, PKCô also relocates to the mitochondria, 
nucleus, endoplasmic reticulum (ER), golgi, as well as plasma membrane in apoptotic cells 
(Brodie and Blumberg, 2003). Translocation of PKCô to the mitochondria was shown to 
facilitate the mitochondrial pore formation, promoting cytochrome C release (Majumder et 
al., 2000) and inducing the redistribution of Bcl-2 family proteins (Murriel et al., 2004; 
Sitailo et al., 2004). The translocation of PKCô to the nucleus was linked to nuclear events 
that either regulate the mitochondrial apoptotic pathway or facilitate the collapse of nuclear 
structure in apoptotic cells (Cross et al., 2000; DeVries et al., 2002). 
We previously demonstrated that PKCô is a downstream target of activated caspase-3 
and its proteolytic activation is associated with a wide range of neurotoxins induced 
apoptosis in dopaminergic neuronal cells (Kaul et al., 2003; Kitazawa et al., 2003; Yang et al., 
2004). However, very little is known about the downstream actions of PKCô following its 
proteolytic activation. In the present study, we investigate the downstream events following 
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proteolytic activation of PKCô and determine the correlation between proteolytic cleavage 
and nuclear translocation of PKCô in dopaminergic neuronal cells. Furthermore, we also 
investigate the function of the activated cleaved PKCô in the nucleus of dieldrin induced 
apoptotic dopaminergic neuronal cells. 
MATERIALS AND METHODS 
Reagents 
Anti-cleaved caspase-3 antibody was obtained from Cell Signaling Technology, Inc. 
(Beverly, MA). Anti-LDH antibody was obtained from Research Diagnostics, Inc. (Flanders, 
NJ). Anti-lamin B antibody was obtained from Abeam, Inc (Cambridge, MA). Dieldrin, 
protease cocktail, purified Histone H2B, ATP, protein-A-sepharose, and anti-p-actin 
antibody were obtained from Sigma-Aldrich (St. Louis, MO); Z-DEVD-FMK was obtained 
from Alexis Biochemicals (San Diego, CA); antibodies to PKCô and PARP were purchased 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-phospho-Histone H2B (Serl4) 
antibody was purchased from Upstate Biotechnology (Waltham, MA). TaqMan Rat PKCô 
and 18s ribosome RNA assay kit and PCR master mix was purchased from Applied 
Biosystems (Foster City, CA). Anti-rabbit and anti-mouse secondary antibodies and the ECL 
chemiluminescence kit were purchased from Amersham Pharmacia Biotech (Piscataway, 
NJ). NE-PER™ nuclear and cytoplasmic extraction reagent was obtained from Pierce 
Biotechnology, Inc (Rockford, IL). Alexa 488 conjugated anti-rabbit secondary antibody and 
Hoechst 33342 were purchased from Molecular Probes, Inc. (Eugene, OR). Cy3 conjugated 
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anti-mouse secondary antibody was obtained from Jackson Laboratory (Bar Harbor, Maine). 
The Cell Death Detection ELISA plus Assay Kit was purchased from Roche Molecular 
Biochemicals (Indianapolis, IN). [y-32P] ATP was purchased from Perkin Elmer Life Science 
Products (Boston, MA). The Bradford protein assay kit was purchased from Bio-Rad 
Laboratories (Hercules, CA). Pfu DNA polymerase was purchased from Stratagene (La Jolla, 
CA). SuperScript III first-strand synthesis system, TRIZOL reagent, ViraPower™ lentiviral 
expresson system, RPMI, Opti-MEM, fetal bovine serum, L-glutamine, blasticidin, 
penicillin, and streptomycin were purchased from Invitrogen, Inc. (Carlsbad, CA). 
Cell culture and treatment 
The immortalized rat mesencephalic dopaminergic neuronal (N27) cell line was a 
kind gift from Dr. Kedar N. Prasad, University of Colorado Health Sciences Center (Denver, 
CO) (Adams et al., 1996; Prasad et al., 1998). N27 cells were grown in RPMI 1640 medium 
containing 10% fetal bovine serum, 2 mM L-glutamine, 50 units penicillin, and 50 |ig/ml 
streptomycin. Cells were grown in a humidified atmosphere of 5% CO2 at 37°C. For dieldrin 
treatment, N27 cells were treated with 60(iM dieldrin in serum-free medium for up to 3hr at 
37°C. In caspase-3 inhibitor studies, cells were co-treated with 50 -100|_iM Z-DEVD-FMK 
and dieldrin. Untreated cells were used as negative control. 
Construction of plasmids 
A series of PKCô-related constructs was prepared, including PKC5-WT (wild type), 
PKCô-CRM (cleavage resistant mutant), PKCô-ÀNLS (deletion of nuclear localization 
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signal), PKCô-DN (dominant negative mutant), PKC5-CF (catalytic fragment), and PKCô-
RF (regulatory fragment). To prepare PKCô-CF, PKCô-RF, PKCô-ÀNLS or PKCô-WT 
fragments, 995-2035bp, 14-982bp, 14-1843bp or full-length of mouse PKCS (gi: 6755081) 
cDNA were first amplified from pGFP-PKCô (kind gift of Dr. Reyland at University of 
Colorado) (DeVries et al., 2002) with the following primer pairs, respectively. For PKCô-CF, 
forward primer: 5' caccatgaacaacgggacctatggcaa 3'; reverse primer: 5' 
aatgtccaggaattgctcaaac 3'; for PKCô-RF, forward primer: 5' caccatggcacccttcctgcgc 3'; 
reverse primer: 5' actcccagagacttctggctt 3'; for PKCô-ÀNLS, forward primer: 
5'caccatggcacccttcctgcgc 3'; reverse primer: 5'ctccaggagggaccagtt 3'; for PKCô-WT, 
forward primer: 5' caccatggcacccttcctgcgc 3'; reverse primer: 5' aatgtccaggaattgctcaaac 3'. 
To prepare PKCô-CRM, full-length mouse PKCô cDNA with a point mutation at 993 (A to 
C) that abolishes the caspase-3 cleavage site of PKCô was amplified with pGFP-PKCÔD327A 
(kind gift of Dr. Reyland at University of Colorado) (DeVries et al., 2002) as template and 
the same primer pairs used for amplification of PKCô-WT. To prepare PKCô-DN, full-length 
mouse PKCô cDNA with a point mutation at 1489 (A to G) that abolishes the ATP binding 
site of PKCô was amplified with pPKCôK376R-EGFP (kind gift of Dr. Reyland at University 
of Colorado) as template and the same primer pairs used for amplification of PKCô-WT. All 
PCR reactions were performed with Pfu DNA polymerase to maintain the fidelity of the 
sequence. All PCR products were directly cloned in-frame into a V5-tagged expression 
vector (at the C terminal) pLenti/TOPO from Invitrogen, to get pLenti/PKCô-CF, 
pLenti/PKCô-RF, pLenti/PKCÔ-ANLS, pLenti/PKCÔ-WT, pLenti/PKCÔ-DN, and 
pLenti/PKCô-CRM. Ail positive clones were confirmed by sequencing. 
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Generation of PKCô-CRM, PKCô-ANLS, PKCô-DN, and PKCÔ-WT stably expressing 
dopaminergic neuronal (N27) cell line 
ViraPower Lentiviral gene expression system from Invitrogen (Carlsbad, CA) was 
employed for the establishment of a stable cell line. To produce lentiviral particles containing 
different constructs, pLenti/PKCô-CRM, pLenti/PKCô-ÀNLS, pLenti/PKCô-DN, or 
pLenti/PKCô-WT, as well as supporting plasmids (provided with the kit) were co-transfected 
into human 293FT cells with the use of lipofectamine 2000, respectively, as described in the 
instruction of the kit. The lentiviral particles in the medium were then collected by 
centrifuging at 3000 rpm for 15 min at 48-72 hr post-transfection. To generate stably 
expressing cell lines, lentiviral particles containing different PKCô constructs were added 
into cultured N27 cells (2xl05) followed by polybrene (6 jag/ml), cells were incubated for 24 
hr, and fresh medium was added and old medium was removed. Positive N27 cells were 
selected by keeping blasticidin (10 fJ-g/ml) in medium for up to 2 weeks. N27 cells stably 
expressing lacZ (pLenti/lacZ was supplied with the kit) were also established to serve as a 
vector control. PKCô-CRM, PKCô-ÀNLS, or PKCô-WT stably expressing N27 cells were 
identified by immunostaining of the C-terminal V5 epitope. 
Transient transaction of N27 cells 
Transient transaction of N27 cells was performed with the use of lipofectomine 2000 
from Invitrogen, Inc (Carlsbad, CA). Briefly, cells (0.7-0.8x10^) were pre-plated in poly L-
lysine coated glass cover slips in a 6-well plate. After 16-24 hr, 4 p.g plasmid (PKCô-CF or 
PKCô-RF) and 10 (il lipofectomine 2000 were first diluted in 250 jal Opti-MEM medium, 
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separately. After a 5 min incubation at RT, diluted plasmid was mixed with diluted 
lipofectomine 2000 and incubated for another 20 min for the formation of DNA-lipid 
complex. The DNA-lipid complex was then added to the cells in a 6-well plate and incubated 
for 16-24 hr at 37°C. 
Preparation of nuclear and cytosolic fractions 
Nuclear and cytosolic fractions were prepared by employing NE-PER™ nuclear and 
cytosolic extraction reagent from Pierce Biotechnology, Inc (Rockford, IL). Briefly, the N27 
cells (lOxlO6) were harvested with trypsin/EDTA and spun at 200xg for 5 min. Cell pellets 
were then washed twice with ice-cold PBS and resuspended in 200 p,l of CERI buffer (pH7.5, 
10 mM HEPES, 10 mM KC1, 1.5 mM MgCl2 and 1:100 dilution of protease inhibitor). To 
lyse the cells, 0.1% Nonide P-40 (NP-40) was added into the sample and incubated for 3 min 
on ice. The lysates were then centrifuged for 30 min at 14,000xg at 4°C and supernatants 
were collected as cytosolic fraction. The nuclei pellets were further resuspended in 50 p.1 
NER buffer (420 nM NaCl, 20 mM HEPES, 1.5 mM MgCl2, 0.2 mM EDTA, and 25% 
glycerol, pH7.9) for 40 min on ice. The nuclear suspension was centrifuged for 10 min at 
14,000xg at 4°C and supernatants were collected as nuclear fraction. The relative purity of 
cytosolic and nuclear fractions was examined by the corresponding marker proteins lactase 
dehydroxylase (LDH) and lamin B. 
Preparation of whole cell homogenates 
After treatment, the N27 cells (lOxlO6) were harvested with trypsin/EDTA and spun 
at 200xg for 5 min. Cell pellets were then washed twice with ice-cold PBS and resuspended 
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in 200 (J.1 of homogenization buffer (pH8.0, 20 mM Tris, 10 mM EOT A, 2 mM EOT A, 2 
mM DTT, 0.5% Triton X-100 and 1:100 dilution of protease inhibitor). After incubation on 
ice for 5 min, the cell lysates were centrifuged for 30 min at 14,000xg at 4°C and 
supernatants were collected as whole cell lysates. 
Western blotting 
Equal amount of protein was loaded in each lane and separated on SDS-
polyacrylamide gel as described previously. Proteins were then transferred to nitrocellulose 
membrane by electro-blotting overnight (4°C, 25V). Non-specific binding sites were blocked 
by treating the nitrocellulose membranes with 5% non-fat dry milk TEST solution (10 mM 
Tris, 150 mM NaCl, and 0.1% Tween 20) for 1 hr. The nitrocellulose membranes were then 
incubated with primary antibodies (1:1000) for 1 hr at RT. The primary antibody treatment 
was followed by treatment with secondary HRP-conjugated anti-rabbit or anti-mouse IgG 
(1:2000) for 1 hr at RT. Secondary antibody-bound proteins were detected using an ECL 
chemiluminescence kit (Amersham). To confirm equal protein loading, blots were reprobed 
with (3-actin antibody (1:5000). Gel photographs and densitometric analysis were performed 
with a Kodak image station (Model 1000R, Rochester, New York). 
Quantitative real time RT-PCR 
After treatment, cells were lysed in 1 ml TRIZOL reagent and total RNA was isolated 
by chloroform extraction and precipitated by ethanol. Total RNA was first treated with 
DNase I to degrade contaminated DNA and then reversely transcribed into first strand cDNA 
using the SuperScript III first-strand synthesis system (Invitrogen, Inc, Carlsbad, CA) as 
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described in the kit instructions. To detect the abundance of PKCô mRNA in the sample, 
quantitative real time PCR was performed with TaqMan rat PKCô and control 18s ribosome 
RNA (rRNA) assay kits. Briefly, about 50 ng cDNA was mixed with primers, TaqMan probe, 
as well as 2x PCR master mix to set up the reaction. For each sample, triplicates were run on 
the same plate. The PCR reaction was performed and data were analyzed in a Mx4000 
multiplex Quantitative PCR system (stratagene, La Jolla, CA). 
Immunocytochemistry 
Cells grown on poly L-lysine coated glass cover slips were first fixed in 4% 
paraformaldehyde, then permeabilized and blocked with blocking reagent (0.4% BSA, 5% 
goat serum, and 0.2% Triton-X 100 in PBS) for 20 min. Cells were then incubated with 
primary antibody (1:1000 in blocking reagent) overnight at 4°C and then washed for 4x8 min 
with PBS. Endogenous PKCô, cleaved caspase-3, Ser 14 phosphorylated histone H2B, or 
overexpressed PKCô-WT, PCKô-CRM, or PKCô-ÀNLS was visualized by incubation with 
Alexa 488-conjugated goat anti-rabbit secondary antibody or Cy3-conjugated goat anti-
mouse secondary antibody (1:2000 in PBS) at RT for 90 min. After another 4x8 min PBS 
wash, Hoechst 33342 (final concentration of 10 gg/ml in PBS) was added to stain the cell 
nuclei at RT for 3 min. Finally, cells were mounted on a slide with antifade mounting 
medium. The cells were observed under regular fluorescence or confocal microscopy. For 
regular fluorescence microscopy, a Nikon inverted fluorescence microscope (Model TE-
2000U) was used and pictures were captured with a SPOT digital camera (Diagnostic 
Instruments, Sterling Heights, MI). For confocal microscopy, a TCS/NT confocal 
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microscopy system (Leica, Bannockburn, IL) was employed. All images were processed in 
MetaMorph 5.07 from Universal imaging (Downingtown, PA). 
Immunoprecipitation kinase assay 
PKCô enzymatic activity was assayed using an immunoprecipitation kinase assay as 
previously described (Anantharam et al., 2002; Reyland et al., 1999). After treatment with 
dieldrin, nuclear lysates of N27 cells (20x106) were first prepared as described above. About 
0.1-0.2 mg protein was immunoprecipitated overnight at 4°C using 2 pg of anti-PKCô 
antibody. The immunoprecipitates were then incubated with protein-A-sepharose for 1 hr at 
4°C. The protein-A bound antigen-antibody complexes were then washed 3 times with lx 
PBS, 3 times with kinase buffer (40 mM Tris, pH7.4, 20 mM MgClz, 20 pM ATP, and 2.5 
mM CaClz), and resuspended in 20 pi of kinase buffer. Reactions were started by adding 20 
pi of reaction buffer containing 0.4 mg purified hi stone H2B and 5pCi of [y-32P] ATP (3,000 
Ci/mM) to the immunoprecipitated samples and incubated for 10 min at 30°C. 2xSDS gel 
loading buffer was then added to terminate the reaction, the samples were boiled for 5 min, 
and the products were separated on a 12% SDS-PAGE gel. The phosphorylated histone 
bands were detected using a Personal Molecular Imager (FX model, Bio-Rad) and quantified 
using Quantity One 4.2.0 software (Bio-Rad, Hercules, CA). 
Acid extraction of histone mixtures 
Briefly, the N27 cells (lOxlO6) were harvested with trypsin/EDTA and spun at 200xg 
for 5 min. Cell pellets were then washed twice with ice-cold PBS and resuspended in 200 pi 
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of homogenization buffer (pH7.5, 10 mM HEPES, 10 mM KC1, 1.5 mM MgCl] and 1:100 
dilution of protease inhibitor). To lyse the cells, 0.5% Triton-X-100 was added into the 
sample and incubated for 5 min on ice. The lysates were then centrifuged for 5 min at 
14,000xg to collect the nuclei pellets. To extract the histones, nuclei pellets were resuspended 
with 100 |il 0.2 M HC1 and shaken at 4°C for 3 hr. Nuclear lysates were then centrifuged at 
14,000xg at 4°C for 10 min and histone mixtures were collected from the supernatant. 
Quantification assay for DNA fragmentation 
DNA fragmentation was measured using a recently developed Cell Death Detection 
ELISA plus Assay Kit (Molecular Biochemicals, Indianapolis, IN). Briefly, cells were spun 
down at 200xg for 5 min and washed twice with IX PBS. Cells were then incubated with 
lysis buffer (supplied with the kit) at RT. After 30 min, samples were centrifuged and 20 jal 
aliquots of the supernatant were then dispensed into streptavidin-coated 96 well microliter 
plates followed by addition of 80 jj.1 of HRP-conjugated antibody cocktail, and incubated for 
2 hr at RT with mild shaking. After incubation, unbound components were removed by 
washing with the incubation buffer supplied with the kit. The nucleosomes retained by the 
antibody cocktail in the immunocomplex were quantified spectrophotometrically with ABTS 
as an HRP substrate. Measurements were made at 405nm and 490nm using a SpectroMax 
190 spectrophotometer (Molecular Devices, Sunnyvale, CA). The difference of absorbance 
between OD 405 and OD 490 nm was used to measure the actual DNA fragmentation level. 
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Data analysis 
Data analysis was performed using Prism 3.0 software (GraphPad Software, San 
Diego, CA). Data from PKCô kinase, DNA fragmentation, and QRT-PCR were first 
analyzed using one-way ANOVA. Bonferroni's post-test was then performed to compare all 
groups and differences with p<0.05 were considered significant. 
RESULTS 
Caspase-3 is primarily activated and remains in the cytoplasm of dopaminergic 
neuronal (N27) cells following dieldrin exposure 
Activation of key apoptotic protease caspase-3 following dieldrin exposure was first 
determined by monitoring the production of cleaved (activated) caspase-3 on immunoblots 
with the use of specific anti-cleaved caspase-3 antibody. Also, to determine the subcellular 
localization of activated caspase-3, the cytosolic and nuclear fractions of N27 cells following 
dieldrin exposure were prepared and separated by 15% SDS-PAGE. As shown in Figure 1A, 
cleaved caspase-3 can be detected starting at 0.5 hr in the cytosolic fraction and the 
maximum intensity of cleaved caspase-3 on immunoblot of the cytosolic fraction is reached 
at the 1 hr time point. However, cleaved caspase-3 is barely detected at the 0.5 hr time point 
on immunoblot of the nuclear fraction, and there is only a weak increase in the intensity of 
cleaved caspase-3 at the 1 hr time point. To show the relative purity of the cytosolic and 
nuclear fractions, cytosolic and nuclear fractions were separated again by SDS-PAGE and 
immunobloted by the cytosolic fraction marker Lactase dehydroxylase (LDH) or nuclear 
fraction marker lamin B. As shown in Figure 1A, only very little LDH was detected in the 
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nuclear fraction and no clear lamin B was detected in the cytosolic fraction. To visualize the 
localization of activated caspase-3 in situ, immunostaining of cleaved caspase-3 and 
counterstaining of nuclei was performed in N27 cells at 1 hr following dieldrin exposure. As 
shown in Figure IB, the immunoreactivity of cleaved caspase-3 was significantly elevated 
following dieldrin exposure for 1 hr. The increased immunoreactivity was also 
predominantly localized in cytoplasm as seen in Figure lBf. Taken together, this result 
suggests that caspase-3 was primarily activated and retained in the cytoplasm; only a very 
small fraction of activated caspase-3 translocated to the nucleus at the later time point. 
Dieldrin exposure induces PKCô cleavage without changing its expression level in 
dopaminergic neuronal (N27) cells 
PKCô was recently identified as one of the downstream targets of caspase-3 that can 
be proteolytically activated in apoptotic cells (Brodie and Blumberg, 2003; Kikkawa et al., 
2002). Here, we examine the cleavage of PKCô induced by dieldrin exposure in 
dopaminergic neuronal cells. Anti-PKCô antibody from Santa Cruz Biotechnology (Santa 
Cruz, CA), which recognizes the C-terminal epitope of PKCô, was employed. As shown in 
Figure 2A, cleaved PKCô fragments (41/38KDa) were detected from whole cell lysates of 
N27 cells starting at 1 hr after dieldrin exposure and decreased at the 3 hr time point, which 
matches the time for caspase-3 activation shown in Figure 1A. To demonstrate that the 
activated caspase-3 indeed starts to cleave its substrates, cleavage of the classical substrate of 
activated caspase-3, poly (ADP-ribose) polymerase (PARP) (Tewari et al., 1995), was also 
examined. The whole cell lysates of N27 cells after dieldrin treatment were separated by 
7.5% SDS-PAGE and immunobloted with anti-PARP antibody. As shown in Figure 2B, the 
cleaved PARP (85KDa) was detected as early as 0.5 hr and the intensity of cleaved PARP on 
immunoblot increased over time up to 3 hr after dieldrin treatment. Both membranes were 
reprobed with anti-(3-actin antibody and the results showed that equal amounts of proteins 
were loaded on the gel. 
To examine whether dieldrin exposure induces transcriptional change in PKCS 
mRNA in N27 cells, the relative abundance of PKCô mRNA copies in control and dieldrin-
treated N27 cells was determined by quantitative real-time RT-PCR assay. After dieldrin 
treatment of 1 and 3 hr, total RNA from control and dieldrin-treated N27 cells was isolated 
and reversely transcribed into cDNA. Equal amounts of cDNAs were then used to perform 
real-time PCR with the use of a TaqMan rat PKCô probe. The 18s ribosome RNA (rRNA) 
probe was employed to serve as endogenous control to equalize the RNA used in the real­
time PCR assay. The real-time amplification plots from control and dieldrin-treated samples 
were shown in Figure 2C and the fluorescence intensity generated as the result of the 
amplification of PKCô cDNA was nearly identical, suggesting that the same amount of 
PKCô between control and dieldrin-treated N27 cells was amplified during PCR. The relative 
quantity of PKCô mRNA in control and dieldrin-treated N27 cells converted by the formula 
2-(ACt PKC5-ACt 18s rRNA) threshold of cycle) (Bustin, 2000, 2002) is presented in Figure 2D; 
no significant difference was found. This result indicates that short exposures to dieldrin 
induce no transcriptional change in PKCô in N27 cells. 
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Nuclear accumulation of cleaved fragments of PCK5 in N27 cells following dieldrin 
exposure 
Subcellular localization of PKCô after its proteolytic activation in neurotoxin-
induced apoptotic dopaminergic neuronal cells has not been determined. We first examined 
the localization of PKCÔ by immunostaining in N27 cells following dieldrin exposure. The 
immunostaining of PKCô was performed at 1 hr following dieldrin exposure. The 
immunoreactivity of PKCô was predominantly found in the cytoplasm rather than in the 
nucleus in control N27 cells (Figure 3Ac). However, in dieldrin-treated N27 cells, a dramatic 
shift of immunoreactivity of PKCÔ from the cytoplasm to the nucleus was observed (Figure 
3Af). To determine the dieldrin-induced subcellular localization change of both full-length 
and cleaved PCKô, nuclear and cytosolic fractions from N27 cells following dieldrin 
exposure up to 3 hr were prepared, separated by 10% SDS-PAGE and immunoblotted with 
anti-PKCô antibody. As shown in Figure 3B, full-length PKCô was largely found in the 
cytosolic fraction and dieldrin exposure did not induce the elevation of PKCô protein level, 
which is consistent with the quantitative RT-PCR result shown in Figure 2D. In addition, no 
significant localization change between the cytoplasm and the nucleus for full-length PKCô 
in N27 cells following dieldrin exposure was observed. On the other hand, the cleaved 
fragments of PKCÔ can be detected in the cytosolic fraction of N27 cells as early as 0.5 hr 
after dieldrin exposure, while cleaved fragments of PKCô in the nuclear fraction ofN27 cells 
only appeared after thel hr time point following dieldrin exposure. 
Since caspase-3 was primarily activated and retained in the cytoplasm as shown in 
Figure 1, and the cleaved fragments of PKCô in the cytosolic fraction appeared at an earlier 
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time point as compared to the nuclear fraction of N27 cells following dieldrin exposure, this 
result suggests that the full-length PKCô is first cleaved in the cytoplasm and then the 
cleaved fragments of PCKô are translocated to the nucleus. To investigate whether the 
nuclear accumulation of cleaved fragments of PKCô was caspase-3 dependent, N27 cells 
were co-treated with dieldrin and the caspase-3 specific inhibitor Z-DEVD-FMK. As shown 
in Figure 3C, cleaved fragments of PKCô appeared in both cytosolic and nuclear fractions 
following dieldrin exposure. Following co-treatment with Z-DEVD-FMK and dieldrin, 
cleaved fragments of PKCô were dramatically decreased in the cytosolic fraction. Similarly, 
the cleaved fragments in the nuclear fraction were also reduced. Notably, however, the 
reduction in cleaved fragments of PKCô in the nuclear fraction was not as significant as that 
observed in the cytosolic fraction. Possibly a small fraction of cleaved fragments of PKCô 
was still generated in the cytoplasm due to the incomplete inhibition of Z-DEVD-FMK; 
therefore, these cleaved fragments of PCKô continued to translocate and accumulate in the 
nucleus. This result matched our previous observation that the cleaved fragments of PKCô 
appeared at an earlier time point in the cytosolic fraction compared to the nuclear fraction, 
reinforcing the model that the full-length PKCô is first cleaved in the cytoplasm and the 
cleaved fragments of PKCô subsequently translocate to the nucleus in N27 cell following 
dieldrin exposure. 
We also tried to directly determine the localization change of the catalytic fragment 
of PKCô in N27 cells following dieldrin exposure. Because antibody specifically detecting 
the catalytic fragment of PCKô is currently unavailable, we then transiently transfected 
PKCô-CF into N27 cells to examine the localization of the catalytic fragment of PKCô 
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(PKCÔ-CF). Immunostaining of the V5 tag and counterstaining of the nucleus were 
performed at 24 hr post-transfection. As shown in Figure 3D, PKCô-CF, revealed by V5 
immunoreactivity, primarily localizes in the nucleus, further indicating that cleaved 
fragments of PKCô translocate to the nucleus. 
Cleavage resistant mutant of PKCô (PKCÔ-CRM) abolishes dieldrin induced 
proteolytic activation of PKCô in N27 cells and protects cells from dieldrin induced 
apoptosis 
In order to investigate the necessity of caspase-3 mediated proteolytic activation of 
PKCô in dieldrin induced apoptosis of N27 cells, the PKCô-CRM stably expressing N27 cell 
line was generated via the ViraPower™ lentiviral expression system (Invitrogen). Figure 4A 
shows that about 80% of N27 cells in this cell line were PKCô-CRM expressing cells, as 
identified by immunostaining of the V5 tag. PKCô-CRM contains a point mutation (D327A) 
in its caspase-3 recognition and cleavage motif, which abolishes the cleavage of PKCô by 
activated caspase-3 (DeVries et al., 2002; Ghayur et al., 1996). As shown in Figure 4B, in the 
control (no transfection) cells, PKCô cleavage was induced at the 1 hr time point following 
dieldrin exposure and was abolished by co-treatment with Z-DEVD-FMK and dieldrin; 
however, in the PKCô-CRM expressing N27 cells, cleaved fragments of PKCô were barely 
detected at the 1 hr time point following dieldrin exposure. 
The detailed mechanism of the inhibition of PKCô-CRM in dieldrin induced cleavage 
of endogenous PKCô is under investigation. Some preliminary results from our lab suggest 
that overexpressed PKCô down-regulates the expression of endogenous PKCô. The 
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overexpressed PKCô-CRM might also inhibit the feedback loop between PKCô and caspase-
3 (Leverrier et al., 2002), resulting in the inhibition of continuous activation of caspase-3. It 
is also possible that the overexpressed PKCô-CRM simply out-competes endogenous PKCô 
for activated caspase-3, thus leaving endogenous PKCô intact. With the co-treatment of Z-
DEVD-FMK and dieldrin in PKCô-CRM cells, dieldrin induced cleavage of PKCô was 
completely blocked. Meanwhile, the PKCÔ kinase activity was also examined in PKCô-CRM 
expressing cells. As shown in Figure 4C, dieldrin treatment for 1 hr in the control (no 
transfection) cells increased PKCô kinase activity to 220% in comparison to untreated 
control cells. However, in PKCô-CRM expressing cells, dieldrin exposure for 1 hr increased 
PKCô kinase activity by only 20% compared to untreated PKCô-CRM cells. 
We next examined whether abolishment of caspase-3 mediated proteolytic activation 
of PKCô by PKCô-CRM protects N27 cells against dieldrin induced apoptotic cell death. In 
control cells, dieldrin exposure for 1 hr induced about 520% increase in the DNA 
fragmentation level compared to untreated control cells; however, in the PKCô-CRM 
expressing N27 cells, only 50% increase in the DNA fragmentation level was induced 
following dieldrin exposure for 1 hr in comparison to untreated PKCô-CRM expressing cells 
(Figure 4D). These results clearly suggest that the caspase-3 mediated proteolytic activation 
of PKCô following dieldrin exposure is required for PKCô's pro-apoptotic function in 
dieldrin induced apoptotic cell death in dopaminergic neuronal cells. 
Lipid-mediated activation of full-length PKCô induces neuronal differentiation but not 
apoptosis in N27 cells 
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Other than proteolytic activation, PKCô can also be activated through the binding of 
lipid (diacylglycerol, phorbol esters) to its CI domain, resulting in subsequent translocation 
to the plasma membrane (Newton, 2003). To investigate whether the lipid-mediated 
activation of full-length PKCô also contributes to apoptosis of dopaminergic neuronal cells, 
N27 cells were treated with either 100 nM bistratene A, the specific PKCô activator (Frey et 
al., 2000; Frey et al., 2001) or 100 nM TP A, the classical pan-PKC activator, for 30 min. The 
immunostaining of PKCô was performed after treatment and observed under confocal 
microscopy. As shown in Figure 5Ai, PKCô showed uniform cytoplasmic distribution, and 
no clear neurites were observed in the untreated N27 cells. After treatment with bistratene A 
for 30 min, PKCô was translocated to the plasma membrane (Figure 5Ad) and differentiation 
of N27 cells were observed (Figure 5Af). Multiple elongated neurites were induced, and the 
cell body became more compact. N27 cells were also treated with TPA. As shown in Figure 
5Aa, plasma membrane translocation of PKCô and differentiation of N27 cells were induced 
following TPA exposure. No PKCô cleavage was induced in N27 cells following either TPA 
or bistratene A exposure for 30 min, as shown in Figure 5B. Following bistratene A or TPA 
exposure, the DNA fragmentation level in N27 cells was also determined. As shown in 
Figure 5C, no significant difference was found in DNA fragmentation levels in N27 cells 
treated with bistratene A or TPA compared to the untreated cells. Taken together, these 
results clearly suggest that although full-length PKCô can be activated through lipid 
molecules, the activated full-length PCKô contributes to neuronal differentiation, but not the 
apoptotic death of dopaminergic neuronal cells. 
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Blockade of the nuclear localization of cleaved fragments of PKCô protects N27 cells 
from apoptosis 
As shown above, dieldrin exposure induces not only caspase-3 mediated proteolytic 
activation of PKCô, but also the nuclear translocation of activated cleaved PKCô. It has been 
recently reported that the C-terminal of PKCô contains a functional nuclear localization 
signal (NLS) (DeVries et al., 2002). Point mutation of this NLS abolishes the nuclear 
translocation of PKCô in rat parotid salivary cells (DeVries et al., 2002). To investigate 
whether the nuclear translocation of activated cleaved PCKô is essential for its function in 
apoptosis, we first prepared PKCô-ÀNLS with the deletion of the complete nuclear 
localization signal (NLS) and generated the N27 cell line stably expressing PKCô-ÀNLS and 
PKCô-WT with the use of the ViraPower™ lentiviral expresson system (Invitrogen). 
The schematic representation of the primary structure of PCKô-WT, PKCô-ÀNLS, 
and PKCô-CRM is shown in Figure 6A. An N27 cell line stably expressing (3-galactosidase 
(LacZ, supplied with the kit) was also generated as a vector control. Expressed PKCô-ÀNLS 
or PKCô-WT could be identified by immunostaining of the V5 tag at the C terminal. Because 
the V5 tag is located at the C-terminal, immunostaining of the V5 tag identified both the full-
length and cleaved catalytic fragment of PKCô. In the PKCô-WT expressing cells, PKCô-
WT, revealed by V5 immunoreactivity, was primarily localized in the cytoplasm in the 
untreated cells (Figure 6Ba). At 1 hr following dieldrin exposure, V5 immunoreactivity 
accumulated in the nucleus, as shown in Figure 6Bd, which is consistent with our observation 
of the endogenous PKCô (Figure 3A). In the PKCô-ÀNLS expressing cells, PKCô-ÀNLS, 
revealed by V5 immunoreactivity, localized only in the cytoplasm regardless of the treatment 
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with dieldrin (Figure 6Bb&e). The subcellular localization of PKCô-CRM was also 
examined. As shown in Figure 6Bc&f, PKCô-CRM, revealed by V5 immunoreactivity, also 
showed predominant localization in the cytoplasm with or without treatment with dieldrin, 
which suggests again that only cleaved fragments of PKCô, not the full-length PKCô, 
translocates to the nucleus. 
We next examined the DNA fragmentation level in PKCô-WT and PKCô-ANLS 
expressing cells following dieldrin exposure. As shown in Figure 6C, DNA fragmentation 
levels following dieldrin exposure only increased by 60% in PKCô-ÀNLS expressing cells 
when compared to untreated PKCÔ-ÀNLS cells; however, an approximate 210% DNA 
fragmentation level was induced following dieldrin exposure in both PKCô-WT expressing 
and vector control cells. Together with the DNA fragmentation result from Figure 4D, our 
study clearly indicates that not only the proteolytic activation of full-length PKCô, but also 
the subsequent nuclear translocation of activated cleaved PCKô, are both necessary for 
PKCô's pro-apoptotic function in dieldrin-induced apoptosis of dopaminergic neuronal (N27) 
cells. 
Activated cleaved PKCô mediates Serl4 phosphorylation of histone H2B following its 
nuclear translocation in dieldrin induced apoptotic N27 cells 
Phosphorylation of histones has been suggested to play a role in the formation of 
chromatin condensation in apoptotic cells (Ajiro, 2000). In particular, histone H2B 
phosphorylation at Serl4 has been ubiquitously found in apoptotic cells (Cheung et al., 2003). 
To investigate whether activated cleaved fragments of PKCô mediate H2B phosphorylation 
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following nuclear translocation, we first examined the Serl4 phosphorylation in dieldrin-
induced apoptotic N27 cells. The immunostaining of phosphorylated H2B was performed 
with the use of anti-phospho-Histone H2B (Serl4) antibody in N27 cells at the 1 hr time 
point following dieldrin exposure. As shown in Figure 7Aa, Serl4 phosphorylated H2B was 
clearly detected in dieldrin-induced apoptotic cells. To ensure that it occurred inside the 
nucleus, nuclei were also counterstained with Hoechst 33342. As shown in Figure 7Ab, a 
condensed nucleus was also observed in the same apoptotic cell and the merged image 
(Figure 7Ac) confirms the co-staining. Histone mixtures were also extracted from the nuclei 
of N27 cells following dieldrin treatment alone or after co-treatment with Z-DEVD-FMK and 
dieldrin, separated by 15% SDS-PAGE, and immunobloted with anti-phospho-Histone H2B 
(Serl4) antibody. As shown in Figure 7B, Z-DEVD-FMK co-treatment reduced dieldrin-
induced Serl4 phosphorylation of H2B, indicating that Serl4 phosphorylation of H2B is 
caspase-3 dependent. 
To directly examine whether PKCô mediated the phosphorylation of H2B, PKCô was 
immunoprecipitated from N27 cells following co-treatment of Z-DEVD-FMK and dieldrin or 
dieldrin treatment alone. Immunoprecipitated PKCô was then performed with an in vitro 
kinase assay with purified H2B as substrate in the presence of 32P. As shown in Figure 7C, 
PKCô immunoprecipitated from cells treated only with dieldrin showed a significant increase 
in phosphorylation of H2B over time (from 1 hr to 3 hr) compared to untreated cells, 
however, Z-DEVD-FMK co-treatment reduced dieldrin-induced phosphorylation of H2B by 
immunoprecipitated PKCô. 
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PKCô-CRM and PCKô-ANLS have been shown above to inhibit the nuclear 
translocation of activated cleaved PKCô. To investigate whether PKCô-CRM and PKCô-
ANLS also block dieldrin-induced Serl4 phosphorylation of H2B, double immunostaining of 
V5 and Serl4 phosphorylated H2B was performed in PKCô-CRM and PKCô-ANLS stably 
expressing N27 cells following dieldrin exposure. In addition, double staining of V5 and 
Serl4 phosphorylated H2B was also performed in dieldrin treated PKCô-WT and PKCô-DN 
stably expressing N27 cells to determine whether PKCô indeed mediates Serl4 
phosphorylation of H2B. As shown in Figure 7Da-d, Serl4 phosphorylated H2B was clearly 
detected in PKCô-WT expressing N27 cells, and fragmentation of the nucleus was also 
observed after dieldrin treatment. However, Serl4 phosphorylated H2B staining could not be 
detected in PKCô-DN (Figure 7Df), PKCô-CRM (Figure 7Dj) and PKCô-ANLS (Figure 7Dn) 
expressing cells. Nuclei of these cells are also intact after dieldrin treatment. The effective 
inhibition of PKCô-DN, PKCô-CRM, and PKCô-NLS indicates that the cleaved, kinase-
active fragments of PKCô, after nuclear translocation, mediate Serl4 phosphorylation of 
H2B and promote dieldrin induced apoptotic death of dopaminergic neuronal cells. 
Catalytic fragment of PKCô directly induces Serl4 phosphorylation of histone H2B and 
apoptosis in dopaminergic neuronal cells 
Next, we directly introduced the catalytic fragment of PKCô (PKCô-CF) in the N27 
cells to investigate whether PKCô-CF itself can induce Serl4 phosphorylation of H2B and 
apoptosis in N27 cells. PKCô-CF was introduced into the N27 cells through lipofectamine-
mediated transfection. PKCô-RF was also introduced into the N27 cells to serve as a control. 
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About 48 hr after transfection, double immunostaining of Serl4 phosphorylated H2B and the 
V5 tag as well as counterstaining of nuclei were performed to visualize the localization of 
PKCô-CF and phosphorylation of H2B. As shown in Figure 8a, PKCô-CF, revealed by V5 
immunoreactivity, only localizes in the nucleus, and strong staining of Serl4 phosphorylated 
H2B was also observed in the same cell (Figure 8b). Nucleus counterstaining showed that the 
nucleus was also broken apart and chromatin became condensed (Figure 8c), confirming that 
this cell indeed underwent apoptosis. In contrast, the nucleus of a PKCô-RF positive N27 cell 
is still intact (Figure 8g) and no clear staining of Serl4 phosphorylated H2B could be 
observed (Figure 8f). The direct induction of Serl4 phosphorylation of H2B and apoptosis by 
the nuclear localized PKCô-CF is consistent with our results above that proteolytic ally 
activated cleaved PKCô mediates neurotoxin-induced Serl4 phosphorylation of H2B and 
apoptosis of dopaminergic neuronal cells. Interestingly, we first tried to generate PKCô-CF 
stably expressing N27 cells with the use of ViraPower™ lentiviral expression system; 
however, generation of a PKCÔ-CF stably expressing N27 cell line was unsuccessful after 
many attempts. N27 cells were either refractory to PKCô-CF or quickly died several days 
after application of the selection antibiotic, blasticidin. This also suggests that PKCô-CF 
itself is toxic and could induce cell death by itself. 
DISCUSSION 
In the present study, we investigated the downstream events after proteolytic cleavage 
of PKCô in dieldrin induced apoptosis of dopaminergic neuronal cells. We demonstrated that 
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the full-length PKCô was first cleaved in the cytoplasm and the activated cleaved fragments 
of PKCô subsequently translocated into the nucleus. By employing the NLS deletion mutant 
(PKCô-ÀNLS) and cleavage resistant mutant of PKCô (PKCô-CRM), we showed that the 
proteolytic activation of full-length PKCô and nuclear translocation of activated cleaved 
PKCô are both necessary for PKCô's pro-apoptotic function in dieldrin-induced apoptosis of 
dopaminergic neuronal cells. Furthermore, we also demonstrated that the activated cleaved 
fragments of PKCô, after nuclear translocation, mediate Serl4 phosphorylation of histone 
H2B. The caspase-3 inhibitors Z-DEVD-FMK, PKCÔ-CRM, PKCô-ANLS, and PKCÔ-DN 
all inhibit Serl4 phosphorylation of H2B, while PKCô-CF itself can directly induce Serl4 
phosphorylation of H2B and apoptosis. Our study suggests that proteolytically activated 
PKCô translocates to the nucleus and mediates Serl4 phosphorylation of histone H2B in 
neurotoxin-induced apoptotic death of dopaminergic neuronal cells. 
Proteolytic activation of PKCô is associated with its nuclear translocation in apoptotic 
cells. Depending on the cell type and apoptotic stimuli, the nuclear translocation of PKCô 
either precedes (Blass et al., 2002; DeVries et al., 2002) or follows (Cross et al., 2000; 
Scheel-Toellner et al., 1999) its proteolytic activation in apoptotic cells. The early 
translocation of the full-length PKCô to the nucleus before its proteolytic activation has been 
suggested to regulate the mitochondrial mediated apoptotic pathway and subsequent 
activation of caspase-3 (DeVries et al., 2002). In etoposide induced apoptotic glioma cells, 
proteolytic activation of PKCô occurred in the nucleus after full-length PKCô was 
translocated to the nucleus. The inhibition of nuclear translocation of the full-length PKCô 
blocked caspase-3 activation and cleavage (Blass et al., 2002). Early nuclear translocation of 
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the full-length PKCô is also implicated in early nuclear events to regulate the mitochondrial 
mediated apoptotic pathway in apoptotic C5 rat parotid salivary acinar cells (DeVries et al., 
2002). In contrast, the late translocation of the activated cleaved PKCô to the nucleus (after 
its proteolytic activation) is more often implicated as a direct effector to accelerate the 
apoptotic process by facilitating caspase-3 mediated cleavage of nuclear substrates, like 
lamin B (Cross et al., 2000) or inactivating survival mechanisms in apoptotic cells (Bharti et 
al., 1998). 
In dieldrin-induced apoptotic dopaminergic neuronal cells, we demonstrated here that 
full-length PKCô is first cleaved in the cytoplasm and only the activated cleaved fragments 
of PKCô subsequently translocate to the nucleus. By employing the cleavage resistant mutant 
(PKCô-CRM) and NLS deletion mutant (PKCô-ANLS), we have further shown that the 
nuclear translocation of activated cleaved PKCô was necessary for its function in dieldrin-
induced apoptosis of dopaminergic neuronal cells. In addition, although few studies reported 
that the allosteric activation of full-length PKCÔ by TPA treatment promoted the cytochrome 
C release and apoptosis (Majumder et al., 2000), our results show that allosteric activation of 
full-length PKCô by treatment with TPA or a PKCô specific activator, bistratene A, induces 
differentiation of dopaminergic neuronal cells, but not apoptotic death. By employing the 
cleavage resistant mutant of PKCô (PKCô-CRM), we further demonstrate that proteolytic 
activation of PKCô is required for its pro-apoptotic function in dieldrin induced apoptosis of 
dopaminergic neuronal cells. Since many other studies have reported that activation of the 
full-length PKCô by lipids mediates signal transduction in a range of normal physiological 
processes, our study suggests that proteolytic activation is the favorable mode for PKCô's 
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activation and pro-apoptotic function in apoptotic dopaminergic neuronal cells. Our study 
further provides insight for the design of better inhibitors that specifically inhibit the 
proteolytic activation of PKCô, and target only the activated cleaved fragments of PKCô for 
protection against neurotoxin induced apoptosis in dopaminergic neuronal cells. 
The downstream nuclear events following nuclear translocation of PKCô in apoptosis 
have just begun to be explored as more and more nuclear targets of PKCô have recently been 
identified. In DNA damage-induced apoptosis, the PKCô catalytic fragments phosphorylate 
the catalytic subunit of DNA dependent protein kinase (DNA-PK) (Bharti et al., 1998), 
inhibiting the function of DNA-PK to form complexes with DNA and to phosphorylate its 
downstream target, p53 (Ferri and Kroemer, 2001). PKCô was also found to interact with 
hRad9, a member of the human DNA damage sensor family to regulate interaction of hRad9 
with Bcl-2 and the hRad9-mediated apoptotic response to DNA damage (Yoshida et al., 
2003). PKCô also phosphorylates transcriptional factors, including p73 (Ren et al., 2002) and 
STAT1 (DeVries et al., 2004), and regulates gene expression in apoptosis. PKCô not only 
regulates the apoptotic signal, but also directly accelerates the collapse of nuclear structure in 
apoptotic cells. It was shown that PKCô can phosphorylate lamin B, which is one of the 
major structural proteins involved in the assembly of the nuclear envelope (Cross et al., 
2000). The phosphorylation of lamin B increases its susceptibility to caspase mediated 
cleavage, eventually leading to the disassembly of nuclear lamina. 
Phosphorylation of histone H2B at Serl4 has been ubiquitously found in apoptotic 
cells in diverse species ranging from frogs to humans (Cheung et al., 2003). The H2B 
phosphorylation and amino-terminal tail of H2B (de la Barre et al., 2001), but not other 
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histones, are essential for chromatin condensation, one of the hallmarks of apoptotic cells. 
Mammalian sterile twenty 1 (Mstl) kinase has been identified as responsible for Serl4 
phosphorylation of H2B (Cheung et al., 2003). Interestingly, Mstl kinase also undergoes 
caspse-3 mediated proteolytic activation, and activated cleaved fragments of Mstl kinase 
also translocate to the nucleus (Graves et al., 1998; Ura et al., 2001). In dopaminergic 
neuronal cells, we demonstrated that dieldrin exposure induces Serl4 phosphorylation of 
H2B, and activated PKCô recovered from N27 cells exposed to dieldrin can phosphorylate 
H2B in vitro in a caspase-3 dependent manner. We further showed that the PKCô catalytic 
fragment (PKCô-CF) itself induces phosphorylation of H2B. These results suggest that other 
than Mstl, activated cleaved fragments of PKCô also mediate phosphorylation of H2B 
directly by itself or indirectly by phosphorylating downstream kinases in apoptotic 
dopaminergic neuronal cells. During preparation of our manuscript, a recent study also 
reported that PKCô mediates phosphorylation of H2B (Mecklenbrauker et al., 2004). 
In conclusion, we demonstrate that the activated cleaved fragments of PKCô 
translocate to the nucleus after proteolytic activation. We also show that proteolytic 
activation of the full-length PKCô and nuclear translocation of the activated cleaved PKCô 
are both necessary for its function in dieldrin-induced apoptosis of dopaminergic neuronal 
cells. In addition, the nuclear active PKCô mediates phosphorylation of H2B and accelerates 
the apoptotic process in dopaminergic neuronal cells. Understanding the detailed 
mechanisms of PKCÔ activity in neurotoxin-induced apoptosis of dopaminergic neuronal 
cells provides insight for drug design to protect dopaminergic neurons against neurotoxin 
induced degeneration. 
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Figure 1: Subcellular localization of activated caspase-3 in dopaminergic neuronal cells 
following dieldrin exposure. 
(A) Immunoblot of cleaved caspase-3 in cytosolic and nuclear fractions of N27 cells 
following dieldrin exposure. After treatment with dieldrin (60 pM) for up to 3 hr in serum-
free medium, cytosolic and nuclear fractions of N27 cells were prepared and separated on 
15% SDS-PAGE. Cleaved (activated) caspase-3 was then detected on the immunoblots with 
the use of specific anti-cleaved caspase-3 antibody. Immunoblot of LDH and lamin B was 
also performed on separate gels for relative purity of cytosolic and nuclear fractions. (B) 
Immunostaining of cleaved caspase-3 in dopaminergic neuronal cells following dieldrin (60 
pM) exposure for 1 hr in serum-free medium. After treatment, cells were fixed and stained 
with anti-cleaved-caspase-3 antibody. The immunoreactivity of cleaved caspase-3 was 
visualized by Alexa488 conjugated secondary antibody (green fluorescence). The cells were 
observed under an LCS/NT confocal microscopy system (Bar =10 pm). Experiments were 
repeated three times and representative images are presented. 
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Figure 2: Dieldrin exposure induces PKCô cleavage without changing its expression in 
N27 cells 
(A) Cleaved fragments of PKCô (38-41kDs) were induced in N27 cells following dieldrin 
exposure. (B) Dieldrin exposure also induced the generation of cleaved fragments of PARP 
(85KD) in N27 cells. N27 cells were treated with 60 pM dieldrin for up to 3 hr in serum-free 
medium. Cells were then lysed and the lysate was used for Western blot analysis to detect 
both the PKCô and PARP cleavage. To confirm equal protein loading in Western blots, the 
membranes were reprobed with (3-actin antibody. (C) Amplification plot of quantitative RT-
PCR of PKC6 mRNA in N27 cells following dieldrin exposure. (D) Relative quantity of 
PKCô mRNA copies in N27 cells following dieldrin exposure. N27 cells were treated with 
60 pM dieldrin for up to 3 hr in serum-free medium. Cells were then lysed and total RNA 
was isolated with TRIZOL reagent and converted to cDNA. The PCR reaction was then set 
up by mixing 50 ng cDNA, rat PKCô TaqMan expression assay reagent as well as 2x PCR 
master mix in a 96-well plate. The PCR reaction was performed in a Mx4000 multiplex 
Quantitative PCR system (Stratagene, La Jolla, CA). To ensure that equal amounts of RNA 
were used in the PCR reaction, 18s ribosome RNA (18s rRNA) was used as an endogenous 
control. The relative quantity of PKCô mRNA was calculated based on the formula 2~(ACt 
PKC5-ACt i8s rRNA) (q. threshold of cycle), and the control was used as a calibrator for 
comparison with other samples. The Ct value was determined by software installed on the 
Mx4000 multiplex Quantitative PCR system. The data represent the mean + SEM from three 
separate experiments in triplicate. 
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Figure 3: Dieldrin exposure induces nuclear translocation of cleaved fragments of 
PKCÔ in N27 cells 
(A) Nuclear accumulation of PKCô immunoreactivity in N27 cells following dieldrin 
exposure. After dieldrin (60 pM) treatment for 1 hr, N27 cells were fixed and stained with 
anti-PKCô antibody (1:1000). The PKCô was visualized then by Alex488 conjugated 
secondary antibody (1:2000) and images were taken under TCS/NT confocal microscopy (B). 
Dieldrin exposure induced nuclear translocation of cleaved fragments of PKCô in N27 cells. 
(C) Co-treatment of N27 cells with Z-DEVD-FMK reduced dieldrin induced PKCô cleavage 
and nuclear translocation of cleaved fragments of PKCô. Cells were treated with dieldrin (60 
pM) alone or co-treated with Z-DEVD-FMK (50 pM or 100 pM) and dieldrin (60 pM) for 
up to 3 hr. Cytosolic and nuclear fractions were then prepared and separated on 10% SDS-
PAGE. Cleaved fragments of PCKô were then detected on both immunoblots with the use of 
anti-PKCô antibody. (D) Nuclear localization of overexpressed PKCô-CF in the N27 cells. 
Immunostaining of V5 was performed 24 hr after transaction. Immunoreactivity of V5 was 
visualized by Cy3 conjugated anti-mouse secondary antibody (1:2000). Nuclei were 
counterstained by Hoechst 33342. Cells were observed under a LCS/NT confocal microscopy 
system (Bar =10 pm). 
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Figure 4: Cleavage resistant mutant of PKCô (PKCô-CRM) abolishes dieldrin induced 
proteolytic activation of PKCô and protects cells from dieldrin induced apoptosis in 
N27 cells. 
(A) Stable expression of PKCô-CRM in dopaminergic neuronal (N27) cells. A ViraPower 
Lentiviral gene expression system (Invitrogen, Inc. Carlsbad, CA) was employed for 
generation of a PKCô-CRM expressing cell line. PKCô-CRM stably expressing cells were 
maintained in normal medium supplemented with 10 pg/ml blasticidin. To identify PKCô-
CRM expressing cells, cells were fixed and stained with anti-V5 antibody (1:1000) and Cy3-
conjugated secondary anti-mouse antibody (1:2000). Cells were observed under a Nikon 
inverted fluorescence microscope (Model TE-2000U). (B) Dieldrin induced PKCô cleavage 
was abolished in PKCô-CRM expressing cells. Control cells and PKCô-CRM expressing 
cells were treated with dieldrin (60 pM) alone or co-treated with Z-DEVD-FMK (50 fiM) 
and dieldrin (60 JJ.M) for 1 hr. The cells were lysed and whole cell lysate was used for 
Western blot analysis to detect the PKCô cleavage. Membrane was reprobed with anti-V5 
antibody (1:5000) to ensure abundant PKCô-CRM was expressed only in the PKCô-CRM 
expressing cell line. (C) Dieldrin exposure induced PKCô kinase activity was attenuated in 
PKCô-CRM stably expressing N27 cells. The cells were lysed and PKCô was first 
immunoprecipitated and an in vitro kinase assay was performed. Significance of difference in 
kinase activity was compared to untreated control cells. (D) PKCô-CRM protects against 
dieldrin induced apoptosis in N27 cells. Significance of difference in DNA fragmentation 
was compared to untreated control cells. The data represent the mean + S EM from two 
separate experiments in triplicate (*, p<0.05; ***, pO.OOl; N=6). 
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Figure 5: Lipid-mediated activation of full-length PKCô induces the differentiation of 
N27 cells but not apoptotic death. 
(A) Plasma membrane translocation of PKCô and differentiation of N27 cells were induced 
by bistratene A or TP A treatment. N27 cells were treated with 100 nM bistratene A or TP A 
for 30 min. PKCô immunostaining was then performed to visualize its subcellular 
distribution and cellular morphological changes. Stained cells were observed under confocal 
microscopy (Bar =10 pm). (B) TP A and Bistratene A treatment didn't induce PKCô 
cleavage in N27 cells. N27 cells were treated with 100 nM TP A or Bis A for 30 min and 
whole cell lysates were isolated. (C) Apoptotic death was not induced in N27 cells following 
bistratene A or TP A treatment. After treatment with 100 nM bistratene A or TP A for 30 min, 
N27 cells were lysed for DNA fragmentation assay. The data represent the mean + SEM 
from two separate experiments in triplicate (N=6). 
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Figure 6: Blockade of nuclear localization of cleaved fragments of PKCô protects N27 
cells from dieldrin induced apoptosis. 
(A) Schematic representation of primary structure of PKCô-WT, PKCô-CRM, and PKCô-
ÀNLS. The V5 tag locates at the C-terminal of the fused protein. (B) Subcellular localization 
of PKCô-WT, PKCô-ANLS, and PKCÔ-CRM in N27 cells following dieldrin exposure. 
PKCô-WT and PKCô-ANLS stably expressing N27 cell lines were also established via 
ViraPower Lenti viral gene expression system (Invitrogen, Inc. Carlsbad, CA). After dieldrin 
(60 pM) exposure for 1 hr, subcellular distribution of PKCô-WT, PKCô-ANLS, and PKCô-
CRM was determined by immunostaining of the C-terminal V5 tag (Bar =10 pm). (C) 
Exclusion of PKCÔ from the nucleus significantly abolished dieldrin induced apoptosis in 
N27 cells. Vector control (LacZ), PKCô-WT, and PKCÔ-ANLS stably expressing N27 cells 
were exposed to dieldrin for 1 hr and cells were then lysed for the DNA fragmentation assay. 
Significance of difference in DNA fragmentation was compared to untreated vector control 
cells. The data represent the mean + S EM from two separate experiments in triplicate (***, 
pO.OOl; N=6). 
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Figure 7: Cleaved fragments of PKCô mediate Serl4 phosphorylation of histone H2B in 
dieldrin induced apoptotic N27 cells. 
(A) In situ detection of Serl4 phosphorylated H2B in dieldrin induced apoptotic cells. After 
dieldrin exposure (60 pM) for 1 hr, N27 cells were fixed and stained with Anti-phospho-
histone H2B (Serl4) antibody (1:1000) and Alex488 conjugated anti-rabbit secondary 
antibody (1:2000). Apoptotic nuclei were also shown by counterstaining of nuclei with 
Hoechst 33342. Cells were observed under a Nikon inverted fluorescence microscope (Model 
TE-2000U). (B) Dieldrin induced Serl4 phosphorylation of H2B was caspase-3 dependent. 
(C) In vitro phosphorylation of H2B by PKCô was caspase-3 dependent. Cells were treated 
with dieldrin (60 pM) alone for up to 3 hr or co-treated with Z-DEVD-FMK (50 pM) and 
dieldrin (60 |iM) for 1 hr. To detect Serl4 phosphorylation of H2B, histone mixtures were 
then isolated from the nuclear fraction of cells and separated by 15% SDS-PAGE for 
immunoblot analysis. For the kinase assay, PKCô was immunoprecipitated from nuclear 
lysate of cells and an in vitro kinase assay was performed with purified H2B as substrate. (D) 
PKCô-CRM, PKCô-DN, and PKCÔ-ANLS blocked dieldrin-induced Serl4 phosphorylation 
of Histone H2B. Double immunostaining of V5 and Serl4 phosphorylated H2B was 
performed after dieldrin treatment for 1 hr. Nuclei were also counterstained by Hoechst 
33342. Cells were observed under a Nikon inverted fluorescence microscope (Model TE-
2000U). Experiments were repeated three times and representative images are presented. 
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Figure 8: Catalytic fragment of PKCô (PKCS-CF) directly induces Serl4 
phosphorylation of H2B. 
PKCô-CF and PKCô-RF were introduced into N27 cells by electroporation. Double 
immunostaining of V5 and Ser 14 phosphorylated H2B was then performed 48 hr after 
transfection. Immunoreactivity of V5 and Ser 14 phosphorylated H2B was visualized by Cy3 
conjugated anti-mouse secondary antibody (1:2000) or Alex488 conjugated anti-rabbit 
secondary antibody (1:2000), respectively. Nuclei were counterstained with Hoechst 33342. 
Cells were observed under a Nikon inverted fluorescence microscope (Model TE-2000U). 
163 
Full-length PKCS 
Caspase-3 
mediated 
cleavage 
Activated cleaved 
PKCS Cytoplasm 
translocation 
Activated cleaved 
PKCS Nucleus 
PKCS-CF 
PKCÔ-DN 
PKCÔ-DN 
PKCS-ANLS 
Z-DEVD-FMK 
PKCS-CRM 
H2B phosphorylation 
Chromatin condensation and 
apoptosis 
Figure 9: Proposed integrated mechanisms of PKCô in dieldrin-induced apoptotic 
death of dopaminergic neuronal (N27) cells. 
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CHAPTER IV: NUCLEAR LOCALIZATION OF PKC8 IS REGULATED BY 
PROXIMITY OF N-TERMINAL C2-LIKE DOMAIN TO THE C-TERMINAL 
NUCLEAR LOCALIZATION SIGNAL (NLS) 
A paper submitted to Proceedings of National Academy of Sciences 
Yongjie Yang, Huajun Jin, Vellareddy Anantharam, Anumantha Kanthasamy 
ABSTRACT 
PKC5 belongs to the novel PKC subfamily that contains a Ca2+-insensitive C2-like 
domain followed by a lipid-binding CI domain in its N-terminal regulatory moiety. Although 
a functional nuclear localization signal (NLS) has been identified in the C-terminal of PKCô, 
it primarily localizes in the cytosol. The mechanisms by which PKCô is retained in the 
cytosol and by which the nuclear/cytosolic trafficking of PKCô is regulated are not known. 
In the present study, we demonstrated that the N- and the C-terminals of PKCô are in close 
proximity in the tertiary structure by fluorescence resonance energy transfer (FRET). FRET 
analysis of N-terminal CFP-FRET and C-terminal YFP FRET of PKCô gives rise to a 
significant FRET signal. Furthermore, by employing the CI or C2-like domain deletion 
mutants of PKCô (PKCô-ACl or PKCÔ-AC2), we show that deletion of the C2-like domain, 
but not the CI domain, induces a strong nuclear localization of PKCô. The exogenously 
expressed catalytic fragment of PKCô (PKCô-CF) also primarily localizes to the nucleus. 
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Sequence analysis of the C2-like domain revealed a possible leucine-rich nuclear export 
signal (NES); however, the C2-like domain is not sensitive to the nuclear export inhibitor 
leptomycin B, suggesting that this leucine-rich motif is not a functional NES. Moreover, the 
C2-like domain alone was fused to the N-terminal of a NES mutated form of Rev protein, the 
RNA binding protein of Equine Infectious Anemia Virus (EIAV), to generate the Rev 
chimera. Interestingly, the Rev chimera with the C2-like domain is still primarily localized 
in the nucleus. Together, our studies suggest that the N-terminal C2-like domain regulates the 
subcellular localization of PKCô by masking the C-terminal NLS through the position 
obstacle in the tertiary structure, but not by employing NES or interacting with anchoring 
proteins. 
INTRODUCTION 
Protein kinase C (PKC) is one of the major cellular signal transducers that mediates 
and regulates signals involved in a range of cellular processes, including cell growth, 
differentiation, apoptosis, neurotransmitter release, and carcinogenesis (Newton, 2003; 
Spitaler and Cantrell, 2004). All PKC family members share a highly conserved C-terminal 
catalytic moiety containing the kinase core; however, their regulatory moiety varies 
dramatically in composition and organization. The function of PKC, as observed in most of 
protein A, B, and C kinases, is primarily regulated by its regulatory moiety (Newton, 2003). 
Two key regulation roles of the regulatory moiety in PKC have been identified so far: the 
regulation of kinase membrane targeting through the CI and C2 domains and the regulation 
of kinase activity through the pseudosubstrate. 
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As a member of the novel PKC (nPKC) subfamily (5, 8, r\, 9), PKCô contains a Ca2+-
insensitive C2-like domain followed by a pseudosubstrate that normally binds to the catalytic 
site of the kinase core to inactivate the kinase (Orr et al., 1992) and a lipid-binding CI 
domain in the N-terminal regulatory moiety. The CI domain is a small globular structure (~8 
KDa) that contains binding sites for small lipid molecules, including diacylglycerol (DAG), 
phorbol esters, and non-hydrolysable analogues of the endogenous ligand (Newton, 1995; 
Zhang et al., 1995). Recent studies have further characterized that the CI domain can be 
divided into two sub-domains: CIA and C1B. These two sub-domains in different PKC 
isoforms preferentially bind to different lipid molecules (Bogi et al., 1999; Toker, 1998). In 
PKCô, C1B is primarily responsible for the binding of DAG (Szallasi et al., 1996). The 
binding of lipid molecules to the CI domain recruits PKCô to the membrane and promotes a 
remarkably high affinity interaction between PKCô and the membrane. This membrane 
interaction provides the energy to promote the conformational change which results in the 
release of pseudosubstrate from the catalytic site and activation of the kinase (Toker, 1998). 
In the conventional PKC (cRKC) subfamily (a, (31, (311, and y), the lipid-mediated 
translocation and activation of kinase is through the synergic action of both the CI and C2 
domains. The C2 domain in cPKC provides a binding site for anionic phospholipids and Ca2+ 
(Nalefski and Falke, 1996; Newton and Johnson, 1998; Ponting and Parker, 1996), and 
together with the binding of lipid to the CI domain promotes the high affinity interaction of 
cPKC with the membrane and subsequent activation of kinase. 
Unlike the conserved CI domain whose function in the regulation of the kinase core 
has been well characterized, the function of the C2-like domain in PKCô, as well as in all 
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other nPKC isoforms, is not fully understood. In particular, the C2-like domain is incapable 
of binding to Ca2+, and therefore loses the response to the Ca2+ signal though it shares 
significant homology with the C2 domain in cPKC (Newton, 1995). The crystallized 
structure of the C2-like domain from PKCô (Pappa et al., 1998) and PKCs (Ochoa et al., 
2001) suggests that it can still interact with the membrane by binding to phospholipids 
(phosphatidic acid and phosphatidylserine) in a Ca2+ independent manner. Pepio, A.M et al. 
showed that phosphorylation of Ser36 in the C2-like domain of Api II, an nPKC isoform 
from Aplysia, increases the binding to phosphatidylserine and induces more efficient 
translocation of kinase to the membranes (Pepio and Sossin, 2001). The C2-like domain of 
PKCô also mediates direct interaction with filamentous actin (F-actin) in neutrophils to 
regulate the migration of neutrophils in host-defense mechanisms against invading pathogens 
(Lopez-Lluch et al., 2001), as well as with non-smooth muscle F-actin in airway epithelial 
cells (Liedtke et al., 2003; Smallwood et al., 2005). 
The function of PKCô in the cell is closely associated with its subcellular localization. 
The precise localization is always the premise for kinase to receive upstream signals and 
transduce them downstream (Teruel and Meyer, 2000). Lipid-mediated translocation of 
PKCô to the membrane allows PKCô to effectively respond to the second messengers 
produced from different receptors (Nishizuka, 1992). PKCô also translocates to the 
mitochondria, Golgi, endoplasmic reticulum (ER), and the nucleus in response to other 
stimuli (Brodie and Blumberg, 2003). However, the mechanisms that regulate the subcellular 
localization of PKCô are poorly understood. Although it has been speculated that the 
isoform-specific localization of PKC is controlled by specific anchoring proteins (Mochly-
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Rosen and Gordon, 1998; Newton, 1997; Newton and Johnson, 1998), like receptors for 
activated C kinase (RACK), very little information is known about the interaction of PKC 
isoforms with different anchoring proteins. Recently, a functional nuclear localization signal 
(NLS) has been identified in the C-terminal of PKCô that induces PKCô translocation to the 
nucleus in response to apoptotic stimuli (DeVries et al., 2002). This NLS alone can also 
localize GFP to the nucleus. Other studies also observed that the exogenously expressed 
catalytic fragment of PKCô itself is primarily localized in the nucleus (Blass et al., 2002; 
DeVries et al., 2002). Interestingly, though PKCô contains the functional NLS at the C-
terminal of the kinase core that drives kinase into the nucleus in response to stimuli, PKCô 
primarily localizes in the cytosol rather than the nucleus in a variety of normal cells. On the 
other hand, the nuclear export signal (NES) has been identified only in the atypical PKC 
(aPKC) isoforms (X and Q (Perander et al., 2001), but not in all other cPKC and nPKC 
isoforms. The mechanisms that retain PKCô in the cytosol and regulate the nuclear/cytosolic 
trafficking of PKCô in normal cells are not clear. 
From the primary structure of PKCÔ, the pseudosubstrate at the middle of the 
regulatory moiety and kinase core at the catalytic moiety are distant from each other (Newton 
and Johnson, 1998). However, the pseudosubstrate constantly binds to the kinase core in 
normal cells to keep the kinase inactive. In order to do that, the primary structure of PKCô 
has to be properly folded to form a specific conformation that brings the pseudosubstrate and 
the kinase core closer for their interaction in the tertiary structure. Although the structure of 
full-length PKCô has not been crystallized, the fold of primary structure certainly brings the 
regulatory and catalytic moieties together. Since the C2-like domain is at the beginning of the 
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regulatory moiety and the NLS is located at the C-terminal of the kinase core, the fold of the 
primary structure may bring the C2-like domain closer to the NLS, which may implicate a 
role of the C2-like domain in the regulation of subcellular localization of PKCô. In the 
present study, we investigate the mechanisms that regulate the cytosolic localization of 
PKCô. We demonstrate that the C2-like domain retains PKCô in the cytosol by directly 
masking the NLS through the close proximity of the N-terminal to the C-terminal in the 
tertiary structure, rather than by binding to potential anchoring proteins or employing 
functional NES. 
MATERIALS AND METHODS 
Cell culture and treatment 
The immortalized rat mesencephalic dopaminergic neuronal (N27) cell line was a 
kind gift from Dr. Kedar N. Prasad, University of Colorado Health Sciences Center (Denver, 
CO) (Prasad et al., 1998). N27 cells were grown in RPMI 1640 medium containing 10% fetal 
bovine serum, 2 mM L-glutamine, 50 units penicillin, and 50 jag/ml streptomycin. Cells were 
grown in a humidified atmosphere of 5% CO2 at 37°C as previously described. For dieldrin 
treatment, dieldrin was prepared in DMSO and cells were exposed to serum-free RPMI 
medium containing dieldrin (final concentration 100 |aM) for up to 1 hr. For leptomycin B 
(LMB) treatment, LMB was dissolved in ethanol and cells were exposed to normal growth 
medium containing LMB (final concentration 0.5-5 ng/ml) for up to 30 min. 
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Cell transfection 
Transient transfection of N27 cells was performed by lipid or electroporation 
mediated approaches. For lipid-mediated transfection, lipofectamine 2000 from Invitrogen 
(Carlsbad, CA) was used. Briefly, cells (0.7-0.8x106) were plated in 35 mm glass bottom 
dishes (MatTek Corporation, Ashland, MA). After 16-24 hr, 4 |_ig plasmid as well as 10 |_il 
lipofectomine 2000 were first diluted in 250 p.1 Opti-MEM medium, separately. After 5 min, 
diluted plasmid was mixed with diluted lipofectamine 2000 and incubated for another 20 min 
for DNA-lipid complex formation. The DNA-lipid complex was then added into a glass 
bottom dish. After 16-24 hr, cells were directly observed under TCS/NT confocal 
microscopy. For electroporation, a nucleofector kit for adherent cell transfection from 
Amaxa bio systems (Cologne, Germany) was employed. Briefly, cultured N27 cells were 
trypsinized and spun down. About l-2xl06 cells were resuspended with 100 |il nucleofector 
solution mixed with 2 p.g plasmid and transferred into a cuvette. The cuvette was then put in 
a nucleofector device (Amaxa biosystems, Cologne, Germany) for electroporation. After 
electroporation, cells were transferred to a 6-well plate and incubated at 37°C. 
Preparation of constructs 
Full-length mouse PKCô (mPKCô) cDNA was amplified from pGFP-PKCô (a kind 
gift from Dr. Reyland at University of Colorado Health Sciences Center, Denver, CO) 
(DeVries et al., 2002) by using the following primer pairs that contain Hind III and BamH I 
sites at each end. Forward primer: 5' atatatataagçttatggcacccttcctgcgc 3'; reverse primer: 5' 
atatatatggatççaatgtccaggaattgctcaaa 3'. The PCR product was digested with Hind III/BamH I 
and then cloned into Hind III/BamH I sites of pEYFP-N 1 or pECFP-Cl (Clontech, Palo Alto, 
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CA) to generate the pEYFPô or pECFPô. pEYFPô was then subjected to Xho I/Xba I 
digestion to digest out the fragment containing mPKCô together with EYFP. This fragment 
was subcloned into Xho I/Xba I site of pECFP-Cl to generate the pFRETS construct. 
For the preparation of expression vectors containing PKC8-WT (wild type), PKC5-
AC2 (C2-like domain deletion mutant), PKCô-ANLS (nuclear localization signal deletion 
mutant), and PKCô-CF (catalytic fragment), 14-2035bp, 428-2035bp, 14-1843bp, and 995-
2035bp of mPKCS cDNA was amplified individually with the following primer pairs. For 
PKCô-WT: 5' caccatggcacccttcctgcgc 3' (F), 5' aatgtccaggaattgctcaaac 3' (R); for PKCô-
AC2: 5' caccatgtttccaaccatgaaccgtcgt 3' (F), 5' aatgtccaggaattgctcaaac 3' (R); for PKCô-
ANLS: 5' caccatggcacccttcctgcgc 3' (F), 5' ctccaggagggaccagtt 3' (R); for PKCô-CF: 5' 
caccatgaacaacgggacctatggcaa 3' (F), 5' aatgtccaggaattgctcaaac 3' (R). To prepare PKCô-AC 1 
(CI domain deletion mutant), the C2-like domain and catalytic fragment (CF) was first 
amplified with the following primer pairs. For the C2-like domain: 5' caccatggcacccttcctgcgc 
3' (F) and 5' atatatatgaattcctttgcctcctcctcacta 3' (R); for CF: 5' atcccagacgaattcaacaacgggacc 
3' (F) and 5' aatgtccaggaattgctcaaac 3' (R). These two PCR fragments were then ligated 
after EcoR I digestion and purification. The ligation reaction was used as template for 
amplification with the following primer pairs: 5' caccatggcacccttcctgcgc 3' (F) and 5' 
aatgtccaggaattgctcaaac 3' (R). All PCR reactions were performed withpfu DNA polymerase 
to ensure the fidelity of amplification. All PCR products were directly subcloned into the V5-
tagged (at the C-terminal) expression vector pLenti/TOPO from Invitrogen, Inc. (Carlsbad, 
CA) to generate pLenti/PKCÔ-WT, pLenti/PKCÔ-AC2, pLenti/PKCÔ-ACl, pLenti/PKCÔ-
ANLS, and pLenti/PKCÔ-CF. 
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Plasmids pEGFP-Rev and pEGFP-RDM4 (nuclear export signal deletion mutant of 
Rev) were kind gifts from Dr. Susan Carpenter (Iowa State University, Ames, IA). To 
prepare pEGFP-C2RDM4, the C2-like domain of PKC5 was first amplified with the 
following primer pairs that contain a Hind III and EcoR I site at each end. Forward primer: 5' 
atatatataagçttatggcacccttcctgcgc 3'; reverse primer: 5' atatatatgaattcctttgcctcctcctcacta 3'. 
The PCR product was digested with Hind III/EcoR I and cloned into Hind III/EcoR I sites of 
pEGFP-RDM4 to generate the pEGFP-C2RDM4. All constructs were confirmed by 
sequencing. 
Establishment of PKC8-AC2, PKC8-AC1, PKCÔ-ANLS, and PKC8-WT stably 
expressing N27 cell lines 
A ViraPower Lentiviral gene expression system from Invitrogen (Carlsbad, CA) was 
used to generate PKC8-AC2, PKC8-AC1, PKCô-ANLS, and PKCô-WT stably expressing 
N27 cell lines. To produce lentivirus, pLenti6/PKCô-AC2, pLenti/PKCô-AC 1, pLenti/PKCô-
ANLS or pLenti/PKCô-WT as well as supporting plasmids (provided with the kit) were co-
transfected into human 293FT cells with the use of lipofectamine 2000 as described in the 
instruction of the kit. The lentivirus particles in the medium were collected by centrifuging at 
3000 rpm for 15 min 48-72 hr post-transfection. To generate a stably expressing cell line, 
lentivirus containing individual pLenti/PKCô-AC2, pLenti/PKCô-AC 1, pLenti/PKCô-ANLS 
or pLenti/PKCô-WT as well as polybrene (6 gg/ml) was added into cultured N27 cells (2X 
105) for 24 hr and replaced with fresh medium. Positive N27 cells were selected by keeping 
blasticidin (10 fJ-g/ml) in the medium for up to 2 weeks. PKCÔ-AC2, PKCô-ACl, PKCô-
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ANLS, or PKCô-WT expressing N27 cells were identified by immunostaining of the dé­
terminai V5 tag. 
Preparation of whole cell homogenates 
After dieldrin treatment or electroporation, the N27 cells were harvested with 
trypsin/EDTA and spun at 200xg for 5 min. Cell pellets were then washed twice with ice-
cold PBS and resuspended in 200 pi of homogenization buffer (pH 8.0, 20 mM Tris, 10 mM 
EGTA, 2 mM EDTA, 2 mM DTT, 0.5% Triton X-100 and 1:100 dilution of protease 
inhibitor). After incubation on ice for 5 min, the cell lysates were centrifuged for 30 min at 
14,000xg at 4°C and supernatants were collected as whole cell lysates. 
Immunoblotting 
An equal amount of protein was loaded in each lane and separated on SDS-
polyacrylamide gel as described previously (Yang et al., 2004). Proteins were then 
transferred to nitrocellulose membrane by electro-blotting overnight (4°C, 25 V). Non­
specific binding sites were blocked by treating the nitrocellulose membranes with 5% non-fat 
dry milk TBST solution (10 mM Tris, 150 mM NaCl, and 0.1% Tween 20) for 1 hr. The 
nitrocellulose membranes were then incubated with primary antibodies (1:1000) for 1 hr at 
RT. The primary antibody treatment was followed by treatment with secondary HRP-
conjugated anti-rabbit or anti-mouse antibody (1:2000) for 1 hr at RT. Secondary antibody-
bound proteins were detected using an ECL chemiluminescence kit (Amersham). To confirm 
equal protein loading, blots were reprobed with (3-actin antibody (1:5000). Gel photographs 
were analyzed with a Kodak image station (Model 1000R, Rochester, New York). 
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Immunostaining 
Immunostaining of the V5 tag was performed in PKCô-WT, PKCô-ACl, PKCÔ-AC2 
and PKCô-ANLS expressing cells, as well as in PKCô-CF transiently transfected N27 cells. 
Cells cultured on poly L-lysine coated glass cover slips were gently washed with PBS twice, 
fixed in 4% paraformaldehyde, washed for 3x7 min with PBS, permeabilized, and blocked 
with blocking reagent (0.4% BSA, 5% goat serum, and 0.2% Triton-X 100 in PBS) for 20 
min. Cells were then incubated with anti-V5 mouse antibody (1:1000 in blocking reagent) 
overnight at 4°C and then washed for 3x7 min with PBS. The V5 tag was visualized by 
incubation with Cy3-conjugated goat anti-mouse secondary antibody (1:2000 in PBS) at RT 
for 90 min. After PBS wash, Hoechst 33342 was added to stain the cell nuclei at RT for 3 
min. Finally, cells were washed twice in PBS and mounted on a slide with antifade mounting 
medium. The cells were observed under TCS/NT confocal systems (Leica, Bannockbum, IL). 
All images were processed in MetaMorph 5.07 (Downingtown, PA). 
Live cell imaging 
Cells were first transfected with plasmid. After 24 hr, transfected cells cultured in 
glass bottom dishes (MatTek Corporation, Ashland, MA) were observed by inverted confocal 
microscopy. To observe the in vivo FRET, cells were excited by Argon laser line at 458 nm 
and image was acquired by using an LP515 emission filter. For ECFP, cells were excited by 
Argon laser line at 458 nm and image was acquired by using a 475±66 emission filter. For 
EYFP, cells were excited by Argon laser line at 488 nm and image was acquired by using an 
LP515 emission filter. For transmitted light images, cells were excited by Krypton laser line 
at 568 nm through a 488/568 double dichroic excitation filter and image was acquired by 
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using a 490±40 emission filter. For time-lapse acquisition of image, FRET, CFP, and YFP 
images were acquired every 5 min for up to 60 min. For visualization of pEGFP-Rev, 
pEGFP-RDM4, and pEGFP-C2RDM4, N27 cells cultured in glass bottom dishes were first 
transfected with plasmid. After 24 hr, Hoechst 33342 was added to the dish and incubated at 
RT for 15 min. The dishes were washed several times with lx PBS and replaced with normal 
growth medium. The cells were then observed under confocal microscopy. The EGFP 
fluorescence was excited by Argon laser line at 488 nm and image was acquired by using a 
BP525/50 emission filter. All images were acquired by a TCS/NT confocal system controlled 
by TCS NT software (Leica, Bannockbum, IL) and processed in MetaMorph 5.07 from 
Universal Imaging (Downingtown, PA). 
RESULTS AND DISCUSSION 
Design and characterization of PKCô-FRET 
To test whether the N-terminal is in close proximity to the C-terminal in the tertiary 
PKCô structure, the hybrid protein PKCô-FRET was designed and genetically engineered. 
The PKCô-FRET is composed of ECFP fused to the N-terminal, followed by the full-length 
mouse PKCô cDNA, and EYFP fused to the C-terminal (Figure 1 A). The ECFP-PKCô and 
PKCô-EYFP were also constructed as a negative control for PKCô-FRET. Because of the 
nature of FRET, in the PKCô-FRET, resonance energy transfer from ECFP to EYFP can be 
observed when the N-terminal is in close proximity to the C-terminal in the tertiary structure 
(Figure 1A). When PKCô undergoes caspase-3 mediated cleavage, the close proximity of 
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the N-terminal to the C-terminal is disrupted, as the regulatory fragment is separated from the 
catalytic fragment (Emoto et al., 1995; Kanthasamy et al., 2003). Because the ECFP and 
EYFP are not covalently linked, resonance energy transfer from ECFP to EYFP can no 
longer be observed. Similar FRET systems have been successfully demonstrated in the 
proteolysis of Bid protein (Onuki et al., 2002) and in monitoring of caspase-3 activity in 
apoptosis (Lee and Segal, 2004; Wang et al., 2005). The resonance energy transfer from 
ECFP to EYFP in hybrid protein PKCô-FRET was directly visualized by employing the 
confocal microscopy system. Live N27 cells transfected with pFRETô were excited with an 
Argon laser line at 458 nm, and emission was monitored by using either a 475±66 (ECFP) or 
LP515 (EYFP) emission filter. The in vivo ECFP fluorescence or fluorescence transferred 
from ECFP to EYFP (FRET) was observed (Figure IBb&c), as well as the EYFP 
fluorescence when excited with 488 nm (Figure IBa). In contrast, when cells transfected with 
pEYFPô were excited with 458 nm and emission was monitored by using either a 475=1=66 or 
LP515 emission filter, no fluorescence was observed (Figure IBe&f), while fluorescence of 
EYFP was observed with excitation at 488 nm and emission at LP515nm (Figure IBd). 
Similarly, no EYFP and FRET fluorescence was observed in cells expressing pECFPô with 
excitation at 488nm and emission at LP515 (Figure lBg&i), while the ECFP fluorescence 
was observed with excitation at 458 nm and emission at 475±66 (Figure lBh). 
Although the structure of full PKCô has not been successfully crystallized, many 
attempts to elucidate the structure of PKC have suggested that regulatory and catalytic 
moieties of PKC are close to each other, and the full protein is tightly compacted and 
globularly shaped (Newton and Johnson, 1998). The tight binding of pseudosubstrate to the 
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kinase core in the tertiary structure of PKC also suggests that the regulatory and catalytic 
moieties must be properly folded. By using FRET, we determined that the N- and C-terminal 
of PKCô are in close proximity in the tertiary structure. Since the C2-like domain is located 
at the beginning of the N-terminal and NLS is located at the very end of the C-terminal 
kinase core, the close proximity of the N- and C-terminals suggests that the C2-like domain 
is very close to the NLS in the tertiary structure. In order to mediate the nuclear translocation 
of protein, the NLS must be recognized and must bind with the nuclear import receptor 
(Kaffman and O'Shea, 1999). The close proximity of the C2-like domain to the NLS may 
provide a position obstacle for the recognition and binding of the NLS with the nuclear 
import receptor, further inhibiting the nuclear localization of PKCô. 
Proteolytic cleavage of PKCô abolishes FRET in vivo 
PKCô has been identified as one of the downstream targets of activated caspase-3 in 
apoptotic cells (Brodie and Blumberg, 2003; Emoto et al., 1995). We first examined PKCô 
cleavage in dopaminergic neuronal cells exposed to the neurotoxin dieldrin (100 jxM) for up 
to 60 min. Anti-PKCô antibody that recognizes the C-terminal epitope was employed. As 
shown in Figure 2A, cleaved PKCô was detected starting from 30 min and increased up to 60 
min following dieldrin exposure. The caspase-3 cleavage site of PKCô has been mapped on 
the hinge region that connects the regulatory and the catalytic moieties (Emoto et al., 1995); 
therefore, the cleavage of PKCô completely separates regulatory and catalytic fragments. To 
test whether the separation of regulatory and catalytic fragments by cleavage disrupts the 
close proximity of the N- to C-terminal in the tertiary structure of PKCô, N27 cells 
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transfected with pFRETô were treated with dieldrin (100 |xM) for up to 60 min. During the 
treatment, live cells were excited with an Argon laser line at 458 nm and emission was 
monitored by using either a 475=1=66 or LP515 emission filter, and the in vivo CFP 
fluorescence or fluorescence transferred from ECFP to EYFP (FRET) was recorded every 5 
min. The ratio of ECFP/EYFP was calculated to represent the FRET efficiency (Violin et al., 
2003). When the close proximity of the N- to C-terminal is disrupted, resonance energy 
transfer from ECFP to EYFP is abolished. Therefore, the ECFP/EYFP ratio increases as 
more ECFP fluorescence is emitted and less EYFP fluorescence is transferred from ECFP. 
As shown in Figure 2Ba, the ECFP/EYFP ratio showed no significant change over time, 
though the value at each time point fluctuated up and down in control N27 cells. In contrast, 
the ECFP/EYFP ratio gradually increased over time in dieldrin-treated N27 cells, indicating 
that the close proximity of the N- to C-terminal was partially disrupted during the period of 
dieldrin treatment. Rapid increases in the ECFP/EYFP ratio were also observed from 15 min 
to 20 min and from 45 min to 60 min, suggesting that disruption of the close proximity of the 
N- to C-terminal was intensive during that period of time. The time period of the two rapid 
decreases in FRET efficiency matches closely with the time point that cleaved PKCô 
appeared (Figure 2A), which indicates that the separation of the regulatory and the catalytic 
fragments by cleavage disrupts the close proximity of the N- to C-terminal. 
To demonstrate that the hybrid protein PKCô-FRET indeed undergoes proteolytic 
cleavage, the N27 cells transfected with pFRETô were treated with dieldrin (100 jaM) for up 
to 60 min. Cells were lysed and subjected to immunoblot analysis by using anti-GFP 
antibody. As shown in Figure 2C, hybrid protein PKCô-FRET was cleaved and the cleaved 
CF - YFP/RF-CFP was detected at 60 min following dieldrin exposure. Since antibody 
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specifically detecting the catalytic fragment of PCKS is currently unavailable, the 
localization change of the catalytic fragment of PKCô in N27 cells following dieldrin 
exposure cannot be directly explored. Thus, we transiently transfected the catalytic fragment 
of PKCô (PKCô-CF) into N27 cells in order to examine the localization of the catalytic 
fragment of PKCô. Immunostaining of the C-terminal V5 tag and counterstaining of the 
nucleus were performed 24 hr post transfection. As shown in Figure 2D, PKCô-CF revealed 
by V5 immunoreactivity primarily localizes in the nucleus. 
These results suggest that there is no covalent link between regulatory and catalytic 
moieties. The separation of the regulatory and catalytic moieties by proteolytic cleavage 
disrupts the close proximity of the N- to C-terminal and abolishes the FRET. We also 
demonstrate that the catalytic fragment of PKCô, by itself, primarily localizes in the nucleus, 
which is consistent with previous studies (Blass et al., 2002; DeVries et al., 2002). The 
primary nuclear localization of PKCô-CF indicates that the recognition of the NLS by the 
nuclear import receptor is not inhibited and the catalytic fragment itself does not contain a 
functional NES to transport PKCô-CF out of the nucleus. 
Deletion of the C2-like domain leads to nuclear localization of PKCô 
A functional nuclear localization signal (NLS) has been identified at the C-terminal 
(611-623) of the kinase core in PKCô (DeVries et al., 2002). Nuclear translocation of PKCô 
was inhibited with mutated NLS. Also, the NLS alone localizes GFP in the nucleus. 
Interestingly, though PKCô contains the C-terminal NLS, it is mainly distributed in the 
cytosol in cells. We demonstrated that the N-terminal is in close proximity to the C-terminal 
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in the tertiary structure of PKCô, and PKCô-CF primarily localizes to the nucleus. The 
regulatory moiety is probably involved in the regulation of the nuclear localization of PKCô. 
We next investigated the involvement of the regulatory moiety in the regulation of 
nuclear localization of PKCô. Expression vectors that express wild-type PKCô (PKCô-WT), 
the Cl or C2-like domain deletion mutant (PKCô-ACl or PKCÔ-AC2), or the NLS deletion 
mutant (PKCô-ANLS) were first constructed. The schematic representation of these 
constructs is shown in Figure 3A. The PKCô-WT, PKCô-ACl, PKCÔ-AC2, and PKCÔ-ANLS 
stably expressing N27 cells were then generated by using the ViraPower Lentiviral gene 
expression system from Invitrogen, Inc. (Carlsbad, CA). V5 immunostaining and nucleus 
counterstaining were performed to investigate the subcellular distribution of wild type and 
mutated PKCô protein. As shown in Figure 3B, PKCô-WT revealed by V5 immunoreactivity 
was primarily localized in the cytosol, though a little was in the nucleus (Figure 3Bc). In the 
PKCÔ-ANLS expressing cells, the PKCô-ANLS was completely excluded from the nucleus 
as expected (Figure 3Bf). Strikingly, PKCÔ-AC2 was primarily localized in the nucleus, with 
only very light V5 immunoreactivity observed in the cytosol (Figure 3B1), while PKCô-ACl 
was still primarily localized in the cytosol (Figure 3Bi). The dramatic shift in V5 
immunoreactivity from the cytosol to the nucleus in PKCô-WT and PKCÔ-AC2 strongly 
suggests that the C2-like domain is involved in the regulation of the nuclear localization of 
PKCÔ. 
Since the C2-like domain is located at the beginning of the N-terminal regulatory 
moiety, and we demonstrated above that the N-terminal is in close proximity to the C-
terminal, the C2-like domain might regulate the nuclear localization of PKCô by 
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preoccupying the position near the NLS to block the potential contact of the nuclear import 
receptor to the NLS. This likely results in the inhibition of the nuclear import of PKCô and 
the normal primary cytosolic localization of PKCô. Although the CI domain could also be in 
close proximity to the NLS in the tertiary structure and block the contact of NLS with the 
nuclear import receptor, the deletion of the CI domain did not result in the shift of PKCô 
localization from the cytosol to the nucleus. When the C2-like domain is deleted or the whole 
regulatory fragment is removed by cleavage, the position obstacle effect of the C2-like 
domain to the NLS disappears, leading to the exposure of the NLS to the nuclear import 
receptor and resulting in the import of PKCô into the nucleus. It is also possible, though, that 
the C2-like domain contains a functional nuclear export signal (NES) to export PKCô out of 
the nucleus, causing the primary cytosolic localization of PKCô. The C2-like domain might 
also interact with anchoring proteins of PKC and inhibit the nuclear import of PKCô, which 
also induces the primary cytosolic localization of PKCô. 
C2-like domain does not contain CRMl-dependent nuclear export signal (NES) 
Similar to the nuclear import, nuclear export of protein is also regulated by the 
recognition of the nuclear export signal (NES) by its receptor (Kaffman and O'Shea, 1999). 
Although new NES and corresponding receptors are being identified, the leucine-rich NES 
and its receptor CRM1 is the major and currently most characterized nuclear export pathway 
in yeast and mammalian cells (Fomerod et al., 1997; Fukuda et al., 1997; Stade et al., 1997). 
To investigate whether the C2-like domain contains leucine-rich NES, the leucine-rich motif 
in the C2-like domain (1-138) was first predicted by using the NETNES 1.1 Server (la Cour 
192 
et al., 2004). NETNES is specifically designed for the prediction of leucine-rich NES in 
eukaryotic proteins. As shown in Figure 4A, no particular motif has an NES score close to or 
higher than the NES threshold, suggesting that the putative leucine-rich NES was not found 
in the C2-like domain. However, we did notice that the sequence from 108-116 contained 
two leucines and gained an NES score. This motif was then aligned with several validated 
leucine-rich NES in human immunodeficiency virus type 1 (HIV-1) Rev protein (Fischer et 
al., 1995), mitogen-activated protein kinase (Fukuda et al., 1996), phospholipase C-ôl 
(PLCôl) (Yamaga et al., 1999), cAMP-dependent protein kinase inhibitor (PKI) (Wen et al., 
1995) as well as two atypical PKC isoforms Ç and X (Perander et al., 2001). The alignment is 
shown in Figure 4B. The C2-like domain contains only two conserved leucines at the first 
and third position, but not the second and fourth leucines shared by all other NES. In addition, 
it contains a hydrophilic cysteine instead of hydrophobic leucine or isoleucine at the fourth 
conserved leucine position. The fourth leucine at the C-terminal has been shown to be critical 
for the function of NES (Perander et al., 2001). The point mutation of this leucine abolished 
the functional nuclear export signal in atypical PKC and caused the accumulation of atypical 
PKC in the nucleus. The lack of sequence homology of the 108-116 region of the C2-like 
domain with other validated leucine-rich NES, especially the lack of the fourth leucine, 
makes it incapable of functioning as a leucine-rich NES. 
It has been well characterized that the leucine-rich NES is specifically recognized by 
its receptor CRM1 in the nuclear export process. This CRM1 mediated nuclear export 
pathway can be effectively inhibited by the fungicide leptomycin B (LMB) through the 
covalent binding of LMB to a cysteine of CRM1 (Fomerod et al., 1997; Kudo et al., 1999). 
The potent and specific inhibition of LMB in the CRM1 mediated pathway provides an 
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excellent tool for the validation of the leucine-rich NES. To further determine if the C2-like 
domain contains the leucine-rich NES, PKCô-WT stably expressing N27 cells were treated 
with LMB (0.5 ng/ml) for up to 30 min. As shown in Figure 4C, LMB did not induce change 
in the subcellular distribution of PKCô-WT, as revealed by V5 immunoreactivity. Cells were 
also treated with ethanol (0.1%) as a vehicle control because LMB was prepared in ethanol. 
Ethanol itself also did not change the subcellular localization of PKCô-WT. We also tested a 
serial combination of LMB concentrations (up to 5 ng/ml) and exposure times (up to 60 min), 
but no change in subcellular localization of PKCô-WT was observed under these conditions. 
The insensitivity of the C2-like domain to LMB further demonstrates that it does not contain 
a leucine-rich nuclear export signal. 
C2-like domain cannot retain the NES deleted Rev in the cytosol 
We determined above that the C2-like domain does not contain the classical leucine-
rich NES. Next, we tried to determine whether the C2-like domain retains PKCô in cytosol 
by employing other types of NES or by interacting with anchoring proteins. To test this, we 
engineered a C2-like domain as a heterogeneous protein that contains functional NLS but not 
NES. The functional NLS allows protein importing to the nucleus after synthesis in the 
cytosol. A NES deleted form of Equine Infectious Anemia Virus (EIAV) Rev protein was 
employed as the heterogeneous protein because it contains functional NLS and is small in 
size (23KDa) (Belshan et al., 1998). Rev is a RNA-binding protein of EIAV that contains 
functional NLS and NES to shuttle itself between the cytosol and nucleus (Fischer et al., 
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1995). The deletion of its NES results in the retention of Rev in the nucleus (Belshan et al., 
1998). 
We first obtained pEGFP-Rev-WT and pEGFP-RDM4 (kind gifts of Dr. Susan 
Carpenter) that express the N-terminal fused wild type Rev or NES deleted form of Rev, 
respectively. The C2-like domain of PKCô was then engineered into the pEGFP-RDM4 to 
generate the pEGFP-C2RDM4. The schematic presentation of the primary structure of these 
constructs is presented at Figure 5A. Subcellular localization of these proteins was then 
visualized by EGFP fluorescence and nucleus staining. In pEGFP-Rev-WT transacted N27 
cells, EGFP-Rev-WT showed mixed subcellular localization, as shown in previous studies 
(Belshan et al., 1998; Belshan et al., 2000). In some cells, EGFP-Rev-WT was mainly 
localized in the cytosol, but in other cells it was primarily localized in the nucleus. A 
representative image of the cytosolic localization of EGFP-Rev-WT in N27 cells is shown in 
Figure 5Ba. However, in pEGFP-RDM4 transfected N27 cells, as shown in Figure 5Bd, 
EGFP-RDM4 uniformly showed strong nuclear localization in all transfected cells because of 
the deletion of the functional NES. In pEGFP-C2RDM4 transfected N27 cells, strong nuclear 
localization of EGFP-C2RDM4 was also uniformly observed in all transfected cells, though a 
little EGFP fluorescence was also observed in the cytosol (Figure 5Bg). The nucleus was 
visualized by Hoechst 33342 staining. These results clearly demonstrate that the C2-like 
domain alone is not capable of compensating for the function of the Rev NES. The failure of 
the C2-like domain alone to retain Rev chimera in the cytosol indicates that the C2-like 
domain alone does not contain NES to export the Rev chimera out of the nucleus, nor does it 
interact with anchoring proteins to retain the Rev chimera in the cytosol in N27 cells. 
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CONCLUSIONS 
In summary, we demonstrate that the C2-like domain at the N-terminal of the 
regulatory moiety regulates the nuclear localization of PKC5 (Figure 6). We first show that 
the N-and C-terminals of PKC5 are in close proximity in the tertiary structure, which is 
disrupted by caspase-3 mediated cleavage. The cleavage of PKC5 or the deletion of the C2-
like domain, which both remove the C2-like domain from the NLS, leads to the primary 
nuclear localization of the kinase. Our results also show that the C2-like domain is not 
capable of retaining a heterogeneous protein in the cytosol. The C2-like domain regulates the 
nuclear localization of PKCô through the position obstacle effect of the C2-like domain, by 
masking the NLS and blocking the recognition of the nuclear import receptor to the NLS. 
Our model suggests that the NLS can be kept incompetent in normal situations. A specific 
signal, like cleavage, can make NLS competent to be recognized by the nuclear import 
receptor for further nuclear translocation and downstream signaling. The maintenance of 
competency of the NLS provides a new and distinct mechanism for kinases to self-regulate 
their subcellular localization and function. 
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Figure 1 : Illustration of FRET system in PKCô. 
(A) Schematic diagram of the FRET system in PKCô. ECFP and EYFP were fused into the 
N-terminal and C-terminal of PKCô, respectively, to generate the PKCô-FRET hybrid 
protein. This FRET system is described in detail in the text. (B) Fluorescent and transmitted 
light images for CFP, YFP, and FRET in live N27 cells. Plasmid pCFPô, pYFPô, and 
pFRETô were transfected into N27 cells by using lipofectamine 2000. Cells cultured in glass 
bottom dishes were directly observed by using the TCS/NT confocal system. The detailed 
procedures for acquisition of images are described in the materials and methods (Bar =10 
Hm). 
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Figure 2: Separation of regulatory fragment from catalytic fragment of PKCô by 
cleavage abolishes FRET. 
(A) Dieldrin treatment induces PKCô cleavage in N27 cells. N27 cells were treated with 
dieldrin (100 pM) in serum-free medium for up to 60 min. Cell homogenates were prepared 
and separated by 10% SDS-PAGE. PKCô cleavage was then detected by using anti-PKCÔ-
antibody that recognizes a C-terminal epitope. (B) Time-lapse recording of FRET signal in 
control and dieldrin-treated N27 cells. N27 cells were first transfected with pFRETô for 24 hr 
and treated with dieldrin (100 [xM) for up to 60 min. During the treatment, the CFP, YFP, 
and FRET images were acquired every 5 min by using the corresponding excitation laser 
wavelength and emission filter set. The intensity of CFP and FRET at each time point was 
measured in Metamorph 5.07. The intensity ratio of CFP/YFP was calculated and plotted in 
Prism 3.0. (C) Cleavage of PKCô-FRET was indeed induced in pFRETô transfected N27 
cells following dieldrin exposure. To get the higher transection efficiency, pFRETô was 
transfected into N27 cells by electroporation. After 24 hr, cells were lysed and whole cell 
lysates were separated by 7.5% SDS-PAGE. The cleavage of PKCô-FRET was detected by 
using anti-GFP antibody. (D) Nuclear localization of the catalytic fragment of PKCô (PKCô-
CF). PKCô-CF was transiently transfected into N27 cells. The localization of PKCô-CF was 
visualized by immunostaining of the V5 tag (Bar =10 p.m). 
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Figure 3: Deletion of C2-like but not CI domain in PKCô induced nuclear localization 
of PCKô. 
(A) Schematic representation of PKCô-WT, PKCô-ACl, PKCÔ-AC2, and PKCô-ANLS. 
Generation of these constructs is described in detail in the materials and methods. (B) 
Subcellular localization of PKCÔ-WT, PKCô-ACl, PKCÔ-AC2, and PKCÔ-ANLS in N27 
cells. PKCô-WT, PKCô-ACl, PKCÔ-AC2, and PKCô-ANLS stably expressing N27 cells 
were generated via the ViraPower Lentiviral gene expression system (Invitrogen, Inc. 
Carlsbad, CA). Cells were then fixed, and immunostaining of the V5 tag was performed. To 
visualize the V5 tag, Cy3-conjugated secondary antibody was used. Subcellular localization 
of PKCô-WT, PKCô-ACl, PKCÔ-AC2, and PKCô-ANLS was revealed by immunoreactivity 
of the V5 tag. Nuclei were counterstained by Hoechst 33342. Stained cells were observed 
under a TCS/NT confocal system and all images were processed in Metamorph 5.07 (Bar = 
10 pm). 
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Figure 4: C2-like domain of PKCô does not contain leucine-rich nuclear export signal 
(NES). 
(A) Analysis of the leucine-rich NES motif in the C2-like domain of PKCô. The amino acid 
sequence (1-138) of the C2-like domain was uploaded to the NETNES 1.1 server 
(http://www.cbs.dtu.dk/services/NetNES/) and we performed NES motif prediction. (B) 
Alignment of the leucine-rich motif in the C2-like domain of PKCô with a validated NES 
motif from Rev, MEK, PLCôl, PKI as well as two atypical PKC isoforms Ç and X. The NES 
motifs from different proteins were directly aligned with the leucine-rich motif (108-118) of 
the C2-like domain in ClustalW 1.8 (http://searchlauncher.bcm.tmc.edu/multi-align/multi-
align.html). (C) Leucine-rich motif in the C2-like domain is not sensitive to the nuclear 
export inhibitor leptomycin B (LMB). Leptomycin B stock (500 ng/ml) was prepared in 
ethanol. PKCô-WT stably expressing cells were treated with ethanol (0.1%) alone as a 
vehicle control or with LMB (0.5 ng/ml) for 5 min, and immunostaining of the V5 tag was 
performed. The immunoreactivity of the V5 tag was visualized by using Cy3-conjugated 
secondary antibody. Subcellular localization of PKCô-WT was revealed by immunoreactivity 
of the V5 tag. Nuclei were counterstained with Hoechst 33342. Stained cells were observed 
under a TCS/NT confocal system and all images were processed in Metamorph 5.07 (Bar = 
10 pm). 
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Figure 5: Incapacity of C2-Iike domain to retain NES deleted form of Rev in the 
cytoplasm. 
(A) Schematic representation of the primary structures of EGFP-Rev-WT, EGFP-RDM4, and 
EGFP-C2RDM4. All functional domains are illustrated as boxes in different colors. (B) 
Subcellular localization of EGFP-Rev-WT, EGFP-RDM4, and EGFP-C2RDM4 inN27 cells. 
EGFP-Rev-WT, EGFP-RDM4, and EGFP-C2RDM4 were transfected into N27 cells cultured 
in glass bottom culture dishes. About 24 hr post-transfection, Hoechst 33342 was added to 
culture dishes and incubated at RT for 15 min. The culture dishes were then washed with 
lxPBS three times and replaced with normal culture medium. To observe the EGFP 
fluorescence from live cells, cells in culture dishes were then directly observed by confocal 
microscopy and all images were processed in Metamorph (Bar =10 |im). 
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CHAPTER V: SELECTIVE EXPRESSION OF OXIDATIVE-STRESS SENSITIVE 
KINASE PROTEIN KINASE C DELTA (PKCÔ) CONTRIBUTES TO THE 
VULNERABILITY OF NIGRAL DOPAMINERGIC NEURONS TO MPP-INDUCED 
DEGENERATION 
A paper submitted to the Journal of Neuroscience 
Yongjie Yang, Latchoumycandane Calivarathan, Danhui Zhang, Siddharth Kaul, Vellareddy 
Anantharam, Anumantha Kanthasamy 
ABSTRACT 
Protein kinase C delta (PKCô) has been shown to be an oxidative stress sensitive 
kinase that promotes neurotoxin-induced apoptotic death of dopaminergic neuronal cells. In 
the present study, we determined the relative expression levels of PKC isoforms, including 
PKCa, PKC|3I, PKCô, PKCs, PKC0, and PKCÇ in the substantia nigra (SN), striatum (St), 
and cortex (Ctx) regions of rodent brains. By employing immunostaining, immunoblot, and 
quantitative RT-PCR, selective expression of PKCô, but not of other PKC isoforms, was 
found in the nigral dopaminergic neurons. Co-localization of abundant PKCÔ with tyrosine 
hydroxylase (TH) in the cytoplasm of nigral dopaminergic neurons was also observed. We 
further demonstrated that PKCô is proteolytically activated in the substantia nigra region of 
the mouse brain. The blockade of proteolytic cleavage of endogenous PKCô by the cleavage 
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resistant mutant of PKCô (PKCô-CRM) not only protects dopaminergic neuronal (N27) cells 
from MPP+-induced apoptotic death, but also protects primary dopaminergic neurons from 
MPP+-induced degeneration. Moreover, the catalytic fragment of PKCô (PKCô-CF), but not 
the regulatory fragment of PKCô (PKCô-RF), can directly induce the degeneration of 
primary dopaminergic neurons. Finally, we demonstrated that the number of nigral 
dopaminergic neurons and the striatum dopamine level are significantly higher in PKCô-/-
mice than in PKCô +/+ mice after administration of MPTP. Taken together, our studies 
suggest that abundant PKCô is one of the inherent factors that contribute to the vulnerability 
of nigral dopaminergic neurons to MPP+-induced degeneration by its proteolytic activation. 
INTRODUCTION 
The severe degeneration of substantia nigra pars compacta (SNc) dopaminergic 
neurons in Parkinson's disease (PD) causes depletion of the neurotransmitter dopamine in the 
striatum, and subsequently changes the neuronal circuitry controlling voluntary movement 
and induces the development of hyperkinesia symptoms, including tremors, bradykinesia, 
and postural instability. The degeneration of dopaminergic neurons in PD is strikingly 
selective, i.e., dopaminergic neurons located in the SNc region are selectively degenerated, 
though degeneration of noradrenergic neurons at the locus coeruleus, serotonergic neurons at 
the raphe, and cholinergic neurons at the nucleus basalis of meynert, dorsal motor nucleus of 
vagus, and cerebral cortex are also observed (Dauer and Przedborski, 2003). MPTP, a 
mitochondrial complex I inhibitor, induces rapid development of an irreversible PD-like 
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syndrome in humans and primates (Langston et al., 1984; Albanese et al., 1993); the 
development of MPTP cell culture and animal models of PD paves the path to investigate the 
mechanism of dopaminergic neuronal degeneration. 
Extensive studies have suggested that oxidative stress is one of the major upstream 
events that contributes to the cell death process of the SNc dopaminergic neurons in PD 
(Cassarino et al., 1997; Greenamyre et al., 2001; Jenner, 2003). Examination of postmortem 
PD brains has revealed that the SNc region has a higher level of oxidative stress, as indicated 
by the level of lipid peroxidation and protein or DNA oxidation (Dexter et al., 1989; Floor 
and Wetzel, 1998; Jenner, 1998). Dopaminergic neurons are particularly susceptible to 
oxidative stress, as their neurotransmitter dopamine can be oxidized to generate toxic 
dopamine-quinone species, superoxide radicals, and hydrogen peroxide (Graham, 1978; 
Lotharius and Brundin, 2002). Oxidative stress induced by MPTP or its active form MPP+ 
(Cassarino et al., 1997; Dauer and Przedborski, 2003; Kaul et al., 2003), as a result of 
mitochondrial complex I inhibition, has also been shown to trigger a series of apoptotic 
cascades, including cytochrome c release (Cassarino et al., 1999), caspase activation 
(Hartmann et al., 2000; Hartmann et al., 2001; Viswanath et al., 2001), and apoptotic cell 
death in numerous cell culture and animal PD models. However, downstream events of 
caspase-3 activation induced by oxidative stress in dopaminergic neurons have not been fully 
characterized. 
Protein kinase C is one of the major cellular signal transducers involved in various 
cellular functions. The PKC family includes 11 isoforms, which are classified mainly into 
three subgroups based on their dependence upon diacylglycerol (DAG) and Ca2+ for 
activation (Newton, 2003). The conventional PKC isoforms (a, (31, (311, and y) require DAG 
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and Ca2+ for activation, the novel PKC isoforms (8, s, r\, and 0) require DAG but not Ca2+ for 
activation and the atypical PKC s (PKC Ç, X, and i) require neither Ca2+ nor DAG for 
activation. Interestingly, a substantial body of evidence has demonstrated that PKCô can be 
proteolytically activated by caspase-3 and promote apoptotic cell death in non-neuronal and 
neuronal cells (Brodie and Blumberg, 2003; Kitazawa et al., 2003; Yang et al., 2004), 
although most of the PKC isoforms have anti-apoptotic properties in the cells (Gutcher et al., 
2003). Our previous studies have also shown that hydrogen peroxide-induced oxidative stress 
also induces caspase-3 dependent proteolytic activation of PKCô in dopaminergic neuronal 
cells (manuscript under review), suggesting that PKCô might be an important downstream 
modulator mediating oxidative stress-induced apoptotic death of dopaminergic neurons. 
Although several expression surveys of PKC isoforms in the central nervous system have 
found that PKC8 is highly expressed in the thalamus, septal nuclei, and purkinje cells in the 
posterior cerebellum (Barmack et al., 2000; Naik et al., 2000), the expression of PKCô in the 
SNc dopaminergic neurons has not been investigated. 
Previously, we demonstrated that protein kinase C delta (PKCô) is proteolytically 
activated by caspase-3 and contributes to the induction of apoptotic death of dopaminergic 
neuronal cells by various neurotoxins (Kaul et al., 2003; Kitazawa et al., 2003; Yang et al., 
2004). Herein, we examined the expression of PKC isoforms in different regions of brain, 
including the nigral dopaminergic neurons, and investigated the role of proteolytic activation 
of PKCô in MPP+-induced degeneration of nigral dopaminergic neurons in primary 
mesencephalic neuronal cultures and in the substantia nigra region of mice brains. 
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MATERIALS AND METHODS 
Materials 
MPP+, protease cocktail, ATP, protein-A-sepharose, and anti-p-actin antibody were 
obtained from Sigma-Aldrich (St. Louis, MO). Antibodies to PKCô, a, and pi were 
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-GAD-6 antibody was 
obtained from the University of Iowa hybridoma facility. TaqMan Rat PKCô, Mouse 
PKCô, 8, and 9, the 18s ribosome RNA expression assay kit, and PCR master mix were 
purchased from Applied Biosystems (Foster City, CA). Anti-rabbit and anti-mouse secondary 
antibodies and the ECL chemiluminescence kit were purchased from Amersham Pharmacia 
Biotech. (Piscataway, NJ). Alexa 488 conjugated anti-rabbit secondary antibody and Hoechst 
33342 were purchased from Molecular Probes, Inc. (Eugene, OR). Cy3 conjugated anti-
mouse secondary antibody was obtained from Jackson Laboratory (Bar Harbor, Maine) The 
Cell Death Detection ELISA plus Assay Kit was purchased from Roche Molecular 
Biochemicals (Indianapolis, IN). [y-32P] ATP was purchased from Perkin Elmer Life Science 
Products (Boston, MA). The Bradford protein assay kit was purchased from Bio-Rad 
Laboratories (Hercules, CA). Brilliant SYBR green QPCR reagent, Brilliant QPCR reagent, 
and Pfu DNA polymerase were purchased from Stratagene (La Jolla, CA). SuperScript III 
first-strand synthesis system, TRIZOL reagent, ViraPower™ lentiviral expression system, 
RPMI, fetal bovine serum, L-glutamine, blasticidin, penicillin, streptomycin, and gentamycin 
were purchased from In vitro gen, Inc. (Carlsbad, CA). Primers were synthesized in IDT 
(Coralville, IA). 
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Animals 
All male C57 black mice (12-16 weeks old) used in the experiments were maintained 
in the College of Veterinary Medicine Animal Care Facility of Iowa State University under 
standard laboratory conditions with water and food available ad libitum. PKCô-/- mice were 
a kind gift from Prof. Keiichi Nakayama (Kyushu University, Fukuoka, Japan) (Miyamoto et 
al., 2002). All experimental procedures involving mice have been approved by the Iowa State 
University Institutional Animal Care and Use Committee. 
Cell culture 
The immortalized rat mesencephalic dopaminergic neuronal cell line (N27) was a gift 
from Dr. Kedar N. Prasad (University of Colorado Health Sciences Center, Denver, CO) 
(Prasad et al., 1998). N27 cells were grown in RPMI 1640 medium containing 10% FBS, 2 
mM L-glutamine, 50 units penicillin, and 50 (ag/ml streptomycin. Cells were maintained in a 
humidified atmosphere of 5% CO2 at 37°C, and 4-5 day old cells were used for the 
experiments. For MPP+ treatment, N27 cells and PKCô-CRM stably expressing N27 cells 
were treated with 300 pM MPP+ for 36 hr in serum-containing medium. 
Primary mesencephalic neuronal culture 
Primary mesencephalic neuronal cultures were prepared from the ventral 
mesencephalon of gestational 15-17 day old rat embryos as described previously (Yang et al., 
2004). Briefly, midbrain tissues were maintained in ice-chilled dissection solution (HBS 
supplemented with 200 units/ml penicillin/streptomycin, 10 mM MgCl], 7 mM pH 7.3 Hepes, 
and 2 mM L-glutamine) during the dissection. The tissue was collected by centrifugation at 
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80 g for 5 min and then treated with Trypsin/EDTA for 20-30 min at 37°C. Trypsin was 
removed by centrifugation and digested tissues were resuspended in culture medium I 
(DMEM supplemented with 10% FBS). The digested tissues were further separated by 
pipetting to obtain the homogenous suspension. The cells were counted and plated at equal 
density (0.5 x 106 cells) on cover slips pre-coated with poly-L-lysine and laminin in 6-well 
plates. After 24 hr, culture medium I was replaced with culture medium II (Neurobasal-A 
medium, supplemented with 0.2% insulin, 0.2% transferring, 5% FBS, 2% B-27 supplement, 
2 mM GlutaMAX I, 1 pg/ml gentamycin, and 5 JJM cytosine arabinoside). The cells were 
maintained in a humidified CO2 incubator (5% CO2,37°C). Half of the culture medium was 
replaced every 2 days. Approximately 6-7 day old cultures were used for experiments. 
MPTP administration to mice 
MPTP dissolved in ddHiO was administered using an acute dosing regimen of 30 
mg/kg intraperitoneally every day for five doses. Control animals were treated with an equal 
volume of ddHzO. All animals were sacrificed the day after the last injection. Experimental 
groups included MPTP-treated PKC5+/+ mice (n=12) and their control (n=12) and MPTP-
treated PKCô-/- mice (n=12) and their control (n=12). 
Immunoblotting 
Different regions of brain, including cortex, striatum, and substantia nigra, were first 
dissected. To prepare the tissue homogenate, brain tissues were homogenized with a mini 
homogenizer in lysis buffer (pH 8.0, 20 mM Tris-Cl, 10 mM EGTA, 2 mM EDTA, 2 mM 
DTT, 0.5% Triton X-100, and 1:100 dilution of protease inhibitor). For cell homogenate 
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preparation, N27 cells (lOxlO6) were harvested with trypsin/EDTA and spun at 200xg for 5 
min. Cell pellets were then washed twice with ice-chilled PBS and resuspended in 200 (il of 
lysis buffer. After incubation on ice for 5 min, the lysates were centrifuged for 30 min at 
14,000xg at 4°C and supematants were collected as whole lysates. Equal amounts of protein 
(20-30 ja.g) were loaded in each lane and separated on a 10% SDS-polyacrylamide gel. 
Proteins were then transferred to nitrocellulose membrane by electro-blotting overnight (4°C, 
25 V). Non-specific binding sites were blocked by treating the nitrocellulose membranes 
with 5% non-fat dry milk TBST solution (10 mM Tris, 150 mM NaCl, and 0.1% Tween 20) 
for 1 hr. The nitrocellulose membranes were then incubated with primary antibodies (1:1000) 
for 1 hr at RT. The primary antibody treatment was followed by treatment with secondary 
HRP-conjugated anti-rabbit or anti-mouse IgG (1:2000) for 1 hr at RT. Secondary antibody-
bound proteins were detected using an ECL chemiluminescence kit (Amersham Biosciences). 
Gel photographs and densitometric analysis were performed with a Kodak image station 
(Model 1000R, Rochester, New York). 
RNA preparation and quantitative real time RT-PCR 
Total RNA was prepared from N27 cells or from different regions of rodent (mouse 
and rat) brains. N27 cells (lxlO6) were first collected by centrifugation and washed with PBS. 
For rodent brain tissue samples, different regions of brain (striatum, cortex, substantia nigra) 
were dissected and frozen in liquid nitrogen. The absolute RNA RT-PCR miniprep kit 
(Stratagene, La Jolla, CA) was used for RNA preparation. Briefly, the cell pellet or brain 
tissue (20 mg) was resuspended in lysis buffer (from the kit). Brain tissue was further 
homogenized with the mini homogenizer. The homogenate was loaded on the spin column 
224 
(from the kit) for the enrichment of RNA in the column. DNase solution (from the kit) was 
added to the column for the degradation of the remaining DNA. After washing with low-salt 
buffer, RNA retained on the membrane was eluted out with elution buffer. Total RNA was 
reversely transcribed into cDNA using the SuperScript III first-strand synthesis system 
(Invitrogen, Inc., Carlsbad, CA) as described in the kit instructions. For quantitative RT-PCR 
(QRT-PCR) of rodent PKC5, PKCs, and PKC0, a TaqMan expression assay kit was used. 
About 50 ng cDNA was mixed with TaqMan primer and probe, as well as 2x QPCR master 
mix to set up the reaction (50 jul). For QRT-PCR of mouse PKCpI and PKCÇ, specific 
primers were designed and SYBR green reagent was employed. Primers used for PKC pi 
were forward: 5' ttctggaagcagttgagctt 3'; reverse: 5' agtgccaaatgtcattcttca 3'; and for PKCÇ, 
forward: 5' cagateacagatgactatgg 3'; reverse: 5' gagattgctctgtctagaag 3'. About 50 ng cDNA 
was mixed with primer (100 nM), reference dye (30 nM), and Brilliant SYBR green QPCR 
master mix to set up the reaction (50 pi). 18s ribosome RNA (rRNA) was used as an 
endogenous control for both TaqMan and SYBR green based QRT-PCR. For each sample, 
triplicates were run on the same plate. All PCR reactions were performed and data were 
analyzed in a Mx4000 multiplex Quantitative PCR system (Stratagene, La Jolla, CA). 
Preparation of constructs 
PKC5-CRM (cleavage resistant mutant), PKC8-CF (catalytic fragment), and PKC5-
RF (regulatory fragment) expression plasmids were prepared. To prepare PKC5-CF and 
PKCô-RF, 995-2035 bp or 14-982 bp of mouse PKCô (gi: 6755081) cDNA were first 
amplified from pGFP-PKCô (a kind gift of Dr. Reyland at University of Colorado) (DeVries 
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et al., 2002) with the following primer pairs, respectively. For PKC6-CF: forward primer: 5' 
caccatgaacaacgggacctatggcaa 3'; reverse primer: 5' aatgtccaggaattgctcaaac 3'; for PKC8-RF: 
forward primer: 5' caccatggcacccttcctgcgc 3'; reverse primer: 5' actcccagagacttctggctt 3'. To 
prepare PKCô-CRM, full-length mouse PKCô cDNA with a point mutation at 993 (A-C) that 
abolishes the caspase-3 cleavage site of PKCô was amplified with pGFP-PKCôD"A327 (a kind 
gift of Dr. Reyland at University of Colorado) as template. The primer pairs used were: 
forward primer: 5' caccatggcacccttcctgcgc 3'; reverse primer: 5' aatgtccaggaattgctcaaac 3'. 
All PCR reactions were performed with Pfu DNA polymerase to maintain the fidelity of the 
sequence. All PCR products were directly cloned in-frame into the V5-tagged expression 
vector (at the C terminal) pLenti/TOPO from Invitrogen to get pLenti/PKCÔ-CRM, 
pLenti/PKCô-CF, and pLenti/PKCô-RF. All positive clones were confirmed by sequencing. 
Establishment of PKCô-CRM stably expressing N27 cell line 
The ViraPower Lentiviral gene expression system from Invitrogen (Carlsbad, CA) 
was employed for the establishment of the PKCô-CRM stably expressing N27 cell line. To 
produce lentiviral particles, pLenti/PKCô-CRM, as well as supporting plasmids (provided by 
the kit) were co-transfected into human 293FT cells with the use of lipofectamine 2000, as 
described in the instruction of the kit. The lentiviral particles in the medium were then 
collected by centrifuging at 3000 rpm for 15 min at 48-72 hr post-transfection. To generate 
the PKCô-CRM stably expressing cell line, lentiviral particles containing pLenti/PKCô-CRM 
and polybrene (6 pg/ml) were added into cultured N27 cells (2x105). After 24 hr, lentiviral 
particles were replaced with fresh medium. Positive N27 cells were selected by keeping 
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blasticidin (10 (J-g/ml) in medium for up to 2 weeks. PKCô-CRM expressing N27 cells were 
identified by immunostaining of the C-terminal V5 epitope. 
Transient transaction of primary neuronal cultures 
Transient transfection of primary neuronal cultures was performed by electroporation. 
A Rat Neuron Nucleofector kit from Amaxa biosystems (Cologne, Germany) was employed. 
Briefly, about L-2xl06 cells were resuspended with 100 JJ.1 nucleofector solution mixed with 
2 p,g plasmid (pLenti/PKCô-CRM, pLenti/PKCô-CF, or pLenti/PKCô-RF) and transferred 
into a cuvette. The cuvette was then put in a nucleofector device (Amaxa biosystems, 
Cologne, Germany) for electroporation. After electroporation, cells were gently transferred to 
a 6-well plate and incubated at 37°C. 
Immunocytochemistry 
Double immunostaining of TH and PKCô, GAD and PKCô, and TH and V5 was 
performed sequentially in primary neuronal cultures. Primary neuronal cultures grown on the 
poly-L-lysine and laminin coated cover slips were first fixed in 4% paraformaldehyde, then 
permeabilized and blocked with blocking reagent (0.4% BSA, 5% goat serum, and 0.2% 
Triton-X 100 in PBS) for 20 min. Cells were then incubated with one of the primary 
antibodies (mouse anti-TH, mouse anti-GAD, or rabbit anti-TH, 1:1000 in blocking reagent) 
overnight at 4°C and then washed 4x8 min with PBS. Immunoreactivity was visualized by 
incubation with Alexa 488-conjugated goat anti-rabbit secondary antibody or Cy3-
conjugated goat anti-mouse secondary antibody (1:2000 in PBS) at RT for 90 min. After the 
wash, cells were incubated with second primary antibodies (rabbit anti-PKCô or mouse anti-
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V5) and the second secondary antibodies. After another 4x8 min PBS wash, Hoechst 33342 
(final concentration of 10 |4.g/ml in PBS) was added to stain the cell nuclei at RT for 3 min. 
Finally, cells were mounted on a slide with antifade mounting medium. The cells were 
observed under a TCS/NT confocal microscopy system (Leica, Bannockburn, IL). All images 
were processed in MetaMorph 5.07 from Universal imaging (Downingtown, PA). 
Immunohistochemistry 
Control and MPTP-treated mice were perfused by the intracardiac route with 5% 
sucrose, followed by 4% paraformaldehyde in PBS. The mice were kept for 2 hr and then 
decapitated. The brains of mice were then removed and immersed for 48 hr in 4% 
paraformaldehyde for fixation. Nigral and striatal cortical sections (25 pm in thickness) were 
then prepared with a cryostat. Double immunostaining of TH and PKCô was then performed 
sequentially. The sections were rinsed with PBS containing 0.1% Triton-X (PBS-T), 
followed by incubation with mouse anti-TH antibody (1:1000) in PBS-T containing 10% 
goat serum overnight at 4°C with continuous shaking. The sections were washed three times 
with PBS and incubated with Cy3-conjugated goat anti-mouse secondary antibody (1:2000) 
at RT for 2 hr. The staining of PKCô was then followed using the same procedure, but with 
the Alexa 488-conjugated goat anti-rabbit secondary antibody. All sections were washed and 
mounted on a slide. Mounted sections were observed under a TCS/NT confocal microscopy 
system (Leica, Bannockburn, IL). All images were processed in MetaMorph 5.07 from 
Universal Imaging (Downingtown, PA). 
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Immunoprecipitation kinase assay 
PKCô enzymatic activity was assayed using an immunoprecipitation kinase assay as 
previously described (Anantharam et al., 2002). Protein (100-200 (j,g) extracted from the 
substantia nigra of control and MPTP-treated mice was immunoprecipitated overnight at 4°C 
using 2 p.g of anti-PKCô antibody. The immunoprecipitates were then incubated with 
protein-A-sepharose for 1 hr at 4°C. The protein-A bound antigen-antibody complexes were 
then washed 3 times with lysis buffer, 3 times with kinase buffer (40 mM Tris, pH 7.4, 20 
mM MgClz, 20 jiM ATP, and 2.5 mM CaClz), and resuspended in 20 pi of kinase buffer. 
Reactions were started by adding 20 jal of reaction buffer containing 0.4 mg Histone Hi and 
5 jaCi of [y-32P] ATP (3,000 Ci/mM) to the immunoprecipitated samples and incubated for 10 
min at 30°C. SDS gel loading buffer (2X) was then added to terminate the reaction, the 
samples were boiled for 5 min, and the products were separated on a 12% SDS-PAGE gel. 
The phosphorylated histone bands were detected using a Personal Molecular Imager (FX 
model, Bio-Rad) and quantified using Quantity One 4.2.0 software (Bio-Rad, Hercules, CA). 
Striatal dopamine and DOPAC measurement 
The mice were sacrificed the day after the last MPTP treatment. Both striata were 
rapidly dissected with the use of a brain slicer and tissue puncher on ice-chilled glass plates. 
The striata were frozen at -70°C immediately after dissection. For the measurement of 
dopamine and its metabolites, the striata were then thawed and resuspended in 0.1 M ice-
chilled perchloric acid (PCA). The resuspensions were sonicated and centrifuged. Aliquots 
were taken for protein quantification with the Bradford assay kit. Other aliquots were used 
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for the measurement of dopamine and its metabolites by HPLC with electrochemical 
detection. Concentrations of dopamine and DOPAC are expressed as pmol/mg protein. 
Quantification assay for DNA fragmentation 
DNA fragmentation was measured using a recently developed Cell Death Detection 
ELISA plus Assay Kit (Molecular Biochemicals, Indianapolis, IN). Briefly, cells were spun 
down at 200xg for 5 min and washed twice with IX PBS. Cells were then incubated with a 
lysis buffer (supplied with the kit) at RT. After 30 min, samples were centrifuged and 20 jal 
aliquots of the supernatant were then dispensed into streptavidin-coated 96 well microtiter 
plates followed by addition of 80 p,l of HRP-conjugated antibody cocktail, and incubated for 
2 hr at RT with mild shaking. After incubation, unbound components were removed by 
washing with the incubation buffer supplied with the kit. The nucleosomes retained by the 
antibody cocktail in the immunocomplex were quantified spectrophotometrically with ABTS 
as an HRP substrate. Measurements were made at 405 nm and 490 nm using a SpectroMax 
190 spectrophotometer (Molecular Devices, Sunnyvale, CA). The difference in absorbance 
between QD405 and QD490 nm was used to measure the actual DNA fragmentation level. 
Data analysis 
Data analysis was performed using Prism 3.0 software (GraphPad Software, San 
Diego, CA). DNA fragmentation, QRT-PCR, the number of TH positive neurons and their 
neuronal processes, and dopamine content were first analyzed using one-way ANOVA. 
Bonferroni's post-test was then performed to compare all groups, and differences with 
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p<0.05 were considered significant. To analyze the PKC8 kinase enzymatic activity results, 
the paired t-test was used. 
RESULTS 
Selectively high expression of PKCô protein in dopaminergic neurons of substantia 
nigra (SN) 
PKCô has been shown to be proteolytically activated under oxidative stress 
conditions in dopaminergic neuronal cells; however, the expression level and subcellular 
localization of PKCô have not been investigated in dopaminergic neurons. Double 
immunostaining of PKCô with tyrosine hydroxylase (TH) or G ABA decarboxylase (GAD) 
was first performed in rat primary mesencephalic neuronal cultures that contain a mixture of 
dopaminergic and GABAergic neurons. TH and GAD serve as markers for dopaminergic and 
GABAergic neurons, respectively. As shown in Figure lAa, clear immunoreactivity of PKCô 
was seen in dopaminergic neurons identified by positive TH immunostaining; PKCô was 
seen mostly in the cytoplasm and neuronal processes that co-localize with TH (Figure 1 Ad). 
In contrast, only very weak immunoreactivity of PKCô was observed in the cytoplasm and 
neuronal processes of GABAergic neurons identified by positive GAD immunostaining. This 
result suggests that PKCô is more abundant in the dopaminergic neurons than in GABAergic 
neurons. To verify this observation in vivo, double immunostaining of PKCô with TH or 
GAD was then performed in the substantia nigra (SN) and striatum sections of mouse brain. 
As shown in Figure IB, immunoreactivity of PKCô in the substantia nigra brain section is 
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consistently intense, appearing only in the dopaminergic neurons identified by positive TH 
staining and also co-localizing very well with TH in the cytoplasm. In the striatum section, 
although some PKCô immunostaining signals were also seen in GABAergic neurons 
identified by positive GAD staining and nucleus staining, these signals were not quite distinct 
from the background. A survey of the expression level of different PKC isoforms in 
substantia nigra was further examined by immunoblot and was compared to that in cortex 
and striatum of the mouse brain. Based on the availability and quality of antibodies against 
different PKC isoforms, immunoblots of PKCa, PKCpI, and PKCô were made (Figure 1C). 
Consistent with the immunostaining results, the immunoblot of PKCô also shows that the 
substantia nigra has the highest protein level of PKCô as compared to the cortex and striatum. 
However, the PKCa protein level is almost the same in the three regions, and the PKCJ3I 
protein level is lower in the substantia nigra region as compared to the cortex and striatum 
regions. The membrane was reprobed with p-actin antibody to ensure equal loading. Taken 
together, these results consistently demonstrate that nigral dopaminergic neurons in mice 
have a selectively higher expression of PKCô. 
Selectively high level of PKCô mRNA in the substantia nigra 
To establish the correlation between the protein and mRNA levels of different PKC 
isoforms we next determined the mRNA levels of different PKC isoforms, including PKCô, 
in the cortex (Ctx), striatum (St), and substantia nigra (SN) regions of mice brains, which 
were first carefully and precisely dissected. Total RNA was then prepared and converted into 
cDNA. For mouse PKCô, PKCs, and PKC0, pre-designed TaqMan probes from Applied 
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Biosystems were employed for quantitative real time PCR (QRT-PCR). Because pre­
designed TaqMan probes are not available for mouse PKCpi and PKCÇ, the SYBR green dye 
based QRT-PCR method was used. 18s Ribosome RNA (18s rRNA) was used as an 
endogenous control to equalize the amount of RNA used in QRT-PCR. The real-time 
amplification plot of PKC5 from the Ctx, St, and SN is shown in Figure 2A. The Ct 
(threshold of cycle) value of amplification from SN cDNA is significantly lower than that in 
Ctx and St cDNA, indicating that the number of PKCô mRNA copies in the SN is much 
higher than that in the Ctx and St. By using Ctx PKCô Ct as the calibrator, the relative 
quantity of PKCô mRNA among the three regions was calculated from the formula 2~(ACt 
PKCs-ACt IBs rRNA) an(j presente(j jn Figure 2B. The number of PKCô mRNA copies in the SN is 
30-fold greater than that in the Ctx, and 2-fold greater than that in the St. Similar results were 
also found in rat: the number of PKCô mRNA copies in the SN is about 5-fold more than that 
in the St and Ctx regions (Figure 4A). The relative quantity of several other PKC isoform 
mRNAs among the SN, Ctx, and St regions was also determined (Ctx as the calibrator). As 
shown in Figure 2C, the relative quantity of PKC(3I and PKCs mRNA among the three 
regions is: SN < St < Ctx, while the relative quantity of PKC0 mRNA is: Ctx < SN < St. 
Both SN and St regions have similar levels of PKCÇ mRNA, which are higher than the level 
in the Ctx. We also attempted to determine the quantity of PKCa mRNA in the three regions. 
Since a pre-designed TaqMan probe for PKCa is unavailable, specific primers for PKCa 
were designed in order to use the SYBR green based QRT-PCR method; however, these 
primers failed to give good amplification and resulted in high background disturbance. 
Nevertheless, none of these PKC isoforms surveyed have more abundant mRNA in the SN 
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region, suggesting that PKCÔ is a unique kinase in the PKC family with a selectively high 
level of mRNA in the SN region. 
Proteolytic activation of PKCô in nigral dopaminergic neurons of mice 
The classic Parkinsonian toxin MPP+ has been shown to induce oxidative stress and 
caspase activation in numerous in vitro and in vivo models of PD (Hartmann et al., 2000; Lee 
et al., 2000; Hartmann et al., 2001; Jenner, 2003). Our previous studies further demonstrated 
that PKCô is proteolytically activated in a caspase-3 dependent manner, followed by MPP+-
induced oxidative stress, and contributes to MPP+-induced apoptotic death of dopaminergic 
neuronal cells (Kaul et al., 2003). To examine whether MPP+ also induces proteolytic 
activation of PKCô in nigral dopaminergic neurons in vivo, mice were administered 30 
mg/kg MPTP for 5d and the substantia nigra region was dissected. Dissected SN was then 
homogenized and proteins were separated by 10% SDS-PAGE. Anti-PKCô antibody from 
Santa Cruz Biotechnology (Santa Cruz, CA) that recognizes the C-terminal epitope of PKCô 
was employed for the detection of both native and cleaved PKCô fragments. As shown in 
Figure 3 A, cleaved PKCô fragments (41/38KDa) were detected from whole tissue lysates of 
the SN region from MPTP treated mice. To demonstrate that proteolytic cleavage of PKCô 
occurs in dopaminergic neurons, the presence of tyrosine hydroxylase (TH) was also 
examined and a clear TH band was detected on the immunoblot. The membrane was also 
reprobed with anti-(3-actin antibody to equalize the protein loaded on the gel. After observing 
the proteolytic cleavage of PKCô, we next examined the PKCô kinase activity following 
MPTP administration. PKCô was immunoprecipitated from whole lysate of the SN region in 
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control and MPTP treated mice and was evaluated in an in vitro kinase assay. As shown in 
Figure 3B, MPTP administration increases PKC5 kinase activity to 220% in comparison to 
untreated control mice, indicating that PKCô is indeed proteolytically activated in mice 
administered MPTP. 
Cleavage resistant mutant of PKCô (PKCô-CRM) attenuates MPP-induced proteolytic 
cleavage of PKCô in N27 cells and protects N27 cells from MPP-induced apoptotic 
death 
RNAi mediated genetic loss-of-function analysis of PKCô has demonstrated a 
promotional role of PKCô in MPP+-induced degeneration of dopaminergic neurons in rat 
primary mesencephalic neuronal cultures (Yang et al., 2004). To determine whether the 
proteolytic cleavage of PKCô is essential for its promotional role in MPP+-induced 
degeneration of dopaminergic neurons, PKCô cleavage was blocked by using the cleavage 
resistant mutant of PKCô (PKCô-CRM), and MPP+-induced apoptotic death of dopaminergic 
neuronal (N27) cells was examined. Dopaminergic neuronal (N27) cells were derived from 
rat mesencephalic dopaminergic neurons and established as an in vitro model of PD (Adams 
et al., 1996; Prasad et al., 1998). The expression level of PKCô in N27 cells is comparable to 
the selectively high expression level of PKCô in the SN region of rodent brain; thus, N27 
cells are a relevant and valid in vitro model of PD with regard to the expression level of 
PKCô. The expression level of PKCô in dopaminergic neuronal (N27) cells was determined 
by the TaqMan probe based QRT-PCR method, and relative abundance of PKCô mRNA in 
N27 cells was compared to that in the Ctx, St, and SN regions of rat brain (Ctx as the 
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calibrator). As shown in Figure 4A, the relative amounts of PKCô mRNA in the three 
regions of rat brain are similar to those observed in mouse brain regions, i.e., SN > St > Ctx. 
The number of PKCô mRNA copies in N27 cells is comparable to that in the SN region and 
is also significantly higher than that in the Ctx and St regions of rat brain. A stable N27 cell 
line that overexpresses PKCô-CRM was generated via the ViraPower™ lentiviral expression 
system from Invitrogen. PKCô-CRM contains a point mutation (D327A) in its caspase-3 
recognition and cleavage motif which abolishes the cleavage of PKCô by activated caspase-3 
(Ghayur et al., 1996). As shown in Figure 4B, PKCô cleavage was induced in the control 
cells at the 36 hr time point following MPP+ exposure; however, cleavage of PKCô was 
significantly abolished at the 36 hr time point following MPP+ exposure in the PKCô-CRM 
stably expressing N27 cells. The membrane was reprobed with anti-V5 antibody to show the 
expression of exogenous PKCô-CRM in PKCô-CRM stably expressing N27 cells. The 
detailed mechanism of the dominant-negative effect of PKCô-CRM in MPP+-induced 
cleavage of endogenous PKCô is still under investigation. Some preliminary results suggest 
that overexpressed PKCô-CRM can down-regulate the expression of endogenous PKCÔ, as 
shown by RT-PCR (data not shown). The overexpressed PKCô-CRM might also inhibit the 
feedback loop between PKCô and caspase-3, resulting in the inhibition of continuous 
activation of caspase-3. Alternatively, the overexpressed PKCÔ-CRM may simply out 
compete endogenous PKCô for activated caspase-3, thus leaving endogenous PKCô intact. 
We next examined whether inhibition of caspase-3 mediated proteolytic cleavage of 
endogenous PKCô by PKCô-CRM protects N27 cells against MPP+-induced apoptotic cell 
death. In control cells, MPP+ exposure for 42 hr induced an approximate 110% increase in 
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the DNA fragmentation level compared to untreated control cells; however, only a 30% 
increase in the DNA fragmentation level was induced in the PKCô-CRM stably expressing 
N27 cells following MPP+ exposure for 42 hr in comparison to untreated control cells (Figure 
4C). The overexpression of PKCô-CRM did not induce any DNA fragmentation (data 
presented in another manuscript). These results clearly show that the caspase-3 mediated 
proteolytic cleavage of PKCô following MPP+ exposure is required for PKCô's pro-apoptotic 
function in MPP+-induced apoptotic death of dopaminergic neuronal cells. 
Cleavage resistant mutant of PKCô (PKCô-CRM) protects primary dopaminergic 
neurons from MPP-induced degeneration 
We next tested whether PKCô-CRM also protects primary dopaminergic neurons 
against MPP+-induced degeneration. Rat primary mesencephalic neuronal cultures were first 
transfected with pLenti/PKCô-CRM by electroporation and then exposed to 10 |_iM MPP+ for 
48 hr. Because of the presence of the V5 epitope in the C-terminal of pLenti/PCKô-CRM, 
double immunostaining of TH and V5 was performed to identify dopaminergic neurons and 
the expression of exogenous PKCô-CRM in dopaminergic neurons. The morphology of TH 
positive neurons among different groups is presented in Figure 5A. This particular 
dopaminergic neuron is intact and has long, multiple-branched neuronal processes in control 
cells, as revealed by TH immunoreactivity. Treatment with 10 pM MPP+ for 48 hr 
substantially decreased the neuronal processes and induced shrinkage of the cell body. 
However, the same MPP+ treatment did not cause any significant degeneration of 
dopaminergic neurons in pLenti/PKCô-CRM transfected primary neuronal cultures. The 
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morphology of this TH positive neuron is also intact with long, multiple-branched neuronal 
processes. The expression of PKCô-CRM in TH positive neurons was revealed by V5 
immunoreactivity (Figure 5B), and this particular TH positive neuron also has normal 
morphology following treatment with 10 p,M MPP+ for 48 hr. Expressed PKCô-CRM is 
primarily localized in the cytoplasm, where it co-localizes with TH (Figure 5B). This is 
consistent with the results in Figure 1. 
The detection of clear V5 immunoreactivity in TH positive neurons indicates PKCô-
CRM was indeed transfected into dopaminergic neurons. The transaction efficiency of 
PKCô-CRM into TH positive neurons is 55%, as calculated from the number of total TH 
positive neurons and the number of TH and V5 double positive neurons. The TH positive 
neurons and their neuronal processes were employed to evaluate the effect of PKCô-CRM on 
MPP+-induced degeneration of dopaminergic neurons, since quantification of TH positive 
neurons is considered to be a reliable method of determining MPP+-induced dopaminergic 
toxicity in primary mesencephalic cultures (Choi et al., 1999; C allier et al., 2002). After 
counting the number of TH positive neurons and measuring their neuronal processes in 
multiple fields (about 5000 cells in each group), the effect of PKCô-CRM on MPP+-induced 
degeneration of dopaminergic neurons was quantified and presented in Figure 5C&D. 
Treatment with 10 |xM MPP+ for 48 hr substantially decreased the number of TH positive 
neurons by over 80% as compared to untreated control cells (Fig. 5C). However, MPP+-
induced loss of TH+ neurons was significantly reduced to 20% in PKCô-CRM-transfected 
primary neuronal cultures, demonstrating a significant neuroprotective effect of PKCô-CRM. 
PKCô-CRM not only protects the number of TH positive neurons, but also protects the 
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neuronal processes of TH positive neurons from MPP+-induced degeneration. As shown in 
Figure 5D, 10 |xM MPP+ exposure for 48 hr causes 83% loss of neuronal processes in TH 
positive neurons as compared to the control; however, only a 20% loss of neuronal processes 
in TH positive neurons was found in PKCô-CRM-transfected primary neuronal cultures. 
Together, these results demonstrate that inhibition of endogenous PKCô cleavage by PKCô-
CRM significantly protects dopaminergic neurons from MPP+-induced degeneration. 
Catalytic fragment of PKCô (PKCô-CF) directly induces degeneration of primary 
dopaminergic neurons 
Proteolytic cleavage of PKCô removes the pseudosubstrate bound to the catalytic site, 
leading to the persistent activation of the kinase (Emoto et al., 1995). The proteolytic 
activation of PKCô has been associated with apoptotic death induced by various stimuli in 
different cells (Brodie and Blumberg, 2003; Kanthasamy et al., 2003). The exogenously 
introduced PKCô-CF has also been shown to directly induce apoptosis in some cells 
(DeVries et al., 2002). However, whether PKCô-CF directly induces the degeneration of 
dopaminergic neurons in primary neuronal cultures is not known. pLenti/PKCô-CF 
expressing the catalytic fragment of PKCô (PKCô-CF) was directly transfected into the rat 
primary neuronal cultures by electroporation. pLenti/PKCô-RF, which expresses the 
regulatory fragment of PKCô (PKCô-RF), was also transfected into the primary neuronal 
culture to serve as control for PKCô-CF. Double immunostaining of TH and V5 was 
performed at 48 hr post-transfection to evaluate the degeneration of dopaminergic neurons 
and examine the expression of PKCô-CF or PKCô-RF in primary dopaminergic neurons. 
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neuronal processes of TH positive neurons from MPP+-induced degeneration. As shown in 
Figure 5D, 10 pM MPP+ exposure for 48 hr causes 83% loss of neuronal processes in TH 
positive neurons as compared to the control; however, only a 20% loss of neuronal processes 
in TH positive neurons was found in PKCô-CRM-transfected primary neuronal cultures. 
Together, these results demonstrate that inhibition of endogenous PKCô cleavage by PKCô-
CRM significantly protects dopaminergic neurons from MPP+-induced degeneration. 
Catalytic fragment of PKCô (PKCô-CF) directly induces degeneration of primary 
dopaminergic neurons 
Proteolytic cleavage of PKCô removes the pseudosubstrate bound to the catalytic site, 
leading to the persistent activation of the kinase (Emoto et al., 1995). The proteolytic 
activation of PKCô has been associated with apoptotic death induced by various stimuli in 
different cells (Brodie and Blumberg, 2003; Kanthasamy et al., 2003). The exogenously 
introduced PKCô-CF has also been shown to directly induce apoptosis in some cells 
(DeVries et al., 2002). However, whether PKCô-CF directly induces the degeneration of 
dopaminergic neurons in primary neuronal cultures is not known. pLenti/PKCô-CF 
expressing the catalytic fragment of PKCô (PKCô-CF) was directly transfected into the rat 
primary neuronal cultures by electroporation. pLenti/PKCÔ-RF, which expresses the 
regulatory fragment of PKCô (PKCÔ-RF), was also transfected into the primary neuronal 
culture to serve as control for PKCô-CF. Double immunostaining of TH and V5 was 
performed at 48 hr post-transfection to evaluate the degeneration of dopaminergic neurons 
and examine the expression of PKCô-CF or PKCô-RF in primary dopaminergic neurons. 
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Representative TH positive neurons expressing either PKCô-CF or PKCô-RF were presented 
in Figure 6A. Neurons expressing PKCô-RF have normal morphology and extended neuronal 
processes; however, TH positive neurons that express PKCô-CF have a shrunken cell body 
and very short neuronal processes, similar to the morphology of the degenerated 
dopaminergic neuron induced by MPP+ (Figure 5 A). To quantify the effect of PKCô-CF on 
the degeneration of dopaminergic neurons, the number of TH positive neurons was counted 
in multiple fields among different groups (about 5000 cells observed in each group). 
Quantitative analysis of the number of TH positive neurons in PKCô-CF and PKCô-RF 
transfected primary neuronal cultures is presented in Figure 6B. The number of TH positive 
neurons was only slightly less (10%) in PKCô-RF transfected primary neuronal cultures than 
in control cells, while the number of TH positive neurons in PKCô-CF transfected primary 
neuronal cultures was dramatically less (60%) than in control cells. These results clearly 
demonstrate that PKCô-CF itself is toxic and directly induces degeneration of dopaminergic 
neurons in rat primary neuronal cultures. 
DISCUSSION 
In the present study, we investigated the expression level of different PKC isoforms 
in the cortex, striatum, and substantia nigra regions of rodent brains and demonstrated that 
the substantia nigra region of rodent brains has a higher level of PKCô protein and mRNA as 
compared to that in the cortex and striatum regions. To our knowledge, this is the first report 
investigating the expression level of PKC isoforms in the substantia nigral dopaminergic 
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neurons of rodent brains. Our results also demonstrate, for the first time, that administration 
of the Parkinsonian toxin MPTP to mice induces in vivo proteolytic activation of PKCô in the 
substantia nigra region. By employing PKCô-/- mice, the cleavage resistant mutant of PKCô 
(PKCô-CRM), and the catalytic fragment of PKCô (PKCô-CF), our studies clearly suggest 
that proteolytic activation of PKCô is an essential downstream event in the degenerative 
process in nigral dopaminergic neurons in the MPTP mouse model of Parkinson's disease. 
The Parkinsonian toxin MPTP has been shown to be a potent mitochondrial complex 
I inhibitor (Fritz et al., 1985; Singer et al., 1988; Marini et al., 1989). In the brain, MPTP is 
metabolized to its active form, MPP+, and selectively accumulates in dopaminergic neurons 
through the dopamine transporter (DAT) (Uhl et al., 1985; Mayer et al., 1986). The MPP+-
induced inhibition of mitochondrial complex I leads to the massive production of reactive 
oxygen species (ROS) (Cassarino et al., 1997), which subsequently initiates a series of 
apoptotic events, including mitochondrial dysfunction, cytochrome C release, and activation 
of the major effector caspase, caspase-3, in dopaminergic neurons (Kaul et al., 2003; Vila 
and Przedborski, 2003). Recent in vitro studies further characterized that PKCô is 
proteolytically activated by caspase-3 in dopaminergic neuronal cells exposed to MPP+ (Kaul 
et al., 2003). PKCô contains the caspase-3 cleavage motif located at the hinge region that 
connects the regulatory and catalytic fragments of PKCô. The proteolytic cleavage of PKCô 
by caspase-3 separates the inhibitory regulatory fragment from the catalytic fragment, thus 
persistently activating the kinase (Emoto et al., 1995; Reyland et al., 1999). The kinase active 
catalytic fragment of PKCô itself is sufficient to induce cell death, as indicated by our 
previous study (manuscript under review) as well as several other studies (DeVries et al., 
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2002; Ren et al., 2002; Basu, 2003). By employing the cleavage resistant mutant of PKCô 
(PKCô-CRM) that abolishes the caspase-3 cleavage motif by point mutation D327A 
(DeVries et al., 2002)), we demonstrated that proteolytic cleavage of PKCô is an essential 
downstream event in MPP+-induced degeneration of nigral dopaminergic neurons. In 
addition, we also showed that the exogenous expression of the kinase active catalytic 
fragment PKCô-CF, but not the regulatory fragment PKCô-RF, directly induces the 
degeneration of dopaminergic neurons. 
Although the pathology of Parkinson's disease has been well characterized, we still 
do not know why nigral dopaminergic neurons are most severely degenerated in PD. Many 
studies have suggested that dopaminergic neurons are particularly susceptible to oxidative 
stress (Lotharius and Brundin, 2002), and the metabolism of the specific neurotransmitter 
dopamine generates many toxic free radicals, including dopamine-quinone species, 
superoxide radicals, and hydrogen peroxide in the cytosol of dopaminergic neurons (Graham, 
1978). Redox active Fe2+, which contributes to the generation of hydroxyl radicals, was also 
selectively elevated in the SNc region of PD brains (Sofic et al., 1991; Jellinger, 2000), 
partially due to the enrichment of Fe2+ by neuromelanin (NM) which is selectively localized 
in nigral dopaminergic neurons (Good et al., 1992; Zecca et al., 1994; Zecca et al., 2003). On 
the other hand, although genetic mutations of several genes, including a-synuclein, Parkin, 
UCHL1, DJ-1, PINK1, and LRRK2, have been implicated in the pathogenesis of familial PD 
patients (Dawson and Dawson, 2003; Shen, 2004), it is not clear how nigral dopaminergic 
neurons are selectively affected by the loss of function of these genes. 
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Our studies showed that the oxidative stress sensitive pro-apoptotic kinase PKCô is 
selectively abundant in nigral dopaminergic neurons. Because proteolytic cleavage of PKCÔ 
is mediated by activated caspase-3, various apoptotic stresses, including oxidative stress, that 
trigger the mitochondrial dependent intrinsic pathway can activate caspase-3 and induce 
subsequent proteolytic cleavage of PKCô. Thus, the selective abundance of PKCô in nigral 
dopaminergic neurons could significantly increase cellular vulnerability due to the potentially 
easier and enhanced generation of pro-apoptotic cleaved activated fragments of PKCô, and 
greatly facilitate oxidative stress-induced degeneration of nigral dopaminergic neurons. We 
also determined the expression level of other representative PKC isoforms, but found a 
relatively lower expression level of these isoforms, particularly PKCe and PKCpi, in nigral 
dopaminergic neurons. Interestingly, most studies indicate that PKC(3I and PKCe are 
predominantly anti-apoptotic PKC kinases (Gutcher et al., 2003). The relatively lower 
expression level of anti-apoptotic PKC isoforms and the higher expression level of pro-
apoptotic PKCô in nigral dopaminergic neurons suggest that the expression level of these 
PKC isoforms potentially contributes to the susceptibility of nigral dopaminergic neurons in 
Parkinson's disease. 
Interestingly, abundant levels of PKCô were also found to co-localize with TH, the 
rate-limiting enzyme in dopamine synthesis. TH is a substrate of various serine/threonine 
protein kinases, including cAMP-dependent protein kinase A (PKA) (Lovenberg et al., 1975), 
cGMP-dependent protein kinase G (PKG) (Roskoski et al., 1987), protein kinase C (PKC) 
(Albert et al., 1984), Ca2+-calmodulin dependent protein kinase II (CaMKII) (Vulliet et al., 
1984), extracellular signal-related kinase (ERK1/2) (Sutherland et al., 1993), and the recently 
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identified cyclin-dependent protein kinase 5 (Cdk5) (Moy and Tsai, 2004). Phosphorylation 
status of TH is closely associated with its activity and the synthesis of dopamine in 
dopaminergic neurons (Dunkley et al., 2004). Studies are underway to elucidate the 
interaction of PKCô with TH and the potential regulatory role of PKCô in TH 
phosphorylation and activity. 
In summary, we demonstrate that MPTP administration induces in vivo proteolytic 
activation of PKCô in nigral dopaminergic neurons, and proteolytic activation of PKCô is an 
essential downstream event following caspase-3 activation in MPTP-induced degeneration of 
nigral dopaminergic neurons. Our studies suggest that the characterization of downstream 
apoptotic molecules in experimental models of PD is important to better understand the 
pathogenesis of this neurodegenerative disorder. 
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Figure 1 : Selectively high expression of PKCô protein in nigral dopaminergic neurons 
(A) Immunostaining of PKCô in dopaminergic and GABAergic neurons in rat primary 
mesencephalic neuronal cultures. (B) Immunostaining of PKCô in dopaminergic and 
GABAergic neurons in brain sections of mice substantia nigra (SN) and striatum (St). Double 
immunostaining of PKCô with TH or GAD in primary neuronal cultures or brain sections 
was performed sequentially. Mouse anti-TH, mouse anti-GAD antibody (1:1000) and rabbit 
anti-PKCÔ antibody (1:1000) were used. Stained cells and sections were observed under a 
TCS/NT confocal microscopy system (Leica, Bannockburn, IL). (C) Protein level of PKC 
isoforms in cortex (Ctx), substantia nigra (SN), and striatum (St) of mice brains. Whole 
tissue lysates were prepared after Ctx, SN, and St regions were carefully dissected and 
separated by 10% SDS-PAGE. 
245 
PKCS TH Nucleus Merge 
PKCS GAD Nucleus Merge 
PKCô 
PKCS Nuclei 
245 
PKCS TH Nucleus Merge 
PKCS GAD Nucleus Merge 
246 
Ctx St SN 
p i  — — —  
P-actin 
246 
247 
Figure 2: Relative quantity of the mRNA level of PKC isoforms in different regions of 
mice brains 
(A) Amplification plot of PKCô mRNA among SN (red), St (blue), and Ctx (green) regions 
of mice brains. (B) Relative PKCô mRNA level among SN, St, and Ctx regions of mice 
brains. (C) Relative PKC(3I, PKCe, PKCÔ, and PKCÇ mRNA levels among SN, St, and Ctx 
regions of mice brains. Total RNA extracted from the SN, St, and Ctx regions of mice brains 
was converted into cDNA. For the QRT-PCR of PKCô, PKCe, and PKCÔ, a TaqMan probe 
based method was used; for the QRT-PCR of PKCpI and PKCÇ, a SYBR green based 
method was used. 18s Ribosome RNA (18s rRNA) was employed as an endogenous control 
to normalize the RNA used in QRT-PCR. The relative PKC isoform mRNA levels among the 
SN, St, and Ctx regions were calculated from the formula 2"(ACt PKC5~ACt 18s rRNA) and the Ct 
value in the cortex was always used as the calibrator. The data represent the mean + SEM 
from two separate experiments in triplicate (*, p<0.05; ***, p<0.001; N=6). 
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Figure 3: MPTP administration induces proteolytic activation of PKCÔ in the 
substantia nigra region of mice brains 
(A) Proteolytic cleavage of PKCô in the substantia nigra region of mice brains following 
MPTP administration for 5d. (B) Increased PKCô kinase activity in the substantia nigra 
region of mice brains following MPTP administration for 5d. MPTP was administered at a 
dose of 30 mg/kg intraperitoneally to mice (n=6) every day for five doses. Control mice (n=6) 
were treated with an equal volume of ddH20. All animals were sacrificed the day after the 
last injection. The data represent the mean + SEM from two separate experiments in triplicate 
(**, p<0.01; N=6). 
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Figure 4: Cleavage resistant mutant of PKCô (PKCÔ-CRM) protects N27 cells from 
MPP-induced apoptotic death 
(A) Relative quantity of PKCô mRNA in N27 cells and in the SN, St, and Ctx regions of rat 
brains. The TaqMan based QRT-PCR method (rat PKCô expression assay kit) was employed 
and 18s rRNA was used as an endogenous control. For comparison of the relative PKCô 
mRNA levels, the Ct value of the Ctx sample was used as the calibrator. (B) MPP+-induced 
PKCô cleavage was abolished in PKCÔ-CRM stably expressing cells. Control cells and 
PKCô-CRM stably expressing cells were treated with 300 JJM MPP+ for 36 hr. The cells 
were lysed and whole cell lysate was used for immunoblot analysis to detect the PKCô 
cleavage. The membrane was reprobed with anti-V5 antibody (1:5000) to ensure the 
expression of PKCô-CRM in the PKCô-CRM stably expressing N27 cell line. (C) PKCô-
CRM protects against MPP+-induced apoptotic death in N27 cells. The data represent the 
mean + SEM from two separate experiments in triplicate (*, p<0.05; ***, pO.OOl; N=6). 
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Figure 5: Cleavage resistant mutant of PKCô (PKCô-CRM) protects primary 
dopaminergic neurons from MPP-induced apoptotic death 
(A) Morphology of representative TH positive neurons from MPP+-treated groups with or 
without pre-transfection of PKCô-CRM, and control group. Cells were observed under a 
Nikon inverted fluorescence microscope (Model TE-2000U). (B) Expression of PKCô-CRM 
in the TH positive neurons of rat primary mesencephalic neuronal cultures. At 24 hr post­
transfusion of PKCô-CRM, primary neuronal cultures were treated with 10 pM MPP+ for 
another 48 hr. Double immunostaining of TH (rabbit anti-TH antibody) and V5 (mouse anti-
V5 antibody) was performed sequentially after treatment. Cells were observed under a 
TCS/NT confocal microscopy system (Leica, Bannockbum, IL). (C) Quantitative analysis of 
the number of TH positive neurons following PKCô-CRM transfection and MPP+ treatment. 
(D) Quantitative analysis of the neuronal processes of TH positive neurons following PKCô-
CRM transfection and MPP+ treatment. After PKCô-CRM transfection, cells were exposed to 
10 |o,M MPP+ for 48 hr and then TH positive neurons were identified using anti-TH antibody 
exposure. The number of TH positive neurons was counted in multiple fields (total 5000 cells) 
and their neuronal processes were measured in MetaMorph 5.07. Data represent the mean + 
SEM from two separate experiments in triplicate (***, pO.OOl; N=6). 
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Figure 6: Catalytic fragment of PKCô (PKC8-CF) directly induces the degeneration of 
dopaminergic neurons in rat primary neuronal cultures 
(A) Morphology of representative TH positive neurons in PKC5-RF or PKCô-CF transfected 
primary neuronal cultures. (B) Quantitative analysis of the number of TH positive neurons 
following PKCô-CF or PKCÔ-RF transfection. Double immunostaining of TH (rabbit anti-
TH antibody) and V5 (mouse anti-V5 antibody) was performed 48 hr post-transfection of 
PKCô-CF or PKCô-RF. Cells were observed under a TCS/NT confocal microscopy system 
(Leica, Bannockburn, IL). Data represent the mean + SEM from two separate experiments in 
triplicate (**, pcO.Ol ; N=6). 
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CHAPTER VI: GENERAL CONCLUSIONS 
The major findings of my research described in the dissertation have already been 
discussed in the discussion sections of each chapter. The overall conclusions derived from 
these studies and integral mechanisms of PKCô in neurotoxin-induced apoptotic death of 
dopaminergic neurons and relevance to the pathogenesis of Parkinson's disease (PD) will be 
discussed here. 
Selectively high expression of oxidative stress sensitive kinase PKCô contributes to the 
vulnerability of nigral dopaminergic neurons to neurotoxin-induced degeneration 
Nigral dopaminergic neurons are most severely degenerated in Parkinson's disease 
partially due to the presence of dopamine in these neurons (Carlsson and Fornstedt, 1991; 
Hirsch et al., 1997). Dopaminergic neurons are persistently exposed to oxidative stress 
because metabolism of free cytosolic dopamine dramatically increases the generation of ROS. 
DAT and VMAT2 regulate the level of free cytosolic dopamine, and therefore, have been 
implicated in the selective vulnerability of dopaminergic neurons (Gonzalez-Hernandez et al., 
2004; Uhl, 1998). In addition, other molecules related to oxidative stress, including 
neuromelanin (NM) and redox active Fe2+, are also selectively rich or elevated in nigral 
dopaminergic neurons (Good et al., 1992; Lotharius and Brundin, 2002; Zecca et al., 2003). 
In this study, we demonstrated that oxidative stress sensitive kinase PKCô is selectively 
abundant in nigral dopaminergic neurons and co-localizes with TH, the rate-limiting enzyme 
in dopamine synthesis. Ongoing studies in our laboratory have demonstrated that abundant 
PKCô normally inhibits TH activity to regulate dopamine synthesis. However, abundant 
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PKC5 becomes sensitive to neurotoxin-induced oxidative stress and is cleaved by caspase-3 
in dopaminergic neuronal cells and in mice. In dopaminergic neuronal cells, we demonstrated 
that caspase-3 mediated cleavage of PKC5 releases the catalytic fragment of PKCÔ (PKCô-
CF), which further translocates to the nucleus. The PKCô-CF serves as effector and promotes 
apoptotic death of dopaminergic neuronal cells by mediating the serl4 phosphorylation of 
histone H2B. 
Proteolytic cleavage of PKCô apparently serves as a switch that converts the 
physiologically important PKCô in the regulation of TH activity and dopamine synthesis to a 
pro-apoptotic kinase promoting degeneration of dopaminergic neurons. Because proteolytic 
cleavage of PKCô is mediated by activated caspase-3, various apoptotic stresses, including 
oxidative stress, which triggers the mitochondrial-dependent intrinsic pathway and 
subsequent activation of caspse-3, can activate this switch. A certain extent of oxidative 
stress and other apoptotic stresses are always present in the central nervous system (Halliwell, 
1992; Jenner, 2003). The selective abundance of PKCô could significantly increase the 
vulnerability of dopaminergic neurons to the same level of insults due to the potentially 
easier and increased generation of pro-apoptotic cleaved activated fragments of PKCô. 
Regulation of the nuclear localization of PKCô by regulatory fragments through 
position obstacle effects in tertiary structure 
The function of some serine/threonine protein kinases in cells is closely related to 
their nuclear/cytoplasmic localization. For example, p21-activated kinase 2 (PAK2) is mainly 
localized in the cytoplasm and promotes cell survival; however, cleaved PAK2p34 is 
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localized in the nucleus and promotes cell death (Jakobi, 2004). The nuclear/cytoplasmic 
localization is mainly regulated by a nucleus localization signal (NLS)Znucleus export signal 
(NES) mediated nuclear import/export (Kaffman and O'Shea, 1999). NLS but not NES has 
been identified in the C-terminal of the catalytic fragment of PKCô (DeVries et al., 2004); 
however, PKCô is primarily localized in the cytoplasm in various cell types, including 
dopaminergic neuronal cells. The regulation of the nuclear localization of PKCÔ is unknown. 
In dopaminergic neuronal cells, we demonstrated that the N- and C-terminals of PKCô are in 
close proximity in the tertiary structure by FRET. By employing the CI or C2-like domain 
deletion mutant of PKCô (PKCô-ACl or PKCÔ-AC2), we showed that deletion of the C2-like 
domain, but not the CI domain, induces strong nuclear localization of PKCô. Meanwhile, 
nuclear translocation of activated cleaved fragments of PKCô generated from caspase-3-
mediated proteolytic cleavage in response to neurotoxin exposure has been observed, and the 
exogenously expressed catalytic fragment of PKCô (PKCô-CF) also primarily localizes to 
the nucleus. Although sequence analysis of the C2-like domain reveals a possible leucine-
rich nuclear export signal (NES), the C2-like domain is not sensitive to the nuclear export 
inhibitor leptomycin B (Fomerod et al., 1997), suggesting that this leucine-rich motif is not a 
functional NES. Moreover, the human immunodeficiency virus (HIV) Rev chimera protein 
was generated by fusing the C2-like domain in the N-terminal of a NES deleted form of Rev, 
the RNA binding protein of HIV, which is still primarily localized in the cytoplasm. Our 
studies suggest that the N-terminal C2-like domain regulates the subcellular localization of 
PKCô by masking the C-terminal NLS through the position obstacle in the tertiary structure, 
but not by employing NES or interacting with anchoring proteins. Our model is consistent 
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with the previously proposed tertiary conformation of PKCô; the pseudosubstrate in the 
middle of the N-terminal regulatory fragment binds to the catalytic site of the C-terminal 
catalytic fragment. 
The presence of NLS is not sufficient but necessary, as shown in our study, to 
localize PKCô into the nucleus. NLS could be normally kept in an incompetent status and 
converted to competent status in response to certain stimuli. The subcellular localization of 
kinases is critical for their close proximity to their activator or substrates; thus, the 
maintenance and regulation of competent status of NLS is important for their functions. In 
addition, the intra-molecular regulation provides more flexibility for kinases to self-regulate 
subcellular localization and functions. 
In summary, we surveyed the expression of different isoforms of PKC in rodent 
brains and determined that PKCô has the highest expression in the SNc dopaminergic 
neurons in rodent brains. We also characterized the molecular mechanisms of PKCô in 
neurotoxin-induced apoptotic death of dopaminergic neuronal cells. Under normal 
physiological conditions, the highly expressed PKCô interacts with tyrosine hydroxylase (TH) 
in dopaminergic neurons. The close proximity of the C2-like domain to the nuclear 
localization signal (NLS) provides the position obstacle to inhibit the recognition of the 
nuclear import receptor to the NLS and retains PKCô in the cytoplasm. However, under 
stressful conditions, abundant PKCô was proteolytically cleaved by caspase-3 activated by 
neurotoxin-induced oxidative stress to release the activated cleaved fragments of PKCô. The 
proteolytic cleavage of PCKô by caspase-3 serves as a switch to convert it from non-
apoptotic to pro-apoptotic kinase and makes highly expressed PKCô a potential inherent 
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factor for the vulnerability of dopaminergic neurons. The removal of the regulatory fragment 
from the catalytic fragment by cleavage also exposes the NLS and induces the nuclear 
translocation of the activated cleaved fragments of PKC5. In the nucleus, we further 
demonstrated that activated PKCô mediated the Serl4 phosphorylation of histone H2B, and 
the catalytic fragment of PKCô (PKCô-CF) itself induced the apoptosis of dopaminergic 
neuronal cells. 
Under stress condition Abundant PKC5 protein in the cytoplasm of dopaminergic neurons 
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Figure 13. Integral mechanisms of PKCô in neurotoxin-induced apoptotic death of dopaminergic neurons 
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